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Abstract
Photodynamic therapy (PDT) describes an interaction of a drug, light and 
oxygen that results in cell killing. The aim of this thesis is to describe the 
potential clinical applications of the three most commonly used drugs in PDT -  
aminolaevulinic acid (ALA), Photofrin® and Foscan®. Before it was considered 
safe to use this therapy on patients, a series of preclinical studies were 
undertaken to establish the safety of the treatment and to try to understand the 
likely clinical effects on normal tissues.
Following this, a series of studies was undertaken to look at the biological effect 
of PDT on normal and neoplastic tissue. These studies showed the treatment to 
be safe and effective in destroying tissue while allowing healing with 
preservation of sufficient tissue structure to maintain tissue contour and 
function.
Next, clinical studies were undertaken on dysplasia, early oral cancer and field 
change disease using the 3 sensitisers. ALA was found to be useful in the 
treatment of dysplasia, but has a very superficial effect so is not indicated for 
treatment of invasive disease. Photofrin® and Foscan® have a much deeper 
effect and can be used to treat early cancer and superficial field change 
disease. Both drugs have problems of prolonged sensitivity to light varying from 
2 weeks (Foscan®) to 3 months (Photofrin®). Treatment times also vary from 
200s (Foscan®) to 1000s (Photofrin®).
The depth of effect limits the use of surface illumination to a maximum of 1cm, 
however, the use of interstitial therapy, where the light is delivered directly into a 
neoplastic tissue target allows more advanced cancers to be treated.
Currently, Foscan® is the only drug licensed for head and neck cancer and then 
only in the advanced or palliative setting where all other options have been 
exhausted or are not appropriate. While there is no single drug or technique for 
the treatment of all stages of oral cancer, PDT is now beginning to be used 
alongside surgery, radiotherapy and chemotherapy.
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Chapter 1: Oral Cavity Cancer - Epidemiology, Risk Factors, 
Histopathology and Prognosis 
1.1 Scope of this Thesis
Head and neck cancer includes cancers of the oral cavity, larynx, oral- and 
hypopharynx and salivary glands. The oral cavity includes the lips, buccal 
mucosa, anterior tongue, floor of mouth, hard and soft palate, upper and lower 
gingiva. Cancers of the oral cavity (orofacial cancers) comprise 40% of head 
and neck cancers and this thesis will concentrate on management of these 
cancers, (ie Lip, Oral cavity ICD 140,141,143-145 -  Appendix 2).
Squamous cell carcinomas (SCC) arise from the squamous epithelial cells lining 
the upper aerodigestive tract. These malignancies, and pre-malignant 
conditions, will be discussed in this thesis. In general, other carcinomas (such 
as basal cell carcinoma, adenocarcinoma, adenoid cystic carcinoma and 
pharynx - ICD 140,146-148 salivary glands ICD 142) are outside the scope of 
the thesis except in cases of advanced disease where palliative interstitial 
treatment was used. (Chapter 11).
1.2 Epidemiology
1.2.1 Geographical Distribution
Worldwide oral cavity cancer constitutes 267 000 cases, amounting to 2.7% of 
all cancers (Parkin et al 2001). While it is difficult to get accurate up to date 
figures, it is estimated that with accurate reporting, the most recent worldwide 
figures suggest there is little change. Globocan 2002 estimates are 274,289 
(Parkin et al 2005).
The highest incidences of head and neck cancer are found in Singapore and 
India. In South East Asia and particularly in India, cancer of the oral cavity is 
the most common cancer, comprising 35% of all cancers in men and 18% of all 
cancers in women (Shah et al 1999). The high incidence in South East Asia is 
attributable to the local habit of chewing paan (a mixture of tobacco, areca nut,
lime and other substances wrapped in a betel leaf). High rates are also 
reported for parts of South America, the Bas Rhin region of France (said to be 
related to Calvados ingestion), Eastern Europe and countries around the West 
Pacific.
In the US, American Cancer Society data suggests oral cavity cancer is the 
ninth most common cancer with 27,700 new cases per annum, accounting for 
2% of all malignancies, with a death rate of 7,200. In 1997, new cases of 
cancer of the oral cavity were estimated at 22,000 (Parker et al 1997) and 
deaths that year were estimated at 6,500. Within the US, there are marked 
geographical variations due to local habits such as the use of smokeless 
tobacco in the rural South (Winn et al 1981). Estimates from the American 
Cancer Society for 2005 are similar to these figures.
In 1990, Black et al (1997), estimated oral cancer (ICD-9 140-149) as the sixth 
most common cancer in men in the European Union (5.6% of all cancers for 
men, 1.4% for women Table 1.1).
Cases 
Per year
% all 
cancers
Mortality % mortality 
(all cancers)
United Kingdom 3655 1.6% 1932 1.2%
UK Males 2295 2% 1201 1.4%
UK Females 1360 1.1% 731 0.9%
European Union 48927 3.6% 19282 2.2%
EU Males 40240 5.6% 15467 3.1%
EU Females 8687 1.4% 3815 1%
Table 1.1: Oral Cancer Incidence (UK and EU, after Black et al 1997)
The incidence amongst the 38 countries in the United Nations defined area of 
Europe of oral cavity cancer (ICD 140 -  145) was nearly 50,000 cases (Bray et 
al 2002). The mortality in 1990 was estimated at 19,200. Across the European 
Union there are wide variations in the incidence, with that of France 
(approximately 50/100,000 men/year) being almost seven times that for Greece.
Such large geographical variation reflects differences in lifestyle risk factors 
such as alcohol drinking, tobacco smoking and the kind of tobacco used, along 
with dietary habits, all of which may have an independent effect on prognosis 
(Esteve et al 1996, Crosignani et al 1996).
1.2.2 Incidence by Anatomical Site
Cancer of the oral cavity is the most common site of head and neck cancers, 
comprising 40% of the total. By site of occurrence, the incidence in the US is as 
follows (Rice & Spiro 1989):
Oral cavity 40%
Larynx 25%
Major salivary glands 17%
Oral/hypopharynx 15%
Remaining head and neck sites 13%
Table 1.2: Cancer Incidence by Site in the Head and Neck
Within the oral cavity, the vast majority of tumours are squamous cell 
carcinomas of the mucosa, tongue and lip. Most primary squamous cell 
carcinomas of the oral cavity are located in those areas of the oral mucosa that 
are exposed to saliva: the lateral border and under-surface of the tongue, and 
the floor of the mouth (Shah et al 1999).
In descending order, the site distribution of primary SCCs is:
- Tongue
- Floor of mouth
- Cheek
- Gum
- Retromolar trigone
- Lip
- Soft palate
- Hard palate
In the areas of South East Asia and India where there is widespread use of 
paan, there is a correspondingly high incidence of carcinoma of the cheek 
mucosa, the retromolar trigone and base of the tongue, at the site where the 
quid is held in the mouth.
1.2.3 Incidence by Gender
In the US, cancers of the oral cavity are far more common in men, affecting
16.7 per 100,000 compared with 2.6 per 100,000 women. In all developed 
countries, the incidence of head and neck cancer in women is lower than in 
men (the overall annual age standardised incidence rate in the European Union 
has been estimated at 26 per 100,000 in men and 3.1 per 100,000 women 
(Black et al 1997) and geographical variability is less pronounced in women. 
However, over the last 50 years, the incidence of tongue carcinoma in women 
has nearly doubled, rising from 15% of all tongue cancers in the 1930s to 40% 
in the 1980s (Franceschi D et al 1993) probably due to an increase in 
consumption of tobacco and alcohol.
In the US, the incidence of carcinoma of the upper aerodigestive tract is two to 
three times higher in men than in women (Blair et al 1994) but the incidence in 
women continues to rise, probably as a result of increasing numbers of female 
smokers.
In areas such as India, where chewing and smoking are common among 
women, the incidence of tongue and other oral cavity cancers for women is 
greater than, or equal to, that for men.
The incidence also varies between socio-economic and racial groups. While 
the incidence and mortality of oral cavity cancer in white men has been falling 
slightly in the past 50 years, there has been a relative increase in black males. 
Black patients demonstrate inferior survival in all head and neck sites when 
compared with their white counterparts and the initial stage of disease at 
presentation tends to be more advanced (Parker et al 1997).
1.2.4 Incidence by Age
The incidence of head and neck cancer increases with age, with around 90% of 
all cases being diagnosed after the age of 40 (Miller et al 1990). The majority 
are diagnosed in the sixth and seventh decades of life (Rice and Spiro 1989).
1.3 Risk Factors
Certain patients have a high genetic and familial predisposition to the 
development of cancer, however, the influence of tobacco and alcohol exposure 
to the upper aerodigestive tract over-rides any underlying genetic predisposition 
that may exist.
1.3.1 Tobacco
The most significant risk factor for the development of head and neck cancers is 
smoking, with 90% of head and neck cancers occurring in smokers. Many 
studies have confirmed the association between smoking and head and neck 
cancer (for example, Keller et al 1965, Kahn 1966, Hinds et al 1980). The risk 
is proportional to the amount smoked (Spitz et al 1988). In parts of the world 
such as Andhra Pradesh, India, where the practice of reverse smoking is 
common, there is an extremely high incidence of oral cavity carcinoma (Reddy 
DG 1957, Reddy CR 1974).
Other forms of tobacco also contribute to the development of oral cancer. 
Chronic use of paan is associated with a high incidence of carcinoma of the 
cheek mucosa, retromolar trigone and base of the tongue in India (Shah et al 
1999, Schonland et al 1969). Smokeless tobacco, which is perceived by some 
to be a safer alternative to cigarettes, is associated with 50-fold increases in the 
incidence of gingival and buccal cancer in chronic snuff users in the US (Winn 
et al 1981, Schottenfeld 1981).
1.3.2 Alcohol
The addition of alcohol increases the risk of developing head and neck cancer 
(Keller et al 1965, Schottenfeld 1979). Either substance alone increases the 
risk of development of head and neck cancer (Herity et al 1982), but when 
tobacco and alcohol are used together, a synergistic effect increases the 
relative risk for development of cancer many times compared with non-users 
(Rothman et al 1972 Table 1.3, McMichael 1978, Hinds et al 1980). While a 
non-drinking heavy smoker is between two and a half (Rothman et al 1972) 
and five (Thompson 1989) times more at risk of developing head and neck 
cancer than a non-smoker, a heavy smoker who also drinks heavily increases 
the risk by a factor of 15 (Thompson 1989).
Cigarettes per day
Ethanol per day 0 1-20 21-39 40+
0 cm3 1.0 1.5 1.4 2.4
1-11 cm3 1.4 1.7 3.2 3.3
12-45 cm3 1.6 4.4 4.5 8.2
46 cm3+ 2.3f 4.1 9.6 15.5
Table 1.3: Relative Risk of Squamous Cell Cancer of the Oral Cavity Stratified 
by Tobacco and Ethanol Consumption
From Rothman et al 1972, computed from a case-controlled study of patients in 
the Veterans Administration Hospitals
Direct contact of the carcinogenic agents in smoke and alcohol appears to be 
an important factor in the mechanism of tumour development, hence the weak 
association between alcohol consumption and cancer of the larynx where 
contact is minimal (Russo et al 1996). These agents appear to induce field 
changes in all the mucous membranes with which they come into contact 
leading to multiple primary cancers (Blitzer 1988).
1.3.3 Genetic Basis
This complex area of research has suggested that a number of genetic events 
are necessary for cancer to develop. Alterations of tumour suppressor genes 
on chromosome 9p and 3p are present in oral cancer and precancer (Roz et al 
1996, Califano et al 1996). Forastiere et al, in the 2001 review, give an 
overview of this subject. They postulate that head and neck cancer derives 
from molecular changes in a common clonal progenitor cell, with inactivation of 
tumour suppressor genes, (most frequently p16 INK4Aand p53) or amplification 
of proto-oncogenes.
Some genetic studies of oral cancer suggest that single cell changes give rise 
to clonally related transformed damaged cells so that in patients with field 
change disease with multiple cancers arising within the same field these are 
often thought to be of a single clonal origin (re: Califano et al 2000 and Bedi 
1996). These clonal changes can affect large areas of the mouth and there is 
data to suggest that tissue most likely to progress to cancer comes from clonal 
genetic changes (Mao et al 1998).
The use of polymerase chain reaction technology has revolutionised our 
understanding of carcinogenesis. Studies using extracted DNA from normal, 
pre-malignant and malignant tissue has allowed the genetic changes that 
happen with progression towards cancer. The essential events are of allelic 
losses (chromosomal deletions) which result in tumour suppressor gene 
inactivation. This requires a two step inactivation process and a point mutation 
of one allele followed by deletion of the second allele resulting in complete loss 
of tumour suppressor function. Specific changes are noted in smoking related 
tumours with 3P21 being among the most frequently damaged chromosomal 
regions.
1.3.4 Other Factors
Dietary factors do not appear to play a direct role in the development of SCCs 
of the oral cavity but may have an effect on survival after diagnosis. It is difficult 
to separate out the role of diet in the aetiology of head and neck cancer as
nutritional deficiency is commonly associated with chronic alcohol consumption 
(Kissin et al 1973).
Less significant factors may also play a part in the development of head and 
neck cancer. For example, it has been noted that there was a topographic 
coincidence between chronic mechanical trauma from dental prostheses and 
tumour development in 44% of oral cancer cases (Thumfart et al 1978). Some 
chronic diseases including syphilis, candidiasis, erosive lichen planus, iron 
deficiency and AIDS have also been shown to be associated with an increased 
risk of oral cavity cancer (Fry et al 1929, Mackenzie et al 1980, Silverman et al 
1974, Watts 1961, Silverman et al 1986). Viral conditions, especially HPV type 
16, have been associated with squamous cancer of the head and neck. 
However, recent PCR work has suggested the importance of this has been 
exaggerated (Ha et al 2002).
Finally, there are some work-related risk factors where exposure to high levels 
of carcinogenic substances or sunlight induces cancers of the lip or oral cavity. 
Another example is the high risk of tongue cancer associated with using 
radioactive paints to paint watch faces although this is now of historical interest 
only.
1.4 Histopathology
Nearly 95% of cancers of the oral cavity arise from the surface epithelium and 
are therefore SCCs, the remainder being minor salivary carcinoma, melanoma, 
lymphoma and sarcoma (Batsakis 1974).
Microscopically, SCCs are graded according to cellular differentiation as well- 
differentiated, moderately differentiated or poorly differentiated.
Pre-malignant changes are often visible or present before the development of 
invasive carcinoma and a wider awareness of these changes would significantly 
improve detection and diagnosis. Most epithelial pre-malignant changes occur 
as white (leukoplakia) or red discolouration (erythroplakia) which are usually 
easily visible on examination. These changes reflect epithelial and sub- 
epithelial histomorphologic disturbances which include disturbances in the
keratin content of the epithelial layer and changes in the cellular cytoplasm. 
Further epithelial changes lead to development of hyperkeratosis, 
parakeratosis, dyskeratosis, carcinoma in situ (ie confined to the epithelium) 
and eventually invasive carcinoma extending through the basement membrane 
to the underlying tissue. These changes are not observed in all patients.
The risk of leukoplakia developing into invasive carcinoma has been estimated 
at approximately 4% to 6% (Pindborg et al 1968, Silverman et al 1984, Waldron 
et al 1975), while the risk of erythroplakia developing into invasive carcinoma is 
as high as 30% (Mashberg et al 1973). These terms have largely been 
abandoned and white or red patches are now graded in histological terms. Mild 
dysplasia is associated with a low risk of transformation (<5%) and severe 
dysplasia with a much higher lifetime risk of about 50%.
A varying degree of keratinization is usually present on the surface of a primary 
tumour, the extent of which is a reflection of the degree of differentiation of the 
underlying malignant process. Highly keratinized tumours are usually well 
differentiated and considered less likely to metastasise than poorly 
differentiated SCCs which show very little or no keratinization. Local extension 
by spread to adjacent structures may lead to invasion of the underlying soft 
tissues and muscles, bone or neurovascular structures. The spread of the 
tumour usually occurs by local invasion through lymphatics to regional lymph 
nodes or less commonly via bloodstream dissemination to distant sites.
1.5 Prognosis
In general, age-adjusted cancer death rates for patients with cancer of the head 
and neck have remained unchanged over the past 30 years (Silverberg et al 
1990). More recent data from Cancer Research UK suggests the situation has 
not changed significantly since this time (CRUK 2005).
Parker et al (1997 Table 1.4) report that overall five-year relative survival rates 
for cancers of the oral cavity and pharynx have remained unchanged at around 
55% since 1974 for white people and have in fact declined slightly for blacks 
(36% down to 33%). Reported survival rates for specific cancers suggest that
there has been little improvement for over 40 years (Martin et al 1940, Harrold 
1971, Martin et al 1935).
Oral cavity and pharynx 1974* 1997*
- all stages 55% 55%
- localised 78% 82%
- regional involvement 43% 44%
- distant metastases 20% 20%
Table 1.4: Representative Five-Year Relative Survival Rates for Cancers of the 
Oral Cavity and Pharynx 
§ Boring et al 1994; ¥ Parker et al 1997
Small improvements in survival rate have been claimed only in a few highly 
specialised treatment centres based on experience gained from a large number 
of cases (Shah et al 1999, Miller et al 1990).
Second primaries are the major threat to long-term survival after therapy of 
early stage head and neck squamous cell carcinomas. The high incidence of 
second primaries in this area probably arises from the same exposure to 
carcinogens that were responsible for the initial primary.
Several studies have demonstrated that the rate of development of second 
primary tumours in these patients is 3 to 4% per year, with 10.6% of patients 
developing a new primary over an average 3.4 year follow up (Day and Blot 
1992, Jovanovic et al 1994). This feature of oral cavity cancer is often referred 
to as "field cancerisation" where an entire region of tissue is exposed to 
carcinogens, thereby increasing the risk of that tissue developing multiple 
independent pre-malignant and malignant areas (Slaughter et al (1953), 
Lippman and Hong 1989 and 1992, Strong et al 1984).
Most patients (70% to 80%) present late in their disease course with advanced 
loco-regional tumour. The majority of patients with squamous cell carcinoma of 
the oral cavity die of local and cervical node recurrence and progression, while 
only around 10% die of distant metastases. (Vokes et al 1993, Dimery et al
1993, lldstad et al 1989). Clearly, improved local control strategies are the key 
to improved survival.
1.5.1 Site of Tumour
The site of the primary tumour has prognostic importance although this may 
partially reflect differences in the early recognition of symptoms and ease of 
assessment and treatment once identified. Early stage cancers of the oral 
cavity have a good prognosis with fairly simple treatment: five-year survival 
rates range from 75% to 85%. With advanced cancer the five-year survival falls 
to about 35% although many deaths are due to intercurrent disease.
The EUROCARE 2 study confirmed that five-year survival rates were highest 
for lip cancer, but low for cancers of the tongue and other parts of the oral 
cavity. Five-year relative survival of male patients with cancer of the tongue, 
mouth and pharynx was 34% (Sant 1999).
Tobias (1994) in his review of the data suggests that survival according to site 
decreases in the following order:
- Lip
- Larynx
- Oropharynx
- Nasal sinus
- Oral cavity
- Nasopharynx
- Hypopharynx
In advanced disease, the following survival rates are to be expected:
Cancer site Males Females
Pharynx - oropharynx 26.3 36.4
- nasopharynx 31.1 39.8
- hypopharynx 15.1 18.5
Oral cavity - alveolus 40.7 58.3
- floor of mouth 39.0 52.3
Table 1.5: Five-Year Percentage Survival Rates in Patients with Advanced 
Head and Neck Cancer (initial treatment with combined chemotherapy and 
radiation with surgery for resistant or recurrent disease)
Tobias 1994 after Cancer Research Campaign facts on Cancer Factsheet No 9
1.5.2 Stage of Disease
Although location of the tumour is a significant independent factor influencing 
survival, clinical stage at initial diagnosis is the single most important prognostic 
factor (see Appendix 1 for an explanation of the staging system). This is the 
case for all tumour sites (lldstad et al 1989). Patients with more advanced 
disease, represented by a larger primary tumour or more nodal involvement 
have less favourable survival prospects, thus confirming the importance of early 
diagnosis and treatment of oral malignancies.
Five-year relative survival rates are strongly linked to stage at diagnosis: 
patients diagnosed while the disease is still localised are four times more likely 
to survive than those presenting with distant spread of disease (Parker et al 
1997 Table 1.6).
Stage Tongue Floor of mouth
1 65 78
II 53 65
III 29 43
IV 20 18
Table 1.6: Overall Average Five-Year Survival for Patients with Squamous Cell 
Carcinoma Tumours (Parker et al 1997)
Each component of T, N and M is independently predictive. Nodal status in 
particular is highly predictive (South East Cooperative Oncology Group 1986) 
with the probability of spread to lymph nodes being highly dependent on the 
primary tumour site. Nasopharyngeal carcinomas, supraglottic larynx , floor of 
mouth, oropharyngeal and hypopharyngeal sites have very high rates of spread 
(Tobias 1994).
The location of the primary tumour is likely to dictate which nodes are involved 
but the sub-mandibular is the most common (level I) followed by upper, middle 
and lower cervical nodes (levels II - IV). The more node groups that are 
involved, the more serious is the prognosis for the patient, as this indicates 
more extensive spread of disease.
1.5.3 Other Factors
Geographical differences in survival between Western European countries are 
probably due to a difference in the case-mix of anatomical sub-sites, whereas 
the difference in survival between Eastern and Western European countries is 
more likely to be due to late diagnosis and referral or poor access to adequate 
treatment in the former (Berrino et al 1998).
Socio-economic background of patients with squamous cell head and neck 
cancer plays a significant role in the success of disease management. Limited 
access to medical care often results in patients presenting with advanced 
disease.
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Patient age at time of initial diagnosis and treatment has a significant influence 
on survival independently of tumour stage or location.
1.5.4 Second Primary Tumours
The co-existence of pre-malignant lesions such as leukoplakia and 
erythroplakia with an existing primary lesion greatly increases the chance of 
developing a second primary cancer (Sarasin 1933; Wilkins and Vogler 1957, 
Moertal and Foss 1958, Shibuya et al 1986).
Leukoplakia, a term describing a white patch or plaque that cannot be 
characterised clinically or pathologically as any other disease entity (Kramer et 
al 1978) has a propensity for malignant transformation. The rate of malignant 
transformation in leucoplakia is approximately 4% to 6% (Pindborg et al 1968, 
Silverman et al 1984, Waldron et al 1975). Histological grading of leucoplakia 
gives a different picture, with malignant transformation of oral epithelial 
dysplasia and leukoplakia with severe dysplasia quoted as 14% and 43%, 
respectively (Axell 1987, Lumerman et al 1995, Maerker and Burkhardt 1978). 
The incidence of multiple oral carcinomas in patients with primary tongue 
carcinomas associated with leukoplakia has been found to be five times greater 
than that of subjects without leukoplakia (Shibuya et al 1986) and has been 
variously reported as being from 7% to 30% (De Vries 1990).
The presence of an erythematous component, erythroplakia, or 
erythroleukoplakia increases almost four-fold the risk of malignant 
transformation (Silverman et al 1984).
The presence of more than one primary carcinoma has a profound influence on 
survival, and therefore management. Cohn and Peppard (1980) found that 75% 
of patients who developed second primary tumours in the upper aerodigestive 
tract died within 12 months of the second diagnosis. Carr and Langdon (1989) 
found that the average survival of patients with index oral cancers who 
developed second primaries was 7 months. Two-thirds of this series died less 
than 6 months after diagnosis of the second tumour. Gluckman and Crissman
(1983) found that overall five-year survival after diagnosis of a second primary 
was 22.3% (compared with 34% for a control group with single lesions).
Close follow up screening of all patients with a diagnosis of upper aerodigestive 
tract carcinoma is necessary to facilitate early detection of a second primary 
and recurrent disease.
1.6 Summary
From the available evidence it is clear that the aetiology of oral cancer is 
complex, with many factors evolving over time. However, chronic exposure of 
the oral cavity to alcohol and tobacco smoke especially when coupled with 
habits such as paan chewing result in widespread genetic alterations that lead 
to dysplasia and invasive cancer. Once this train of events has been set in 
motion, patients who develop oral cancer once have sufficient genetic damage 
to remain at risk of further metachronous tumours for the rest of their lives.
Chapter 2: Diagnosis and Management of Oral Cancer
2.1 Diagnosis
2.1.1 Clinical Presentation
Cancer of the oral cavity may present in many ways and any of the following 
signs are regarded with suspicion: ulceration which fails to heal, induration of a 
mucosal lesion, fungation or growth, fixation of the mucosa, failure to heal of a 
wound or extraction, white or red patches of the mucosa, pain or dysphagia with 
no apparent cause. Epithelial dysplasia indicates an increased risk of malignant 
change which may be prevented with early intervention.
Tumours usually appear as whitish plaques or ulcerations. They may be:
- Ulcerative: usually accompanied by irregular edge and induration of the 
underlying soft tissue
- Exophytic: may present either as a cauliflower-like irregular growth, or a flat 
pinkish-white proliferative lesion. SCCs with excessive keratin production and 
verrucous carcinomas appear as white lesions with varying degrees of keratin 
debris on the surface
- Endophytic: small surface component with substantial soft-tissue induration 
beneath the surface
- Superficial proliferative lesions
White lesions may be confused with mucositis, candidiasis, lichen planus or 
simple tissue irritation. Those that persist despite removal of local irritating 
factors should undergo biopsy.
Exophytic carcinomas usually have clear borders and also have a lower rate of 
lymph node metastasis. These lesions are suitable for surgery or interstitial 
radiation as the borders are well-defined and the chance of missing the margins 
is low. Overall, they tend to respond better to treatment of any kind.
The poorly differentiated tumours tend to be more infiltrative, with fingers of 
tumour cells extending far beyond the visible borders. This growth pattern is 
associated with a higher rate of regional lymph node metastasis and is usually 
more difficult to treat with surgery.
Dysphagia, glossodynia, otalgia, hoarseness, pain, weight loss and unexplained 
neck mass are very common presenting symptoms requiring further 
investigation.
2.1.2 Vital Staining
A number of vital staining techniques have been investigated such as toluidine 
blue and lugols iodine. The only commonly used technique is a modified 
toluidine blue application that is commercially available as Orascreen. This can 
increase diagnostic yield especially for the inexperienced clinician. (Mashberg 
et al 1989).
2.1.3 Optical Interrogation
Normal tissue has certain physical properties such as fluorescent impedance 
and light scattering that are different to those seen in abnormal tissue, either 
cancerous or pre-cancerous. These changes can be exploited in a non- 
invasive fashion using optical interrogation. Currently, Raman spectroscopy, 
auto- and enhanced fluorescence and elastic light scattering are all being 
investigated. The techniques tend to be inexpensive but as yet are not fully 
validated.
2.1.4 Genetic Analysis
There has been a great deal of interest in genetic changes (aberration) in oral 
squamous cell carcinoma. It is clear that series of molecular genetic events 
coupled with a reduced ability to repair or destroy dysfunctional cells is a pre­
cursor to the development of cancer. Identification of these changes 
(biomarkers) may help improve surveillance and identify high risk pre-malignant 
lesions.
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2.1.5 Imaging Techniques
Tumours of the head and neck can be fairly readily inspected and palpated, but 
there are occasions where imaging is appropriate and necessary, for instance, 
to assess the extent of bone invasion by a tumour of the jaw. Magnetic 
Resonance Imaging (MRI), Computerised Tomography (CT) and ultrasound 
scans (US) are important tools in the assessment of advanced tumours, 
particularly those in non-surface sites such as the base of the skull.
In evaluation of the nodal neck disease the issues are not so clear. CT and 
MRI are routinely used in disease staging. The management of the No neck is 
contentious and in the best hands ultrasound guided fine needle aspiration 
cytology increases sensitivity and specificity. Positron Emission Tomography is 
now in routine use in major centres around Europe and the United States. It 
images glucose avid tissues (the brain and tumours have increased glucose 
turnover) and at the same time localises this tissue to a CT scan to facilitate 
anatomical interpretation. This is particularly useful for identification of second 
primaries and metastases. It is also thought useful for follow up surveillance. 
Sentinel node studies have an established role in tumour staging of malignant 
melanoma and to some extent oral cancer. Both are the subject of clinical trials 
but are outwith the scope of this thesis.
2.2 Treatment Options for Oral Cancer
Clinically these tumours pose exceptional problems in management due to the 
poor prognosis in advanced cases, the inter-current medical problems 
frequently experienced by patients, and the adverse effects of treatment on oral 
and pharyngeal function. The proximity to vital structures in the head and neck 
region makes treatment difficult and often severely deforming.
Tumours in the oral cavity are often referred to as a single entity but are in fact 
a heterogeneous collection, with the natural history, prognosis and preferred 
therapy heavily dependent on the site of the original tumour. The goals of 
treatment are:
- To cure the cancer
- To preserve or restore form and function
- To minimise sequelae of treatment
- To prevent second primary tumours
Unfortunately, with existing treatments, the attainment of some of these goals is 
usually only achieved at the expense of others.
Surgical resection and radiotherapy, either singly or combined, are currently the 
main treatments for oral cancer. For small primary cancers (stages I and II,
without regional spread), either technique on its own can provide good local
control and long-term survival but often at the cost of functional or cosmetic 
impairment in the case of surgery, or short- and long-term side effects in the 
case of radiotherapy.
The initial choice of treatment is influenced by:
- site, size, location of tumour, proximity to bone and pathology
- status of cervical lymph nodes
- previous treatment
- patient's age, general medical condition, occupation, tolerance to treatment, 
anticipated compliance with treatment, lifestyle and socio-economic status
A patient with, for example, an early tumour of the larynx may be best treated 
with radiation initially as surgical treatment would almost certainly result in 
significant disruption to normal function. Multiple simultaneous primary lesions 
can be more easily treated with radiation than surgery. However, small lesions 
of the oral cavity - such as those on the lip, lower gum and retrimolar trigone, tip 
of the tongue, epiglottis, - can be treated effectively with surgery, with little 
disruption to function or cosmesis, thus avoiding the long-term adverse effects 
associated with radiation.
The oral cavity has several subgroups of patients who pose particularly difficult 
therapeutic challenges.
Dysplastic lesions of the oral mucosa may affect multiple sites and have diffuse 
margins, however, there are no widely accepted criteria for defining the 
presence and degree of dysplasia. It is also unclear which lesions require 
treatment, nor how aggressively such lesions should be treated (Speight et al
1993). Malignant transformation rates vary from 4% to 6% (Pindborg et al 
1968, Silverman et al 1984, Waldron et al 1975), while the risk of erythroplakia 
developing into invasive carcinoma is as high as 30% (Mashberg et al 1973). 
Leukoplakia may occur in conjunction with one or more primary tumours, -  a 
condition first described by Slaughter et al (1953) as field carcinogenesis or field 
cancerisation. Several studies have demonstrated that the rate of development 
of second primary tumours in these patients is 3 to 4% per year (Day and Blot 
1992, Jovanovic et al 1994). Many such patients exhibit a field change effect, 
so it may be necessary to treat large areas. Clearly a more helpful way of 
viewing this phemonenon is based on the genetic changes found in all these 
conditions (see 1.3.3).
In these circumstances, it may be difficult to treat all affected areas at any one 
time, so re-treatment may be necessary. Consequently, a modality that can be 
applied to large areas of the oral cavity that has little cumulative toxicity would 
be valuable.
All other factors being equal, isolated tumours in young patients may best be 
treated with an operation, to avoid the risk of long-term radiotherapy 
complications, while an elderly or frail patient may well be referred for 
radiotherapy even for lesions that could easily be treated by surgery.
2.2.1 Surgery
Surgery allows for more accurate tumour staging and determination of the 
pattern of spread of invasion and, given the high incidence of subsequent 
primaries in the head and neck, there is an advantage in withholding 
radiotherapy for subsequent use if required. However, if regional nodal 
involvement is suspected, then early radiotherapy of the nodes at risk is 
advised.
Conventional ablative surgery of the oral cavity involves tissue loss, scarring 
and the risk of damage to adjacent or underlying structures, as well as an 
overall 30 day operative mortality rate of around 1% to 2%. Early complications 
of surgery include haemorrhage, aspiration pneumonia and wound breakdown. 
Delayed complications include tissue loss -  particularly innervated tissue and 
contracture which affects function and appearance: however skilled the surgeon 
may be, operations for intra-oral carcinoma produce deformity and loss of 
function (Marchetta 1976).
Sophisticated reconstructive procedures have been developed and are often 
cited as evidence that surgery to the head and neck region can be non­
mutilating, but these are usually only available in highly specialised centres 
where they reflect the concentration of excellence associated with such 
institutions. Even in centres of excellence, patients who undergo glossectomy 
or composite resection will have significant residual cosmetic and functional 
debilities.
For many patients, surgery is simply not an option, because of generally poor 
health, or perhaps because of previous surgery to the head and neck region.
2.2.2 Radiotherapy
Radiation therapy is effective in the treatment of loco-regional disease. For 
early lesions, it gives results comparable to those achieved by surgery. SCCs 
of the head and neck are moderately radio-responsive, meaning that fairly large 
dosages of radiation are required to achieve good tumour control but these 
dosages are generally within the tolerance of the various structures of the head 
and neck. Many different radiation treatment schedules are in use and under 
investigation. In the US, a regimen of 180 to 200 cGy once a day for five days 
over six weeks has become standard for most patients (Eisbruch A et al 1999).
It is generally accepted that radiotherapy preserves function and cosmesis 
better than surgery but the treatment course itself is usually prolonged (five to 
seven weeks) and there are many associated short- and long-term unwanted 
effects.
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The primary target of radiation in the cell is DNA and most radiation-induced cell 
death results from radiation-induced DNA damage. This interferes with the 
reproductive capability of the cell which is usually manifested after several cell 
divisions. The effect therefore depends on the number of cells actively 
proliferating and the length of the reproductive cycle. Acute radiotherapy effects 
occur in tissues with high cell turnover: skin, bone marrow, gastrointestinal 
mucosa and hair follicles.
Short-term effects include skin desquamation, mucositis and aspiration. 
Radiation kills the stem cells in the basal layer, and several weeks later the cells 
in the superficial layers are not replaced when they are lost through normal 
physiological processes. This denudes the epithelium, giving rise to mucositis 
which greatly inhibits a patient's ability to swallow. The daily treatment 
schedule, in which the delivery of radiation is delayed, evolved to allow 
regeneration of normal tissue in an attempt to minimise this effect.
The major limiting factor to treatment is the total radiation dose, which can 
cause long-term unwanted effects on normal tissue. Long-term complications 
include dry mouth, muscle and subcutaneous fibrosis, soft-tissue and bone 
necrosis, spinal cord damage, blindness, cranial neuropathy, hypopituitarism 
and hypothyroidism (Berger et al 1977, Decroix et al 1981, Million and Cassisi 
1994, Samaan 1975). Eisbruch A and Dawson (1999) estimate that a total of 
65 to 79GY delivered in fractionated doses would lead to a 5% risk, over 5 
years, of developing osteoradionecrosis (ORN).
Salivary gland function and taste perception are altered by radiation (Mossman 
1983, Mossman et al 1979 & 1981). Decrease in saliva (xerostomia) and 
changes to its chemical composition cause alterations in the micro-organisms 
inhabiting the mouth, which in turn can cause a marked increase in caries. To 
reduce this problem and the potential for osteoradionecrosis, prophylactic 
dental treatment, including extractions, is usually carried out before treatment 
rather than waiting until problems occur in a heavily irradiated field.
Modern radiation techniques have diminished, but have not eliminated, these 
problems.
Concern has also frequently been expressed about the possibility of 
radiotherapy converting pre-malignant disease into anaplastic and frankly 
invasive carcinoma, and the long-term effect of radiation on the regional field 
mucosa remains unclear. Normal oral mucosa exposed to ionising radiation 
during the treatment of orofacial tumours displays abnormal DNA profiles, which 
although returning to normal within six weeks, retains the potential for latent 
radiation damage (Ogden et al 1989). Children and adolescents exposed to 
irradiation show a predisposition to neoplasia in the head and neck (Martin et al 
1970, Southwick 1977, De Groot et al 1983). Robinson et al (1991) report 
decreased mean survival times for patients with second primary head and neck 
cancers where index tumours received radiotherapy over patients who had 
surgery alone. For simultaneous primary cancers surgical resection may be 
feasible if two or more primary lesions are in close geographical proximity, but 
may require extensive reconstruction with unacceptable loss of function and 
cosmesis if occurring at different sites.
2.2.3 Combined Therapy
Patients with moderately advanced lesions will usually benefit from combined 
therapy given at the outset: loco-regional control rates with single-modality 
therapy are much less satisfactory than combined therapy in stage III and IV 
lesions.
The aims of pre-operative radiotherapy are to treat microscopic disease outside 
the resection field and to shrink the tumour before surgery. A dosage of 50 Gy 
over 5 to 51/4 weeks is usually given (Fletcher 1984).
Used post-operatively, radiotherapy can be tailored more accurately based on 
the surgical and pathological findings of the initial operation, and a greater 
knowledge of the tumour spread. However, a larger treatment volume may be 
required to cover surgical dissections and scars and there will inevitably be a 
delay to the start of radiotherapy in the post-operative recovery phase. When 
radiotherapy is post-operative, the site of the tumour has a disrupted blood 
supply due to the surgery, and higher doses will be required because of the
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increased likelihood that tumour cells will by hypoxic and therefore less radio­
sensitive. It is therefore usual to give doses of 55 to 60 Gy post-operatively.
Available data suggests that there is little difference in loco-regional control or 
survival between pre-operative and post-operative radiotherapy but post­
operative radiotherapy is the preferred option as operative morbidity is generally 
lower (Million and Cassisi 1994).
2.2.4 Salvage Procedures
If surgery or radiotherapy fail to control the primary tumour, salvage procedures 
are often compromised: surgery at the same site is often difficult, sometimes 
impossible, and repeated radiotherapy is not an option if the patient has already 
received the maximum allowable exposure of radiation (Million and Cassisi
1994).
The time required for late radiation complications to become clinically apparent 
ranges from 6 months to 2 years. As many re-irradiated patients do not survive 
that long, some studies on re-irradiation report an artificially low rate of 
complications. Stevens et al (1994) recommend re-irradiation only for patients 
showing minimum clinical evidence of late normal-tissue effects following the 
first course of radiation. The 5-year actuarial survival for patients selected and 
treated in this way was 37% for those with new tumours and 17% for those with 
recurrences. The total radiotherapy dose delivered to the volume of overlap 
ranged from 69 to 180Gy and severe adverse effects were seen in 9% of 
patients, including carotid artery rupture, brain necrosis, cranial nerve paralysis 
and narcotic overdose resulting from the need for strong pain relief.
Surgery can be carried out at previously irradiated sites and vice versa, as in 
the treatment of more advanced disease where surgery and radiotherapy are 
often combined, but neither salvage procedure is without difficulty. If irradiation 
is unsuccessful, the cancer almost always recurs in the centre of the original 
lesion and a rescue operation may result in a much more severe functional or 
cosmetic loss than if it had been performed initially. Also because radiotherapy 
produces an irreversible endarteritis oblitterans, tissue oxygenation is
permanently impaired. This diminishes tissue healing, hence surgical 
complication rates are generally increased following radiation. If surgery is 
performed as the primary treatment, there is concern about tissue oxygenation 
as a result of scar tissue formation. Radiotherapy response rates fall in areas of 
reduced oxygenation, so generally radiotherapists prefer to treat primarily and 
reserve surgery for salvage. Surgical recurrences usually develop at the 
margins of the resection where it is difficult to distinguish the normal surgical 
scar from recurrent disease. Diagnosis of recurrence is therefore often delayed 
and response of the tumour to radiation is poor. Salvage of surgical resection 
by radiotherapy is less effective than surgical salvage of radiotherapy failure 
(Wolfet al 1993).
Overall, salvage surgery or radiotherapy after initial definitive treatment has a 
very low success rate (Zieske et al 1986).
2.2.5 Chemotherapy
There is little evidence to support the role of chemotherapy in the management 
of locally advanced head and neck cancer. Chemotherapy has been shown to 
produce a high rate of tumour response, with rapid shrinkage when used before 
radiation or surgery. However, there has been little overall improvement in 
survival, probably because of the toxicity associated with chemotherapeutic 
agents.
Two recent reviews confirm that the role of chemotherapy is as an adjunctive to 
other treatments in advanced disease but has no role in early disease.
Adelstein et al (1996) report that many chemotherapeutic agents demonstrate 
excellent (anti)neoplastic activity yet have a minimal impact on survival in 
relapsed patients with median survivals ranging between five and seven 
months.
El-Sayed and Nelson (1996) reviewed prospective and randomised 
chemotherapy trials in the management of squamous cell carcinoma of the 
head and neck region. They confirmed that toxicity and morbidity were 
significantly increased (relative proportion 2.17) for a survival gain of 11%.
A more recent review (Pignon et al 2000) concludes that the impact on survival 
is too small to recommend the routine use of chemotherapy, particularly in early 
disease.
2.2.6 Combined Chemoradiation
Recently, there has been a move towards organ preserving therapies. This 
approach has been pioneered by Robbins in the USA and Lefebvre in Europe. 
Most studies have focusesd on laryngeal cancer, but advanced oral cavity 
cancer has also been treated. (Kumar and Robbins 2001, Lefebvre JL 2005).
2.3 Treatment Outcomes
Representative two year local control rates for squamous cell carcinoma of 
various sites of the oral cavity treated by radiotherapy with surgical salvage 
were reviewed by Laramore (1989). Percentages of each group going on to 
surgery and causes of death in patients with local control are not specified.
Tumour stage Local control (%) Survival (%)
Oral cavity - T1 80-90 75-80
T2 60-85 40-60
T3 30-50 20-30
Floor of mouth - T1 75-85 70-85
T2 60-80 50-60
T3 30-50 15-40
Base of tongue - T1 80-95 65-85
T2 60-75 40-55
T3 40-65 15-20
Soft palate - T1 90-100 90-95
T2 75-85 65-75
T3 60-70 30-40
Table 2.1: Representative two year local control rates and survival for SCC of 
common oral cavity sites. Note: Includes surgical salvage of radiation failures. 
After Laramore (1989)
2.3.1 Lip
Lip cancers of less than 2cm in size can be successfully treated with either 
surgery or radiotherapy with cure rates of about 90% for stage I tumours (Bailey 
1977), while still providing the patient with a lip that is competent for speech and 
chewing and without severely compromising appearance. Larger lesions are 
best treated with surgical resection and reconstruction (Jesse 1967) to eliminate 
the risk of osteoradionecrosis of the mandible. Lesions with extensive 
infiltration, bone involvement or lymphatic metastases are usually managed with 
combined surgery and radiation.
2.3.2 Oral Tongue
These account for around 25% of oral cavity SCCs. Almost all tumours of the 
tongue arise in the anterior two-thirds of the tongue on the lateral and ventral 
surfaces. Around 30-40% of patients present with neck nodes (Decroix et al 
1981, Spiro 1985) possibly due to the plentiful vascular and lymphatic supply to 
the tongue. Surgery and radiotherapy both produce similar local control rates 
for early tumours (Ti and T2).
For Stage I cancers, surgery can control the tumour with good preservation of 
function. However, for Stage II lesions, although hemiglossectomy achieves 
good control, it results in significant functional morbidity, seriously affecting 
speech and deglutition. Interstitial brachytherapy is therefore often selected to 
reduce the effect on function. To achieve the same control rates as surgery, 
brachytherapy has to be combined with external beam radiotherapy. 
Complications of radiotherapy to the tongue include soft-tissue necrosis which 
can affect nearly one-quarter of patients and mandibular necrosis which may 
affect around 13% of patients (Decroix et al 1981).
If the tumour has invaded bone, radiation therapy is less effective, requiring 
doses that would increase the risk of osteoradionecrosis. Complication rates for 
surgical salvage of failed interstitial implants are extremely high, particularly 
from fistulisation, exposed bone and failure of reconstruction efforts (Wolf et al 
1993).
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2.3.3 Floor of Mouth
The floor of mouth consists of the sulcus lying between the oral tongue and the 
lower gum or gingiva. Tumours in this region are usually squamous cell 
carcinomas, with an occasional minor salivary gland tumour being encountered. 
Unlike early tongue tumours, early floor of mouth tumours frequently involve the 
adjacent mandible, in which case surgery is the preferred primary treatment, 
necessitating some bone removal in order to ensure an adequate margin. 
Reconstruction of the mucosal defect may require local or free flaps and 
replacement bone segments where bone has had to be removed.
Radiotherapy to small floor of mouth cancers usually involves external radiation 
and brachytherapy. As thirty to forty per cent of patients with floor of mouth 
tumours have nodal metastases in the neck, bilateral elective neck dissections 
or radiation to the neck are commonly carried out (DiTroia 1972).
The outcome for early floor of mouth tumours is similar whether they are treated 
with surgery or radiotherapy (Guillamandequi et al 1980, Nakissa et al 1978) but 
the preferred option is surgery in order to reserve radiation for salvage therapy 
(Chu et al 1978, Shaha et al 1984).
2.3.4 Base of Tongue
Tumours of the base of tongue typically present late, and usually have a poor 
prognosis compared with oral tongue tumours. Although surgery and 
radiotherapy are equally effective for early base of tongue tumours, surgery is 
technically difficult because of the problem of exposure and invariably results in 
significant morbidity. Resections of the base of tongue disturb the swallowing 
mechanism and often speech. For these reasons primary radiation therapy, is 
favoured by most institutions for these tumours. This also has the advantage of 
treating associated nodal metastases, which are seen in about 68% of base of 
tongue tumours (Gibbs et al 2003).
2.3.5 Gingiva and Buccal Mucosa
These occur most commonly (80%) in the lower gingiva posterior to the 
premolar teeth. Overall, regional metastases occur in 30% of gingival cancers 
(Byers et al 1981) and 50% of buccal cancers (Bloom et al 1980). Small, 
superficial cancers of both sites can be treated with either surgery or 
radiotherapy with good preservation of function. Radiation therapy has the 
advantage of including the draining lymphatics in the treatment field but 
increases the risk of post-treatment fibrosis and trismus. Overall survival rates 
have improved over recent years as surgical management has replaced 
radiation therapy as primary treatment in the UK though not in parts of Europe 
and the USA.
2.4 Summary
While great advances have been made in surgery, radiotherapy and 
chemotherapy, all have drawbacks. There is clearly a need for a therapy that 
will achieve at least the same control rates as surgery and radiotherapy, with 
reduced morbidity, functional impairment and disfigurement, with the option for 
re-treatment at the same site, and which will not compromise surgery, 
radiotherapy or chemotherapy should they subsequently be necessary.
Chapter 3: Development of Photodynamic Therapy
3.1 Introduction
Photodynamic therapy has only become a viable treatment for cancer in the last 
two decades, largely through the efforts of German, French, Dutch and English 
workers, but the treatment of various conditions with light has a very long 
history.
One of the most easily understood and appreciated manifestations of the 
photodynamic effect is the photosynthetic reaction which takes place in all 
green plants, where natural daylight interacts with chlorophyll to absorb carbon 
dioxide and produce oxygen. At the same time, singlet oxygen is formed which 
would be immediately destructive if it were not quenched by orange and yellow 
pigments in plants.
The production of singlet oxygen is the fundamental action upon which all 
therapeutic applications of photodynamic therapy are based. In the clinical 
setting, a photosensitising dye is administered which is subsequently activated 
by light - usually a laser - the beam of which is directed at the area to be 
treated. When the sensitiser absorbs light of the appropriate wavelength it is 
converted from a stable state to the excited singlet state and a longer-lived 
triplet state. The triplet state interacts with molecular oxygen to produce singlet 
oxygen which is the highly cytotoxic species responsible for the therapeutic 
effect of photodynamic therapy.
3.2 A Brief History of Photodynamic Therapy
3.2.1 The Use of Light in Medicine
Nearly 3,000 years ago, the Greeks advocated a practice called heliotherapy in 
which the body was exposed to sunlight for unspecified beneficial purposes. 
Without being clear about the mechanisms, Herodotus, in the 2nd century 
stressed the value of exposure to the sun for "the restoration of health" (Daniell 
et al 1991). There is evidence that the Egyptians, Chinese and Indians used
light as a therapeutic agent in the treatment of diseases including vitiligo, 
rickets, psoriasis, skin cancer and some psychoses (Spikes 1985, Epstein 
1990). In 1815, it was reported that sunlight was effective therapy for rickets, 
although the role of vitamin D was not understood until much later. Cauvin, a 
French physician, stated that "sunlight is a curative agent for scrofula, rickets, 
scurvy, rheumatism, paralysis, swellings and dropsy and muscle weakness" 
(Cauvin 1815).
In the late-nineteenth century, a Danish physician, Niels Finsen, was 
responsible for establishing phototherapy as an area for serious scientific study. 
He reported in 1893 that treatment of smallpox lesions with red light could 
prevent suppuration and later established that it was the ultra-violet rays in 
sunlight that were responsible for their bactericidal properties. This led him to 
develop a method of treatment for lupus vulgaris using carbon arc phototherapy 
for which he was awarded the Nobel Prize in 1903 (Finsen 1901).
Princess Alexandra, who was to become the wife of Edward VII, brought her 
compatriot's technique to England and encouraged doctors in the London 
Hospital to use phototherapy. Phototherapy is still widely used today to treat 
neonatal jaundice.
Fig 3.1 : Finsen lamp treatment clinic early C20
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3.2.2 The Use of Sensitisers
Photochemotherapy, where exogenous sensitisers are used to absorb light, 
also has a long history, extending as far back as 1400 BC. There are 
descriptions of treatments in the Atharva-veda which show that Hindus gave 
oral administrations of extracts of Psoralea corylifolia followed by exposure to 
sunlight, for the treatment of vitiligo. It is now known that these extracts contain 
furocoumarins which are activated by light (FitzPatrick et al 1959).
In the 12th century AD, the Egyptians obtained psoralens from another plant, the 
Anmi majus which grows by the Nile and used it in the treatment of leucoderma. 
Much later in 1834, Kalbrunner isolated the active chemical bergapten (5- 
methoxypsoralen) from bergamot oil but there is no evidence that he used it in 
the same way as the Indians or Egyptians. It was not until 1974 that psoralen 
dyes activated by ultraviolet A radiation (PUVA) were found to be effective in 
the treatment of psoriasis (Harber and Bickers 1981).
The first clear demonstration of the photodynamic effect was made by Raab 
(1900) in the treatment of paramecia with acridine and light. His experiments 
led him to conclude that acridine could only kill the paramecia in the presence of 
light, but light could not kill the paramecia in the absence of acridine (Raab 
1900; von Tappeiner et al 1900). Development of the topic by von Tappeiner 
and other workers led to a recognition that oxygen is the third essential 
component of the photodynamic effect (von Tappeiner et al 1904) and in 1907, 
von Tappeiner first employed the term "photodynamic therapy" to describe the 
process of oxygen-dependent photosensitisation (von Tappeiner et al 1907).
Von Tappeiner was also the first person to attempt phototherapy of tumours in 
1904, when he used a topical application of 5% eosin solution - in some cases 
supplemented by intra-tumour injection - to treat lip cancers.
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Fig 3.2 : Eosin PDT for lip cancer 1905 (after Von Tappeiner)
3.3 Haematoporphyrin and it’s Derivatives
Haematoporphyrin was first made in 1841, by Scherer who added concentrated 
sulphuric acid to dried blood and washed the precipitate free of iron (Scherer 
1841). In 1867, the spectrum and fluorescence characteristics of this substance 
were described by Thudichum (Thudichum 1867). Hoppe-Seyler first described 
the purple substance found in iron-free haematin as haematoporphyrin, deriving 
the name from the Greek 'porphuros' which means red-purple (Hoppe-Seyler 
1871).
A number of animal studies were carried out in the early 20th century to 
establish the biological properties of haematoporphyrin (Hausmann 1908, 
Hausmann 1911, Pfeiffer 1911) and the first experiment in humans came in 
1913 when a German scientist, Friedrich Meyer-Betz injected himself with the 
substance (Meyer-Betz 1913). After deliberate light exposure he noticed that 
there was severe pain and swelling in the light-exposed areas and he had to 
avoid light for over two months.
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Fig 3.3: Meyer-Betz pre & post light exposure 1913
Over the next three decades Meyer-Betz and a German chemist Fischer, 
investigated various porphyrin structures for their phototoxicity, while other 
scientists began the first experiments of photodynamic therapy in tumour tissue.
In 1924 in Lyon, Policard observed that there was selective localisation of 
porphyrin to tumour tissue (Policard 1924) and this was confirmed in 1942 by 
Auler and Banzer, working in Berlin, who investigated the uptake of 
haematoporphyrin by tumour tissue in experimental tumours and found higher 
levels than in surrounding tissues (Auler et al 1942).
After the Second World War, Schwartz and colleagues (1955) found 
haematoporphyrin to be a variable mixture of numerous different porphyrins, the 
most pure of which also had the least affinity for tumours (Schwartz et al 1955). 
He made new preparations from the other fractions in order to isolate the more 
active components and eventually produced an acetic-sulphuric acid porphyrin 
which has come to be known as haematoporphyrin derivative (HpD).
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With this new agent, Lipson and colleagues at the Mayo Clinic localised 
tumours in the bronchus, oesophagus and cervix, achieving good correlation 
between fluorescing sites and biopsy-proven cancers (Lipson et al 1960, 1961, 
1964).
It wasn't until the 1960s that photodynamic therapy with HpD was used to treat 
tumours in humans. The first use of HpD to treat a large recurrent breast 
tumour was reported in a meeting in 1966 (Lipson et al 1996) and a single case 
of bladder carcinoma was reported in 1975 (Kelly et al). The first systematic 
trials in humans were initiated by Dougherty and colleagues in 1978 on a group 
of 25 patients, achieving complete or partial response in 111 of 113 cutaneous 
or subcutaneous malignant lesions (Dougherty et al 1978). The tumours 
included metastases from carcinomas of the breast, colon, prostate, squamous 
cell, basal cell and endometrium, malignant melanoma, mycosis fungoides, 
chondrosarcoma and angiosarcomas. It is interesting to note Dougherty 
includes malignant melanoma. One can only assume that this must be an 
amelanotic type, as light does not penetrate black melanotic tissue.
An important finding was that no tumour type was unresponsive to treatment: 
when applied correctly, photodynamic therapy will always produce necrosis.
Since these important early studies, HpD was investigated and found to be 
effective in a wide variety of tumours, using various light doses and sources 
(Misazumi et al 1983, Hayata et al 1982, Thomas et al 1987, Ward et al 1982). 
Although there was much room for improvement in the development of better 
photosensitisers and light sources, the principle of photodynamic therapy had 
been firmly established.
The next chapter describes in more detail the mechanisms of the photodynamic 
process and reviews the development of more pure and more active 
photosensitisers.
Chapter 4: Current Status of Photodynamic Therapy
4.1 Basics of Photodynamic Therapy
The three fundamental elements of PDT have been identified as oxygen, a 
photosensitiser and light. The photosensitiser is excited and activated by the 
light and interacts with molecular oxygen to produce an excited state - singlet 
oxygen - which is highly cytotoxic with a short lifetime (<0.04ps) and a short 
radius of action (<0.02pm). This reaction - called a type II reaction - is the most 
frequent photochemical pathway to cell destruction (Athar et al 1989, 
Grossweiner et al 1982), but the activated sensitiser may also react directly with 
parts of the cell structure causing the release of free radicals which then react 
further with molecular oxygen (type I). The initial photochemical reaction 
produces further radical chain oxidative reactions and a cascade of cell damage 
that make it difficult to isolate the initial site of action.
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Fig 4.1 : The principles of photodynamic therapy: Type I and Type II reactions 
[source: Bonnett 1995 p20, fig 2]
The direct cytotoxic activity and microvascular damage contribute to the 
destruction of tumour cells, which is manifested as swelling and formation of 
necrotic tissue (Foote 1990). This eventually sloughs away (or is re-sorbed) 
and is followed by normal healing and re-epithelialisation of the treated site.
The importance of oxygen in the phototoxic process is illustrated by the 
observation that hypoxic cells respond less well to photodynamic therapy (Pass 
1993, Denekamp 1992, Fingar et al 1992). Oxygen requires 94 kJ/mol to raise 
it from the triplet ground state to the excited singlet state. In photodynamic 
therapy this energy is acquired from the photosensitiser which has itself been 
raised to a high energy state. Only light-absorbing compounds which can emit 
energy greater than 94kJ/mol are therefore capable of activating ground state 
oxygen. This corresponds to an absorption wavelength of around 850nm: 
photosensitisers are therefore only suitable for photodynamic therapy if their 
activation wavelength is below this figure.
4.1.1 Mechanisms of Cell Killing
The mechanisms by which tumour cells are killed have been extensively 
researched (eg Lofgren et al 1994 and 1995, Foote 1990). Photosensitisers 
tend to accumulate in the mitochondria, lysosomes, and plasma membranes. 
Photosensitisers that localise in the cellular membranes have a direct cytotoxic 
effect which is noticeable within minutes of light exposure. On a light 
microscopy scale this can be seen as swelling and bleb formation. At a sub- 
cellular level there is shedding of vesicles containing plasma membrane marker 
enzymes, depolarisation of the membrane and general collapse of the ionic 
balance and cell structure.
Photosensitisers such as Photofrin® and 5-ALA which accumulate in the 
mitochondria may also achieve their photochemical effect through apoptosis. 
Apoptosis is a mechanism whereby organisms initiate a programmed cell death 
- or 'suicide' - resulting in fragmentation of nuclear DNA and dissociation of the 
cell into membrane-bound particles that are absorbed by other cells. Malignant 
cells often cannot undergo apoptosis which perhaps explains their resistance to 
chemotherapy (Vaux et al 1996, Samali et al 1996).
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Photodynamic therapy can induce an apoptotic response (Agarwal et al 1991) 
through the release of cytochrome c and other mitochondrial factors, which 
bypasses the normal programmed cell death mechanisms. Apoptosis can 
therefore be induced even in those malignant cells that have lost the ability to 
initiate their own cell death.
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Fig 4.2: PDT induced apoptosis showing blebbing of the plasma membrane 
with vesicle formation and karyorrhexis (discontinuity of the nuclear envelope)
(T Patrice, Nantes, France 1998)
The vascular effects of photodynamic therapy are also important in tumour 
control. The mechanisms differ according to which photosensitiser is used and 
include platelet activation and release of thromboxane, increased vascular 
leakage, platelet aggregation and blood flow stasis. The end result is the same: 
the microvasculature is damaged and tumour hypoxia results (Star et al 1986).
It is now generally believed that if light activation is carried out at a short interval 
following drug administration (the drug-light interval) cell death results from 
microvasculature shutdown with subsequent tumour anoxia and necrosis 
(Korbelik et al 1994, van Geel et al 1996, Wang et al 1997). If the drug-light 
interval is longer, cell death is achieved either via membrane rupture or 
apoptosis (Luo et al 1996, Kessel et al 1997, Ketabchi et al 1998).
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Research suggests that there may also be an immune response generated by 
photodynamic therapy (Korbelik 1996 and et al 1997). Korbelik et al claim that 
photodynamic therapy induces inflammation at the treated site, which causes 
invasion of activated myeloid cells. The implications of this are highly significant 
as it may be that application of photodynamic therapy to a local tumour could 
induce cell death in distant metastatic cells.
4.1.2 Selectivity of Effect
Although most photodynamic therapy treatments are carried out by the 
application of light to a very well-defined area such as a tumour or other lesion, 
one of the goals of photodynamic therapy was - and still is - to develop 
photosensitisers which will collect preferentially in the cells requiring treatment, 
while being completely cleared from surrounding normal tissue. It would then 
be possible to shine the activating light over a large area around the tumour, 
inducing necrosis in the tumour, but leaving normal tissue unharmed. In 
addition to simplifying routine treatments, this would be particularly useful in the 
treatment of multiple or poorly differentiated lesions. These present a particular 
challenge to the surgeon due to the difficulty in identifying the tumour margins 
and in removing rapidly advancing 'threads' of tumour cells that may extend far 
beyond the main tumour bulk.
There is evidence that photosensitisers are taken up and retained preferentially 
by neoplastic tissue but as yet this effect is not sufficiently pronounced to allow 
for a completely selective clinical response. If sufficient light is delivered then 
any tissue will be destroyed. The concentration difference between tumour and 
normal tissue ranges from 4:1 to over 12:1 for different photosensitisers (Ronn 
1999; Lofgren et al 1994). The highest tumour to normal tissue ratios are 
generally found in brain tissue (Kostron et al 1996).
The mechanisms of preferential distribution of photosensitisers in tumours are 
not yet fully understood and a number of explanations for the effect have been 
suggested. Probably more than one mechanism is involved. Simple pooling 
and retention of the photosensitiser could take place due to the large interstitial 
spaces and poor lymphatic network in tumour tissue (Henderson et al 1992).
Another suggestion is that the increased density of lipoprotein receptors in 
tumour cells could increase uptake of LDL-bound photosensitiser (Kessel D 
1986). This is clearly not the only mechanism as some photosensitisers that 
associate well with lipoproteins are poor tumour localisers; while other 
photosensitisers that are excellent tumour localisers have a poor affinity for 
lipoproteins.
A major focus of current research is to develop photosensitisers with increased 
selectivity for tumour cells.
As activated photosensitisers may also fluoresce while returning to the ground 
state, selective accumulation can be exploited in the fluorescence detection of 
tumours allowing a one-step process of detection and treatment.
4.1.3 Depth of Effect
Most photosensitisers are administered systemically, although some can be 
applied topically in the treatment of skin cancer and dermatological conditions. 
After a period of time to allow maximal accumulation of the photosensitiser in 
the target tissue, low power light of the appropriate wavelength is directed onto 
the tumour. The depth of effect which can be achieved depends on the 
absorption peaks of the photosensitiser employed. Photofrin® (porfimer 
sodium) for example has a number of absorption peaks between 400nm and 
650nm; benzopoporphyrin derivative has a maximum absorption peak at 690nm 
and Foscan® (temoporfin, mTHPC) has a strong absorption peak at 652nm.
As light passes through human tissue, a proportion is lost through scattering, 
reflection and absorption. This rate of loss per unit of thickness is called the co­
efficient of extinction and varies with the type of tissue and the wavelength of 
the light. Human tissue transmits light most effectively in the red part of the 
visible spectrum (Figure 4.3), and current research is directed towards 
developing photosensitisers with longer activation wavelengths which can be 
activated in this region, allowing for a greater depth of photodynamic effect. 
Photofrin® is usually activated at 630nm achieving a maximum depth of effect 
of 0.5cm (Gomer et al 1984, Wilson et al 1985) while temoporfin activated at
652nm has a depth of effect ranging from 1 to 1.5cm (Lofgren et al 1994, 
Berenbaum 1986b, Ris et al 1991).
Fig 4.3 : Transmission of light by human tissue
As most photosensitisers have more than one absorption band, this property 
can be exploited to control the depth of effect for various clinical applications by 
using different activating wavelengths. For example, temoporfin activated by 
green light at 514nm produces a depth of effect of 0.5cm.
4.1.4 Effect on Underlying Structures
As PDT is a cold photochemical process, there is no tissue heating involved, so 
it would be expected that connective tissues such as collagen and elastin would 
be largely unaffected. Barr et al (1987a) have demonstrated that collagen is 
preserved in the sub-mucosal layers of the rat colon treated with PDT using a 
sulphonated aluminium phthalocyanine. Although cross-linking of collagen 
fibres can be induced by singlet oxygen photo-oxidation, this process does not 
appear to compromise the mechanical properties and may even increase its 
resistance to deformation (Verweji et al 1981).
Endothelial cells have been shown to be highly sensitive to PDT injury, and 
indeed it has been suggested that this is directly responsible for the tumour 
necrosis observed following PDT (Berenbaum et al 1986a and 1990, Zhou et al
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1988, He et al 1991). Chaudhuri et al (1987) found that endothelial cells were 
more susceptible to PDT injury than tumour cells.
Photochemical injury results in a different type of injury from that observed with 
heat injury created by thermal lasers or diathermy. This non-thermal 
photodynamic injury does not damage or denature the sub-epithelial collagen 
and elastin, and the preservation of non-cellular supporting elements has been 
demonstrated, which suggests that the tissue architecture may be maintained 
while cellular and vascular elements are damaged. This may provide a matrix 
for regeneration of normal tissues and account for the excellent healing 
observed in most animal studies. The indications are that there is much less 
risk to the integrity of underlying structures than with thermal laser techniques 
and surgery.
Part of the research programme described in this thesis was directed at an 
assessment of the effect of photodynamic therapy on arteries (see Chapter 6).
4.1.5 Light Dose
The aim of photodynamic therapy is to disperse low power light over the surface 
area (or into the volume) of the tumour to initiate the photochemical process 
without inducing side effects such as thermal damage. This is in contrast to 
surgical laser treatments in which the light is used to cut or coagulate or for 
photoacoustic effects.
The light dose (or fluence) is expressed in terms of joules per unit of area: J/cm2 
and the rate at which this light is delivered (the fluence rate) is expressed in 
milliwatts per unit area: mW/cm2. This is relevant clinically as there is a limit to 
the rate of energy delivery which can be delivered to normal tissue before 
unwanted thermal effects are induced. Photofrin® typically requires light 
energies of 25 to 300J/cm2 to induce photoactivation for surface treatment and 
for interstitial treatment 100 to 400J for point sources or 100 to 400J/cm for 
diffuser applications. Foscan® on the other hand can be activated with light 
doses of less than 20J/cm2.
The fluence rate is an important factor in the efficiency of tumour response to 
PDT. At high fluence rates, it is hypothesised that oxygen consumption can 
outpace the rate of oxygen diffusion from surrounding capillaries resulting in a 
decrease of oxygen in the treated area and a reduced response (Foster et al
1991). High fluence rates (over 150 mW/cm2) also cause tissue heating so that 
a combination of PDT plus thermal effects results. Lowering the fluence rate 
has been shown to improve tumour response but also increases treatment 
times.
Reports from several centres have suggested that PDT effects might be 
enhanced by fractionating the light (van der Veen et al 1995, Foster et al 1991, 
Pe et al 1994, Messmann et al 1995). Using ALA, Van der Veen et al (1995) 
found that a 75-minute period between light treatments enhanced the effect 
(although the total light dose was higher in the fractionated dose experiments). 
Messmann et al (1995) found that a single break of 150 seconds during a 250- 
second exposure was capable of increasing the area of a PDT-induced ulcer in 
normal rat colon by a factor of 5 compared with the same total light dose 
administered without a break. They suggested that the break permitted re­
oxygenation of the tissue, therefore when the light was applied for the second 
fraction, there was more oxygen available for a PDT effect.
The time at which the break was made markedly influenced the effect (the effect 
was greater with an earlier break) but there was no advantage in having more 
than one break. It is not clear from this work whether fractionating the light 
increased the maximum area of necrosis achievable or just made it possible to 
achieve the same area of necrosis with a smaller total light dose.
4.1.6 Treatment Times
Treatment times vary considerably and are related to the absorption of light by 
the photosensitiser and the efficiency of conversion of the light to oxygen.
As was described in the introduction to this section, only those sensitisers that 
can emit more energy than 94kJ/mol are capable of activating singlet oxygen. 
The most efficient photosensitiser therefore would be one which yields one
molecule of singlet oxygen for each photon absorbed - the quantum yield. The 
more efficient photosensitisers have a higher quantum yield: Photofrin® has a 
quantum yield of around 0.5 and is not therefore a particularly active 
photosensitiser whereas Foscan® is a more efficient generator of singlet 
oxygen with a quantum yield of around 0.87.
In order to achieve the desired level of tissue necrosis, Photofrin® requires 
treatment times which can be unacceptably long if large areas have to be 
treated. Typical treatment times for these earlier sensitisers are 15 to 40 
minutes; newer photosensitisers such as Foscan® can induce effective cell 
killing with the application of around 200s of low power laser light.
4.1.7 Side Effects of Photodynamic Therapy
All photosensitisers currently in use or in development are inherent of very low 
systemic toxicity in the absence of light. However, systemic administration of 
the photosensitiser leads to a period of unwanted residual photosensitivity that 
must be managed until the drug is eliminated. Exposure to sunlight before the 
photosensitiser has been eliminated causes a reaction which resembles 
sunburn but is in fact simply a continuation of the photodynamic reaction. If 
exposure continues for long enough, blistering and full thickness necrosis will 
occur. During faulty administration, high concentrations of photosensitiser can 
build up in extravasated areas. These must be covered with opaque dressings 
to avoid serious burns. The earlier photosensitisers have a residual 
photosensitivity of eight to ten weeks; this has been reduced to two weeks with 
the newer agents and is expected to decrease still further as new 
photosensitisers are developed.
While residual photosensitivity is a problem and can be inconvenient to the 
patient, it is of relatively little significance compared to the adverse effects of 
chemotherapy and radiotherapy.
Unlike treatment with laser ablation, the light used in PDT is 'cold'. However, a 
significant number of patients complain of a burning sensation during treatment 
with power densities of up to 100mW/cm2 despite the fact that measurements of
skin temperature during treatment have recorded no increase (McCaughan 
1999). The burning sensation is probably due to the photodynamic process 
rather than any thermal effects.
Since most photodynamic therapy photosensitisers do not accumulate in cell 
nuclei, photodynamic therapy is unlikely to cause DNA damage, mutations or 
carcinogenesis (Moan 1986). This is in direct contrast to cytotoxic 
chemotherapy, which is specifically designed to interfere with cell replication.
4.1.8 Light Sources
Light emitting diodes (LEDs) and xenon lamp sources are commonly used for 
dermatological applications, but lasers provide the most convenient and 
controllable light source. Laser light is coherent and monochromatic and can be 
directed along fibre optic cables, allowing light to be introduced into hollow 
organs and deep-seated tumours.
A number of metal vapour and tuned-dye lasers are available which can be 
adjusted to emit over a range of wavelengths appropriate to various 
photosensitisers. These are expensive and large but do have the advantage of 
being tunable to various wavelengths, which may become a more valuable 
characteristic when photodynamic therapy is a mainstream treatment in PDT 
units employing a number of photosensitisers.
Diode lasers, which are much less expensive and more portable than metal 
vapour or tuned-dye lasers, have become an attractive light source. Multiple 
low power diodes are used in phased arrays to produce a high power light 
beam. Diode lasers operating in the region of 660 to 700nm and others 
operating in the region of 780 to 850nm are now readily available.
The laser beam is usually guided through a fibre attached to a microlens to 
allow for uniform irradiation. Spherical or cylindrical diffusing tips are usually 
used for direct insertion of the fibre into a tumour mass.
4.2 Photosensitisers
Most photosensitisers - with the exception of 5-aminolaevulinic acid are 
composed of interlinked pentacyclic hydrocarbon rings which resemble the 
basic porphyrin structure (the tetrapyrole group). While the porphyrin skeleton 
is not a prerequisite for photodynamic activity, the advantages of this structure 
are that it seems to lead to compounds that are efficient generators of singlet 
oxygen when activated by light; are usually non-toxic in the absence of light; 
have good to strong absorption bands in the red part of the visible spectrum and 
are reasonably stable.
The main compounds currently in development, are the macrocyclic 
tetrapyroles -  porphyrins, chlorines (similar to chlorophyll a), purpurins, 
benzoporphyrins, and naphthalocyanines.
The four photosensitisers used in this research programme are described 
below.
4.2.1 Photofrin® (porfimer sodium)
More than one hundred years after the isolation of the first haematoporphyrin, 
Photofrin®, a pure and reasonably consistent derivative, was made available 
commercially by QLT, Canada. Photofrin® was developed by Dougherty et al 
(1984) and is the most active photosensitiser component in haematoporphyrin 
derivative. Even in this purified state, the commercial preparation contains 
around 20% of inactive monomers and 80% of the active porphyrin dimers and 
oligomers.
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Fig 4.4 : Structure of Haematoporphyrin [source after Bonnett 2000]
It is given intravenously at a dose of 2 to 5mg/kg bodyweight and circulates in a 
number of forms: as unbound aggregated components; bound to albumin and 
globulins (monomer); and lipoproteins (dimers and oligomers) (Jori 1989). The 
active component of Photofrin® is mostly deposited in the mitochondria, 
lysosomes and plasma membrane.
The optimum drug-light interval is one to two days and although the drug has a 
strong absorption peak in the blue/violet region at 405nm, the weakest peak at 
630nm is usually used in order to maximise the penetration of light into human 
tissue (Gomer et al 1984, Wilson et al 1985).
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Fig 4.5: Absorption peaks [Axcan Pharmaceuticals Inc].
At this wavelength (650nm), the penetration of light is in the range of 1 to 5mm 
(Driver et al 1991, Wilson 1986) therefore the achievable depth of effect with 
Photofrin® is limited to 0.5cm.
Relative uptake between tumour and normal tissue is not high being in the 
region of 4:1 with no discernible difference in for instance the pancreas.
Residual cutaneous photosensitivity is around eight to ten weeks (Dougherty et 
al 1978, Oseroff 1993, Pass 1993). The efficiency of conversion of light to 
cytotoxic products (the quantum yield) is moderate (~0.5) and treatment times 
are therefore relatively long.
Despite these limitations, Photofrin® is a useful drug that established the 
credentials of photodynamic therapy as a valid treatment for a wide range of 
malignant and non-malignant conditions. It is licensed in various countries for 
the treatment of early and late-stage lung and oesophageal cancer and for 
gastric and cervical cancer, and is being studied in other areas such as Barrett's 
oesophagus, cancer of the larynx and prostate, skin cancers and metastatic 
cutaneous and subcutaneous breast cancers.
4.2.2 5-Aminolaevulinic Acid
Instead of administering an exogenous porphyrin, 5-aminolaevulinic acid has 
been used to generate endogenous protoporphyrin. 5-aminolaevulinic acid
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(ALA) is a naturally-occurring precursor of haem whose production is controlled 
by negative feedback inhibition of the end product on the enzyme ALA synthase 
(Rimington 1966). However, if excess exogenous ALA is given, this feedback 
control is bypassed, leading to a build-up of protoporphyrin IX (PPIX) (Divaris et 
al 1990). Since PPIX is an effective photosensitiser (Malik et al 1987) this 
mechanism makes it possible to sensitise cells capable of haem synthesis. 
Because administration of ALA only temporarily overloads the natural synthetic 
pathway, photosensitisation lasts no more than several hours.
Glycine + Succinyl CoA 
ALA synthetase j  4 ■ —
ALAr
Porphobijinogen 
Uroporphyrin III ■*—  Uroporphyrinogen III NEGATIVE
Coproporphyrin III <—  Coproporphyrinogen III
I
PPIX
Ferrochelatase
Fe++
Rate limiting 
step
HAEM
FEEDBACK
Fig 4.6 : The haem synthetic pathway -  administration of ALA results in an 
increase of PPIX
ALA has an optimal drug-light interval of three to six hours and requires a light 
dose of around 50J/cm2 delivered at 630m, but it can also be activated by green 
light at 543 to 548nm (Fritsch et al 1997) and blue light.
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Fig 4.7 : Structure of 5-aminolaevulinic Acid
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Fig 4.8 : Structure of Protoporphyrin IX. [source: Bonnett 1995 p26]
A major advantage of ALA is that, even after systemic administration, 
cutaneous photosensitivity lasts at the most one to two days (Mustajoki et al
1992). Tissues treated with ALA photodynamic therapy heal remarkably well, 
making it feasible to treat extensive superficial lesions in the mouth (Grant et al 
1993b).
PPIX has been shown to accumulate more in the epithelium than in the 
underlying muscle of hollow organs like the Gl tract (Loh et al 1993b) with the 
consequent possibility of selective damage to this layer following PDT.
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ALA can be delivered in topical, oral or intravenous formulations. The 
maximum dose of ALA tolerated by mouth may be only just above the threshold 
dose for producing a PDT effect (ie 60mg/kg). Intravenous formulations halve 
the dose required to achieve specific tissue levels (30mg/kg), therefore the first 
pass metabolism in the liver which leads to increased transaminase levels 
associated with oral administration (Regula et al 1995) is avoided and the 
maximum tolerable dose may be higher.
The uses of 5-aminolaevulinic acid are constrained by its depth of effect 
(<0.2cm) to superficial lesions. 5-aminolaevulinic acid has been licensed for the 
treatment of actinic keratosis and has shown good results in the treatment of 
basal cell carcinoma (Kennedy et al 1990, Peng et al 1995, Calzalvara-Pinton 
1995, Wennberg et al 1996). Areas under investigation include the oesophagus 
(Gossner et al 1998), metastatic breast cancer to the skin (Cairnduff et al 1994) 
and superficial urothelial cancer (Peng et al 1997).
4.2.3 Sulphonated Aluminium Phthalocyanine
The phthalocyanine structure is similar to the porphyrin configuration but with 
some differences which shift absorbance to the 650 to 700nm region. 
Phthalocyanine and the related naphthalocyanines have intense absorbance in 
the red region, with the naphthalocyanine absorbance band reaching as high as 
800nm. Due to the high extinction co-efficients, some phthalocyanines are very 
potent PDT agents. They are conjugated with a number of metals, the most 
efficient being zinc and aluminium which extend the triplet state lifetime.
Disulphonated aluminium phthalocyanine given in typical doses of 0.5 to 
1.5mg/kg is illuminated at 675nm and light is delivered between 150 and 
600J/cm2 at a fluence rate of more than 50mW/cm2. This is a high light dose, 
which leads to relatively long treatment times for any but the smallest tumours.
Disulphonated phthalocyanine has been shown to be a highly potent sensitiser 
in vivo in a variety of animal tissues (Chatlani et al 1991, Nuutinen et al 1991, 
Loh et al 1992). They have been extensively investigated by Stranadko et al 
(1994 and 1997) in various clinical applications such as gynaecological and oral
malignancies. However, despite extensive use in Russia, this group of drugs 
has not been used in human studies in the UK. Animal studies suggest a 
similar effect to Photofrin® but with a marked reduction in photosensitivity post 
administration.
Fig 4.9 : Structure of Pthalocyanine [source: Bonnett 1995 p29]
4.2.4 Tetra(m-hydroxyphenyl)chlorin, mTHPC, Foscan®
Foscan® belongs to a group called the chlorins in which the double bonds on 
the porphyrin rings are progressively saturated. Chlorin has one double bond of 
porphyrin reduced, bacteriochlorin has two bonds reduced. This results in a 
shift of the absorption peaks towards the visible red region. Foscan® is a single 
compound of 98% purity (Wagnieres et al 1998) and is isometrically pure. The 
drug is only sparingly soluble in water and therefore requires formulation to 
obtain an injectable product.
Fig 4.10: Structure of mTHPC [source: Bonnett et al 1989]
Major absorption peaks for Foscan® are at 652 and 514nm. Red light of 652nm 
penetrates human tissue better than at 630nm, so a greater depth of effect can 
be obtained. It is a little unclear why such an enhanced depth of necrosis is 
obtained with such a small wavelength shift so generating tissue necrosis of 
over 1.5cm.
The optimum drug-light interval is four days and the usual dose for therapeutic 
PDT is 0.15mg/kg. It preferentially accumulates in tumour tissue to a 
concentration of up to twenty times normal tissue. Early clinical work with PDT 
on the tumour bed after resection of mesotheliomas showed that a dose of 
0.3mg/kg mTHPC, activated at 650nm with a dose of 10 J/cm2 could produce 
10 mm depth of necrosis with good healing.
Residual photosensitivity is in the region of two weeks (Wagnieres et al 1998).
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Fig 4.11: Absorption peaks for mTHPC
Foscan® is the most active of all photosensitisers currently undergoing 
investigation, with a quantum yield of singlet oxygen of 87 when activated at 
652 nm. It has a low activation energy at 652 nm requiring light doses as low 
as 10 J/cm2 for photodynamic effect, although the usual light dose is 20 J/cm2 
with a fluence rate of 100 mW/cm2.
Drug doses are also correspondingly low, being only 0.1 mg/kg to produce a 
therapeutic effect. Treatment times under these conditions are typically in the 
order of 200s. A study on the murine-RIF-1 tumour showed that Photofrin® 
requires a light dose 4 to 13 times higher than that required by Foscan® for a 
similar anti-tumour effect (van Geel et al 1995).
4.3 Advantages of Photodynamic Therapy
Photodynamic therapy (PDT) is a relatively new approach to the treatment of 
malignant conditions. It is minimally invasive and unlike ionising irradiation, can
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be carried out repeatedly at the same site. It has particular appeal in oncology 
as the use of chemotherapy, ionising radiation or surgery does not preclude the 
use of PDT, and all of these techniques can be used in the PDT-treated patient.
The simplicity of the process has much to offer the clinician. Treatment of 
superficial tumours is often carried out with local anaesthesia and sedation.
The lack of major systemic toxicity (other than residual photosensitivity) limits 
the need for post-treatment co-medication. Superficial treatments do not 
require sterile theatre conditions and may be carried out in an out-patient clinic.
Using interstitial techniques photodynamic therapy can be applied to large and 
deeply buried tumours that would otherwise require extensive resection, or may 
even be impossible to treat with surgery. On the other hand, the depth of effect 
in superficial applications can be controlled to treat extensive areas of diffuse 
pre-malignant change without major morbidity.
It appears that every type of tumour cell, whether mesodermal, endodermal or 
ectrodermal in origin is sensitive to the PDT process. The problem of multi-drug 
resistance, which is a serious limitation in conventional oncology, does not 
apply to PDT; even cell lines showing multi-drug resistance can be killed by 
PDT (Stewart 1999).
4.4 Potential Applications of PDT in the Oral Cavity
Pre-malignant dysplastic lesions or non-invasive cancers are common in the 
mucosa of the aerodigestive tract. Treatment of a pre-malignant lesion before it 
becomes invasive is clearly desirable and preferable to treatment of a solid 
malignancy. Eradication of the lesion at this stage will also minimise the risk of 
metastatic disease. However, current treatments for pre-malignant conditions 
are far from satisfactory (see Chapter 2). Surgery requires general anaesthesia 
and carries significant morbidity including functional impairment and 
disfigurement. Radiation therapy is effective but is rarely justified in terms of the 
acute and long-term adverse effects and can typically only be administered 
once.
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Photodynamic therapy is emerging as an attractive treatment for mucosal 
dysplasia and CIS as a wide area of mucosa, including areas of apparently 
normal mucosa, can be treated superficially.
The studies described in the remainder of this thesis were designed to 
investigate the safety of PDT and its efficacy in early and advanced disease of 
the oral cavity.
Despite all of the potential mechanisms of cell death following PDT there is no 
doubt that the chemical reaction in response to singlet oxygen production is a 
very rapid event following illumination. Some of the mechanisms may be by 
apotosis and necrosis, which are dependent on variable drug dose, light dose 
interval and light dose as well as the physiology of the tumour. Some tumour 
effects seem to be related to microvascular damage with some subsequent 
anoxia. However, as cell death is of rapid onset following PDT it is not really 
necessary to speculate on events that occur beyond the immediate illumination 
time to explain the outcome of treatment (Thibaut et al 2002).
Chapter 5: Description of the Research Programme
5.1 Introduction
The overall aim of the research programme at UCL was to define the clinical 
response of normal and malignant tissues in the oral cavity to photodynamic 
therapy using a number of different photosensitisers, and in conditions ranging 
from pre-malignancy through early disease to advanced disease. Two initial 
safety studies were carried out, followed by clinical studies in which the 
intention was both curative and palliative. The four photosensitisers used in the 
programme were 5-aminolaevulinic acid, Photofrin®, di-sulphonated aluminium 
phthalocyanine and Foscan®, although to date I have not carried out any 
human treatments with di-sulphonated aluminium phthalocyanine.
At the start of this clinical programme, there had been a number of studies 
carried out on animal models, but very little clinical work. The main body of 
experimental work relevant to oral cavity cancer was carried out by Maurice 
Meyer (Meyer et al 1991), who studied the effects of disulphonated aluminium 
phthalocyanine PDT on the oral mucosa and other tissues of the rabbit. He 
designed an ingenious series of experiments using the socket of an extracted 
lower incisor tooth of the rabbit. By passing a laser fibre along the socket 
(which is about 4cm long), he was able to carry out a series of treatments in 
which the mandible, salivary gland tissue, muscle, cartilage and oral mucosa 
were illuminated.
Salivary gland
Tooth socket
Salivary gland
Fig 5.1: Experimental set-up for PDT effects on normal rabbit mandible and 
surrounding tissues (Meyer et al 1991)
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A number of rabbits received disulphonated aluminium phthalocyanine PDT at 
varying doses and with varying light doses. Some control rabbits received drug 
and no light and others received light and no drug. After serial sacrifice Meyer 
made a number of important observations of the histological effects of 
disulphonated aluminium phthalocyanine PDT on normal oral tissues, which are 
summarised below.
Tissue treated PDT effect
Mucosa / gingival Sensitive at low doses. Necrosis with complete 
regeneration.
Muscle Dose-related, sensitive at high doses. Necrosis with 
scarring
Salivary gland Dose-related, sensitive at high doses. Some necrosis 
with scarring
Nerves Little effect
Bone Little damage. Slight delay in healing
Cartilage No effect
Table 5.1: Summary of PDT effects on normal rabbit mandible and surrounding 
tissues (Meyer et al 1991)
Although this was a study on normal tissue, there was little selectivity of effect 
between different tissues. However, the key finding was that almost all tissues 
healed or regenerated well following PDT. In particular, mucosa underwent 
consistent full thickness necrosis, but healed without any noticeable scarring. 
This of course has major implications for the treatment of large areas of oral 
mucosa, as it suggests that it would be possible to achieve healing without any 
disruption of the mucosal surface. The damage to the salivary glands was of 
some concern, but this was to some extent reversible and merely localised to 
the area of illumination and bone cartilage and nerves were relatively 
unaffected.
5.2 Other Safety Studies
A small number of other safety studies had been carried out. Suzuki et al 
(1987) described endothelial cell loss in aortas of rats treated with HpD PDT. 
They observed no other damage to the vessel wall and found that endothelial 
cell regeneration occurred within five days. The thickness of these large 
vessels may have allowed preservation of the endothelium along the posterior 
surface of the aorta due to limited light penetration, allowing the opportunity for 
endothelial regeneration in a short time.
Studies of PDT-treated rat colons (Barr et al 1987b) and rat tracheas (Smith et 
al 1993) have shown preservation of mural collagen and no reduction in the 
hydrostatic pressure required to rupture the treated organ. These studies 
clearly demonstrated that the PDT effect was generally well tolerated by normal 
(animal) tissue, but the extent of experience at this stage was very limited. PDT 
effects on skin had been studied in the 80s by, for example Benstead and 
Moore (1988) showed skin necrosis was dependent on the size of the 
illumination spot and that shielded tissues provided capillaries to grow into 
treated areas and prevent necrosis
5.3 Clinical Studies
At the start of this programme (in 1991), there was little published clinical data 
for head and neck cancer. While the work carried out by Hayata and Kato 
(1982, 1984 and 1993-Hayata only) in Japan using haematoporphyrin and 
Photofrin® had demonstrated a clear use for PDT in the management of lung 
cancer, the situation with head and neck cancer was less clear. Zhao in Beijing 
reported a series of 72 patients with oral squamous cell carcinoma using 
haematoporphyrin derivative (Zhao et al 1991). While the results were very 
impressive, there was a huge variation in drug and light dose used with no clear 
indication how or why the treatment parameters were chosen.
Wenig and Gluckman had just published their experiences with HPD and 
Photofrin®. These studies were more consistent in their design with light doses 
of 50 or 100J/cm2 (Gluckman 1991b) and 125J/cm2 (Wenig et al 1990). The
numbers at specific anatomical sites and the stages of disease were varied so 
that numbers of patients in each group were small. However, the results of 
treating T1 and T2 oral cavity cancers were certainly encouraging with initial 
complete response rates of 77% (Wenig 1990) and 85% (Gluckman 1991b).
5.4 Research Programme
The above is a brief outline of the state of PDT knowledge at the time of setting 
up the programme. Clearly there were a number of unanswered questions 
about normal tissue tolerance to PDT and there was almost no scientific 
rationale for treating head and neck cancer in humans. Sporadic clinical reports 
had appeared in the literature, but there was no standardization of treatment 
parameters. The goal of the research programme carried out at UCL was to 
establish the safety and efficacy of PDT as a treatment for oral cancers. The 
studies described below were carried out.
5.4.1 Animal studies to Determine The Effects of Photodynamic Therapy 
on Vital Structures
Several studies were undertaken under my co supervision to determine the 
ability of normal tissue to tolerate PDT treatment. The most important of these 
were on major blood vessels in the neck
5.4.2 Pilot Studies to Assess Photodynamic Therapy Effects on Human 
Tissue
In this series of studies, we tried to evaluate the PDT effects on (human) oral 
cancer and the surrounding normal tissue. This was done with a series of treat 
and excise and treat and biopsy studies. Three sensitisers were used 
Photofrin®, Aminolaevulinic Acid and Foscan®.
5.4.3 Clinical Studies of Photodynamic Therapy at Different Stages of 
Oral Cancer in Humans
Having worked out the histopathological effects of PDT on normal and 
neoplastic tissue, we were then able to investigate the treatment of various 
stages of oral cancer from dysplasia to advanced disease. We used three 
photosensitisers and tried to identify the most appropriate treatment for each 
disease stage.
All aspects of these clinical studies were under my direct care and supervision 
and carried out at University College London Hospitals NHS Trust.
Chapter 6: Animal Studies to Investigate the Photodynamic Therapy 
Effect on Normal Tissues 
6.1 Introduction
Despite continued attempts to develop photosensitisers with improved 
selectivity, the concentration difference between normal and tumour tissue is 
still not sufficient to allow for effective tumour killing without some injury to 
surrounding normal tissue. It is therefore vital to determine the precise effects 
that photodynamic therapy will have on surrounding tissues, and to estimate 
their ability to recover over time (Bown 1990).
This is particularly important in the treatment of oral cavity cancers, where major 
blood vessels run in close proximity to the tumour and where tumours may be 
adjacent to, or may even have invaded, bone. It is also important to understand 
PDT effects on mucosa, muscle, nerves and salivary glands. A series of animal 
experiments were undertaken to look at some of these questions. The work in 
this section was co-supervised by me at the National Medical Laser Centre -  
the work on blood vessels was carried out by Mr W E Grant out between 1993 
and 1994, before we had access to Foscan® and the bone study by Dr FMK 
Fan between 1994 and 1996.
6.2 PDT Effects on Blood Vessels
It is obviously important that we understand the effect of PDT on blood vessels 
in the head and neck. There are a number of large vessels whose rupture 
results in rapid death. The most obvious of these are the carotid arteries.
Two cases of fatal haemorrhage of the carotid artery 24 and 72 hours after 
photodynamic therapy have been reported in the literature (Schuller et al 1985, 
Gluckman 1991a). It is unclear if these were due entirely to the PDT effect or to 
direct tumour invasion of the artery.
Occlusion of the microvasculature is generally thought to be part of the 
mechanism of photodynamic therapy necrosis (see 4.1.1) but this conclusion
was reached through the study of small vessels such as arterioles, venules and 
capillaries. Small vessels with relatively little mural supporting connective tissue 
may be more likely to undergo occlusion or haemorrhage than larger arteries 
which have more smooth muscle, collagen and elastin components.
In order to evaluate the PDT effects on large vessels, two studies were 
undertaken, the first on the rat femoral artery and the second on the rabbit 
carotid artery.
6.2.1 PDT Effects on the Rat Femoral Artery
The response of larger vessels to photodynamic therapy was assessed in the 
rat femoral artery using ALA and disulphonated aluminium phthalocyanine: 
these two photosensitisers were selected for study due to the limited light 
penetration, inadequate tumour selectivity and residual photosensitivity of 
Photofrin®.
6.2.1.1 Materials and Methods
The normal femoral artery of the rat was chosen for study. This is a small 
muscular artery of 0.2 to 0.4mm in diameter, which consists of an intima with 
endothelial cells lying on a basement membrane, bounded by an inner elastic 
lamina, a media predominantly composed of smooth muscle cells, and an outer 
adventitial connective tissue layer.
Preliminary pharmacokinetic studies were undertaken to assess sensitiser 
distribution in the individual arterial layers and adjacent structures in order to 
establish the most appropriate timing of PDT. These studies showed that the 
fluorescence distribution pattern of phthalocyanine- and ALA-induced 
protoporphyrin IX was similar for both drugs. Maximal arterial fluorescence was 
detected in the intimal layer of each artery and similar fluorescence was seen in 
the adjacent thin-walled vein. This fluorescence was attributed to retention of 
circulating sensitiser by the endothelial cells in the case of the phthalocyanine 
and to uptake and metabolism of ALA to protoporphyrin IX, in the case of ALA- 
sensitised animals. Peak fluorescence was detected at 1 hour following
sensitisation with disulphonated aluminium phthalocyanine and at 3 hours with 
ALA sensitisation. The fluorescence ratio between arterial intima and media 
reached a maximum of 5:1 for disulphonated aluminium phthalocyanine and 3:1 
for ALA at the same time as peak fluorescence was detected (1 and 3 hours 
respectively).
A second series of young adult female Wistar rats, were sensitised with ALA 
(200mg/kg) or disulphonated aluminium phthalocyanine (5mg/kg) and then 
treated at times corresponding to peak fluorescence (1 hour following 
sensitisation with disulphonated aluminium phthalocyanine, and 3 hours 
following ALA sensitisation). The rats were anaesthetised with Hypnorm and 
Diazepam, and a groin incision made on one side to expose the femoral 
neurovascular bundle, care being taken to avoid any surgical manipulation of 
the vessels which might result in damage to the delicate endothelium.
1cm segments of the femoral artery were exposed to laser light delivered by a 
copper vapour pumped tunable dye laser. Irradiation at 630nm was used for 
the ALA group as in previous studies from this unit (Bedwell et al 1992) 
although the in vivo excitation efficiency is slightly higher at 635nm; 675nm was 
used for the phthalocyanine group, which is in accord with the in vivo action 
spectrum (Cubeddu et al 1992).
In each drug group, eight rats were treated per time point, four at 100J/cm2 and 
four at 250J/cm2 delivered light using a surface illumination technique over a 
1cm2 area with a 400pm fused-silica optical fibre and a microlens attachment to 
ensure even light distribution. Power density was kept below 150mW/cm2 to 
avoid thermal injury. This was confirmed in selected experiments using a 
copper-constantan thermocouple (Jenway, model 7905) placed immediately 
below the irradiated muscle surface to monitor temperature changes during the 
treatment; no rise in temperature was detected over the treatment times for 
either wavelength or light exposure. Following photodynamic therapy, the mid­
point of the 1cm treated segment was marked by a 5:0 silk suture placed in the 
muscle at a distance from the treated zone, and the incisions closed. In the 
early phase of the investigation some rats removed their own sutures with 
wound dehiscence and sepsis; these animals were excluded from the study and
the procedure repeated in other animals using a transverse groin incision and 
closure, which did not suffer the same fate.
Animals were sacrificed at 3, 7, 14, 28, 84 and 168 days (6 months), the legs 
were severed the skin was removed, and fixed in 10% buffered formalin for 
three days. The legs were then decalcified and two or more sections were 
taken transversely through the mid-point of the treated segment. Sections were 
stained with haematoxylin and eosin (H&E), and the treated vessels identified 
and photographed at x40 using a Zeiss photomicroscope. Selected specimens 
were stained with elastin van Gieson for collagen and elastin, and Martius red 
scarlet blue for fibrin.
Three groups of control animals were studied at three days and one week: 
those that received light only at 250J/cm2 at 630nm (two animals) and 675nm 
(two animals) and surgical exposure only (two animals). The contra-lateral non­
treated leg was sampled in two animals from each treatment group at each time 
point up to six months and these acted as drug-only controls.
The luminal cross-sectional areas of the arteries were then measured on 
standard photomicrographs using a computer-aided image analysis system 
(Quantimet, Q520, Cambridge Instruments UK). Mean values were determined 
for each treatment group and compared with contra-lateral non-treated legs. 
This enabled a plot of cross-sectional area versus time to be constructed. 
Results were subjected to statistical analysis using Student's f-test.
6.2.2 Results
6.2.2.1 Nature of Injury
The arteries in control animals sacrificed at 3 and 7 days were patent and 
showed normal endothelium and normal media, indicating that light alone, 
surgical exposure alone or drug administration alone did not cause thermal or 
other significant injury. Subsequently contra-lateral non-treated arteries were 
used as controls for morphological comparison as these were matched for 
growth in the animals. No macroscopic change in the arterial configuration was
observed at any time. No arteries underwent occlusion, thrombosis, 
haemorrhage or rupture, or aneurysmal dilation, and all remained patent.
PDT-treated arteries in each drug group and at both light doses demonstrated a 
similar early response to PDT injury. Loss of endothelium and preservation of 
an intact inner elastic lamina (IEL) was characteristic. In spite of the loss of 
endothelium, no thrombus formation could be detected.
A striking feature was replacement of the entire smooth muscle cell population 
of the media by an homogeneous eosinophilic layer. No smooth muscle nuclei 
could be detected on light microscopy (see Figures 6.1a and d). There was 
complete loss of muscle tone with wide dilation of the artery and smooth 
configuration of the inner elastic lamina, a structure that was observed in all 
controls to be corrugated owing to the smooth muscle tone of the vessel. PDT 
thus appeared to render the vessel an acellular conduit.
c f
Fig 6.1 : PDT effects on rat femoral artery
Haematoxylin and eosin light micrographs of arteries treated with PDT at times 
up to six months. Photomicrographs on the left show arteries sensitised with 
5mg/kg disulphonated aluminium phthalocyanine and treated with 100J/cm2 
laser light at 675nm, sacrificed at (a) 3 days (b) 14 days and (c) 168 days. On 
the right are shown arteries sensitised with 200mg/kg ALA and treated with 
100J/cm2 laser light at 630nm (d,e and, f) again showing the appearance at 3, 
14 and 168 days respectively. At 3 days in both groups there is complete 
cellular depletion throughout the vessel wall, and the intact inner elastic lamina 
is clearly seen. The endothelium has regenerated by 14 days in both drug
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groups. At 168 days only the disulphonated aluminium phthalocyanine group 
showed complete re-population of the media with functional smooth muscle 
cells, the ALA-treated artery remaining persistently dilated, with no medial 
smooth muscle cells. Scale bar in bottom right corner represents 50|am for a, b, 
d, e (x100) and 100 pm for c and f (x40)
In spite of obvious extensive cell death there was no evidence of an 
inflammatory response at any time following treatment. The findings were 
similar for both the low and high drug doses and for both photosensitisers.
S.2.2.2 Healing and Recovery
The lost endothelium was the first structure that was seen to regenerate, 
presumably from the adjacent normal untreated ends of the artery. This 
process appeared to be complete by two weeks in both groups (see Figures 
6.1b and 6.1e). In the disulphonated aluminium phthalocyanine group, re­
population of the media with smooth muscle cells took between three and six 
months (see Figure 6.1c). Only the occasional vessel showed evidence of 
slight neo-intimal hyperplasia that was of a few cells' thickness.
Normal contractility and vascular tone was seen with the return of the 
corrugated appearance of the I EL. By contrast, the vessels treated with ALA- 
PDT failed to re-populate the media with smooth muscle cells. After six months, 
the vessels remained thin walled and dilated with no medial re-population 
(Figure 6.1 g). The IEL remained smooth and straight, reflecting this finding. All 
vessels remained patent with no evidence of thrombosis at any stage.
The cross-sectional area of the treated vessels was significantly greater in all 
treatment groups when compared with controls up to four weeks. This 
corresponded to the observed loss of media muscle tone of the vessels. By six 
months the vessels had recovered in the disulphonated aluminium 
phthalocyanine group but remained significantly dilated in the ALA-treated 
group (Table 1). However, no macroscopic aneurysmal dilation was observed.
Time
(days)
Controls AIS2Pc
100J/cm2
AIS2Pc
250J/cm2
ALA
100J/cm2
ALA
250J/cm2
3 0.011 (±0.003) 0.062(±0.001) 0.056(±0.004) 0.071 (±0.007) 0.065(±0.010)
7 0.008(±0.002) 0.056(±0.002) 0.050(±0.001) 0.064(±0.008) 0.074(±0.005)
14 0.012(±0.003) 0.0467(±0.003) 0.054(±0.003) 0.043(±0.005) 0.064(±0.020)
28 0.009(±0.003) 0.058(±0.016*) 0.028(±0.008)
NS
0.060(±0.005) 0.066(±0.005*)
84 0.011 (±0.003) 0.042(±0.011*) 0.027(±0.009)
NS
0.085(±0.005) 0.087(±0.003)
168 0.011 (±0.003) 0.009(±0.001)
NS
0.016(±0.003)
NS
0.096(±0.002) 0.091 (±0.004)
Table 6.1: Mean (± standard error mean) of arterial luminal cross-sectional 
areas
Values are in mm2 for cross-sectional areas at each time point. Figures are 
means, with standard error of the mean given in brackets. Control values 
showed no significant difference between drug groups and therefore mean and 
standard error of mean values are presented for all controls at each time point. 
NS = not statistically different from control values. * = significant at the P<0.05 
level; remainder significant at P<0.001 level.
6.2.3 Discussion
The observation that there was no difference in histological response between 
the 100J/cm2 and the 250J/cm2 light doses in either of the drug groups indicates 
that both light doses are above a threshold for injury, and that above this 
threshold, damage does not appear to increase with light dose. The similarity of 
response in the early phase following PDT in both the ALA and disulphonated 
aluminium phthalocyanine groups indicates that a similar photodynamic 
mechanism is responsible for the injury in each group.
The patency of all treated vessels, and the lack of evidence of thrombosis in 
spite of elimination of the endothelium, is encouraging and suggests that 
occlusion of major blood vessels due to PDT is unlikely to be a problem. 
Furthermore, the vessel walls all remained intact, suggesting a resistance of the 
injured walls to haemorrhage or disintegration under physiological stresses in
spite of full-thickness cell death. It has been postulated that there was 
preservation of an intact inner elastic lamina, as well as the preservation of 
normal adventitial collagen. This indicates that these acellular supportive 
elements are not denatured by PDT, and contribute to the preservation of the 
mechanical integrity of the vessels.
The absence of mural inflammation in the presence of the apparent extensive 
cell death, together with the persistent function of the vessels, suggests that 
typical cell necrosis may not be taking place, and that the features might be 
consistent with a form of programmed cell death, or apoptosis (see Section 
4.1.1).
It is well established that PDT in tumour therapy brings about necrosis at least 
in part by virtue of its action on the microvasculature and endothelial cells have 
also been shown to be highly sensitive to PDT injury (see Section 4.1.1). 
Certainly the endothelium in this study convincingly demonstrated maximal 
fluorescence for both drugs used, suggesting the likelihood of high susceptibility 
to photodynamic injury. This is in contrast to the work of LaMuraglia et al 
(1993) who found fluorescence in the full thickness of the arterial wall.
While relatively low levels of fluorescence were seen in the smooth muscle of 
the vascular media, treatment groups showed a dramatic response to light 
exposure. Light-only and drug-only groups showed no medial injury. Therefore, 
in spite of low fluorescence detection, these cells appear to be highly 
susceptible to photodynamic injury.
Blood vessels of this size are oxygenated by circulating blood in the lumen and 
do not have vasa vasorum, indicating that a direct phototoxic effect was 
responsible rather than the injury being secondary to ischaemia due to 
microvascular shutdown.
In contrast to Suzuki et al (1987) who found that endothelial cell regeneration in 
rats occurred within five days, in this study, the endothelium, although showing 
some evidence of regeneration at one week, was not complete until two weeks. 
Chevretton et al (1992) reporting on skeletal muscle injury after PDT using a
variety of sensitisers noted loss of endothelium, and intravascular thrombosis in 
arterioles. An eosinophilic necrosis of arteriolar smooth muscle was also 
described and the changes were reminiscent of those seen in acute 
hypertension.
These findings are similar to our observations with the exception that there was 
no evidence of thrombosis in the larger arteries examined in this study.
Our study also looked at the long-term effects of PDT on normal arteries at 
follow-up times of up to six months in the treated groups. Re-population of the 
cell-depleted media took from three to six months in the disulphonated 
aluminium phthalocyanine groups. This re-population was associated with the 
observation that occasional vessels showed intimal hyperplasia of only one or 
two layers' thickness and did not appear to have any degree of stenosis. As no 
significant intimal hyperplasia was demonstrated by six months in the present 
study group, long after endothelial regeneration was completed, we concluded it 
was therefore unlikely to develop.
In the ALA group, medial re-population had not occurred by six months, and 
was thus similarly felt unlikely to occur at all. This finding was difficult to explain 
and suggests a local, perhaps biochemical, inhibitory effect resulting from a 
difference in the nature of the injury not detected by the morphological 
investigations carried out. The effect on the treated arteries in this group was to 
transform the artery into a wider bore non-contractile vessel with an adventitia 
and an intima but no functional media. While vein-grafted stenoses in man tend 
to undergo arterialisation by migration of smooth muscle cells from adjacent 
arterial ends (Dilley et al 1988), this had not taken place by six months. This 
may have clinical relevance in that vessels treated following sensitisation with 
ALA may be even less likely to develop intimal hyperplasia. A possible 
outcome may be long-term weakness of the vessels and a tendency to 
aneurysmal dilation, however this was not observed macroscopically in this 
study.
In spite of obvious extensive injury both to endothelial cells and medial smooth 
muscle cells, neither stenosis nor intimal proliferation of smooth muscle cells
was observed in this study. This may reflect the total nature of the injury to the 
vessel walls studied leaving behind no residual SMCs in the treated segments.
A possible explanation for the lack of intimal hyperplasia is that endothelial 
regeneration occurs at a much faster rate than medial re-population, and once 
completed acts to prevent migration of proliferating SMC. The endothelium in 
balloon-denuded vessels regenerates from the ends of the denuded segment 
(Clowes et al 1983) and it is likely that a similar process occurs in PDT-injured 
vessels for both endothelial cells and smooth muscle cells.
The cross-sectional areas looked at in this study illustrate the effects of PDT 
injury to the vessel wall, with significant dilation being observed compared to 
controls at up to 14 days in all treatment groups. They further reflect the 
observed medial re-population in the disulphonated aluminium phthalocyanine 
group at six months, confirming that functional recovery takes place in this 
group and that the SMCs are phenotypically contractile.
The persistent increase in cross-sectional area in the ALA group even at six 
months illustrates the failure to re-populate the media with functional SMCs. A 
criticism of the method is that the harvested vessels were not perfusion fixed, 
and therefore may not exhibit their in vivo configuration. However, consistent 
results were obtained, and clearly demonstrate a statistically significant 
difference in response to PDT between controls and ALA- and disulphonated 
aluminium phthalocyanine-treated groups.
As has been discussed in Chapter 4, PDT tumour necrosis is brought about at 
least in part by microvascular collapse with thrombosis and haemorrhage. It 
would appear from this study that larger vessels with sufficient supporting mural 
connective tissue elements are resistant to such collapse. It remains to be 
determined which size of vessel represents the cut-off point for haemorrhage 
and occlusion.
Furthermore, should tumour fluorescence profiles differ significantly from those 
demonstrated in large blood vessels, it may be possible to identify times at 
which tumour PDT would not result in significant vascular injury.
6.3 PDT Effect on Rabbit Arteries
Following this, a second study using the carotid artery in rabbits was carried out 
to determine whether the photodynamic effect weakened the walls of larger 
vessels, thereby increasing the risk of haemorrhage through loss of mechanical 
integrity and rupture of the artery wall. In this study, the strength of treated 
vessel walls was assessed by intra-luminal hydrostatic distention to bursting 
point.
6.3.1 Materials and Methods
New Zealand white rabbits, under fentanyl and fluanisone sedation, were 
injected with either ALA at 200mg/kg (Sigma Chemicals) in phosphate buffered 
saline or disulphonated aluminium phthalocyanine (in solution as prepared by 
the Department of Chemistry, Imperial College London) at 1 mg/kg via an ear 
vein.
Photodynamic therapy was applied by anaesthetising the animals at appropriate 
periods and gently dissecting the common carotid arteries on both sides. The 
arteries were optically isolated from surrounding structures by placing a piece of 
foil-lined opaque card between them and the underlying tissues. A 1cm length 
of each artery was exposed to a 100J/cm2 dose of light from a copper-vapour 
pumped dye laser. A light dose of this order corresponds to a typical 
tumouricidal dose (Grant et al 1993a). Light at 630nm was used for ALA- 
treated rabbits, and light at 675nm was used for disulphonated aluminium 
phthalocyanine-treated rabbits. These wavelengths correspond to peaks in the 
absorption spectra of protoporphyrin IX and disulphonated aluminium 
phthalocyanine respectively. The surface was illuminated using a 400pm fused 
silica optical fibre with a microlens attachment.
The rabbits underwent PDT three hours after receiving ALA and one hour after 
receiving disulphonated aluminium phthalocyanine. These times were chosen 
to correspond with peak levels of sensitiser as determined by fluorescence 
photometry studies (Loh et al 1992, Grant et al 1993b [Chapter 10], Bedwell et 
al 1992, Grant et al 1994 [pd study referred to in chapter 6]).
The treated segments were marked by placing two 5:0 silk sutures in the 
adjacent fascia of the carotid sheath. After PDT, the incisions were closed, and 
the animals were revived and returned to their cages. No animals suffered any 
obvious adverse effect from the therapy.
To confirm that PDT produced vascular injury, four rabbits (two from each drug 
group) were sacrificed at three days. Their carotid arteries were removed and 
were fixed for haematoxylin and eosin (H&E) and elastin van Gieson staining. 
Transverse sections were taken from the treated segments and from adjacent 
segments that were not exposed to light; the latter served as the controls with 
'drug plus dissection but no light'. Two other rabbits that received the same 
dose of light but without prior photosensitisation served as the 'light only' 
controls; these animals were also sacrificed at three days.
A further 18 rabbits underwent identical treatments: nine with ALA and nine with 
disulphonated aluminium phthalocyanine. Three rabbits from each group were 
sacrificed on day three, three more from each group were sacrificed on day 
seven, and the last three from each group were sacrificed on day 21.
After sacrifice, the neck incisions were re-opened, the carotid arteries were 
re-excised, and the treated segments were identified. A blunted 18-gauge 
butterfly needle was inserted into each of the treated sections, and the section 
was then gently irrigated with normal saline. Next the needle was isolated in 
half of the treated section using 4:0 silk ligatures. The needle was connected to 
a three-way tap coupled to a pressure transducer and to the output of a water- 
filled pressurised vessel. The pressure transducer was connected to a power 
supply, a chart recorder, and a digital voltmeter. The input to the pressure 
vessel was connected to a compressed-air cylinder through a manual pressure 
regulator capable of delivering up to 16 bar (12,000mmHg) see Figure 6.2. This 
enabled pressure to be gradually increased until the isolated vessel segment 
ruptured, which usually happened after several seconds.
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Fig 6.2: Apparatus and method of isolation and hydrostatic distention used in 
treated segments of carotid artery (PS = power supply; DVM = digital voltmeter; 
CR = chart recorder; PT = pressure transducer)
The procedure was repeated for the other half of the treated segment, as well 
as for the proximal and distal normal segments of the same artery, which 
served as controls. The procedure was also repeated on the contra-lateral 
treated and untreated segments of carotid artery. Consequently, four treatment 
values and four control values were obtained for each rabbit.
Mean values for treated and control segments were calculated. Bursting 
pressure measurements from each treatment group were compared with the 
measurements from the controls and were statistically analysed using Student's 
t test.
6.3.2 Results
All rabbits tolerated the treatment satisfactorily and showed no ill effects in the 
post-operative period. When the treated and control arteries were exposed, no 
evidence of dilatation, aneurysm formation, or obvious diminished blood flow 
could be determined. Macroscopically, the treated sections appeared a little 
paler than the adjacent untreated segments.
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The treated arteries sampled at three days all showed evidence of characteristic 
PDT injury. The same injury was observed in both drug groups on histologic 
examination after H&E staining. The injury consisted of loss of endothelium and 
evidence of complete cell death throughout the media and adventitia. In 
contrast, all sections from the control arteries showed normal arterial features, 
with an intact and cellular intima, media, and adventitia. Histological 
examination following elastin and collagen van Gieson staining demonstrated 
no discernible difference between treated and control arteries. Both showed 
normal configuration of collagen in the media and the adventitia, as well as an 
intact inner elastic lamina and intact medial elastic laminae (Figure 6.3).
Fig 6.3: Photomicrographs of rabbit carotid arteries treated with PDT 
(a) H&E-stained normal rabbit carotid artery, (b) carotid artery three days after 
photodynamic therapy using ALA. Sub-intimal pyknotic nuclei and nuclear 
debris are seen in the photomicrograph, (c) carotid artery three days after PDT 
using disulphonated aluminium phthalocyanine. (d) Van Gieson-stained vessel 
after treatment with PDT using ALA. The inner elastic lamina and medial elastic 
laminae demonstrate a normal configuration. A similar staining pattern (not 
shown) was observed following PDT with disulphonated aluminium
a
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phthalocyanine (original magnification x 60 Bar at bottom right represents 
100pm).
Control arterial segments (drug plus dissection but no light) were found to burst 
at a mean of 5100mmHg (SD= ±1 lOOmmHg) in the phthalocyanine group and 
5200mmHg (SD = ±1300 mmHg) in the ALA group. The overall mean was 
5100mmHg (SD= ±990). At three days, there was no significant difference in 
the hydrostatic pressure required to burst the treated or control segments. At 
seven and 21 days, however, considerably greater pressure was required to 
burst the treated segments than the control segments (Table 6.2). The 
pressure required to burst all vessels was 50 to 70 times the arterial blood 
pressure. Both control and treated arteries tended to rupture in a linear split 
along the length of the isolated segment.
Disulphonated aluminium 
phthalocyanine
ALA
Time after 
PDT
Control
segment
PDT segment Control
segment
PDT segment
3 days 5100 (±1100) 5400 (±800) 5200(±1300) 5100 (±900)
7 days 4900 (±900) 6200 (±1600) 5100 (±800) 6800 (±1300)
21 days 5500 (±800) 7300 (±1600) 5100 (±1000) 6800 (±1800)
All controls 5200 (±900) 5100 (±1000)
Table 6.2: Mean bursting pressures in mmHg for control and treated segments 
of rabbit carotid arteries that received PDT using disulphonated aluminium 
phthalocyanine or ALA
6.3.3 Discussion
The expected histologic effects of PDT using ALA and disulphonated aluminium 
phthalocyanine as photosensitisers was observed. Endothelial cells were lost 
from the intima, and cellular structures were completely lost in the media. 
Similar findings were observed in a previous study (Section 6.2) and by other 
investigators (Ortu et al 1992).
All treated segments demonstrated that full circumferential injury was caused by 
the chosen treatment parameters. The control 'drug plus dissection but no light' 
groups and the 'light only' groups demonstrated preservation of normal cellular 
intima, media and adventitia. The fact that bilateral PDT of the common carotid 
artery did not result in thrombotic occlusion is demonstrated by the failure of any 
treated rabbit to show signs of stroke. Furthermore, no histologic evidence of 
mural thrombosis was found.
This study demonstrates that, despite the full-thickness cell death PDT induces 
in the vessel wall, no weakening or loss of mechanical integrity occurs. It is not 
unreasonable to suppose that an inflammatory response might be observed 
with such extensive necrosis and that the release of inflammatory mediators 
might contribute to weakening of the vessel wall. It is possible that PDT in this 
situation provokes instead a form of programmed cell death, similar to 
apoptosis, in which no inflammatory response occurs (see 4.1.1). This would 
help to explain the preservation of the mechanical integrity of the vessels in this 
study. Furthermore, the fact that PDT does not result in degradation or 
denaturation of collagen and elastin probably contributes to the preservation of 
function (Barr 1987a).
Other studies of PDT-treated rat colons (Barr 1987b) and rat tracheas (Smith 
1993) have shown preservation of mural collagen and no reduction in the 
hydrostatic pressure required to rupture the treated organ. One possible 
contributory factor is that through singlet oxygen reactions, PDT brings about 
the cross-linking of collagen, which increases its resistance to deformation 
(Verweji et al 1981). The increase in pressure required to burst the vessels at 7 
and 21 days might be explained further by the re-population of the media and to 
a lesser extent the intima, by proliferating smooth muscle cells, resulting in a 
minor degree of neointimal hyperplasia.
6.4 Conclusion: PDT Effect on Arteries
These two studies demonstrated that arteries treated with photodynamic 
therapy using disulphonated aluminium phthalocyanine and ALA remain patent 
without rupture, haemorrhage or thrombotic occlusion. Furthermore they
provided reassurance that, despite full-thickness vascular mural cell death 
following PDT, mechanical weakening of the treated vessel walls does not 
occur.
Non-cellular structural elements such as collagen and elastin are preserved and 
this, coupled with the lack of inflammatory response in the arterial wall in spite 
of extensive cell death, indicate that mechanical integrity is preserved. Long­
term patency was demonstrated with minimal risk of development of intimal 
hyperplasia.
These findings indicate that arteries exposed to PDT during tumour therapy are 
unlikely to be at risk, provided there is no direct invasion of the artery wall by 
tumour. This has significance for the use of PDT in tumours located near major 
vessels, such as may occur in the head and neck, and for the intra-operative 
adjunctive use of PDT to ablate microscopic residual disease. However, while 
one must be cautious about the extrapolation of these results to other 
photosensitisers, recent work by Kubler using Foscan® had similar results. So 
this effect probably translates to most currently available photosensitising 
agents.
6.5 PDT Effect on Bone
6.5.1 Bone
Studies on the rabbit mandible (Meyer et al 1991) using disulphonated 
aluminium phthalocyanine suggest that bone is resistant to PDT treatment. 
However, these studies did not look at the three sensitizers that are currently 
used in clinical practice: 5-aminolaevulinic acid, Photofrin® and mTHPC. The 
study below was designed to address this issue and evaluate PDT effects on 
normal bone.
6.5.2 Materials and Methods
Fifty-eight female New Zealand White rabbits were used in two series of 
experiments: the first to determine the effect of PDT on the bone of the tooth
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socket and the second to verify that the parameters used were capable of 
producing necrosis.
Three photosensitisers were used: Photofrin®, 5-aminolaevulinic acid and 
mTHPC. Photofrin® was reconstituted using 5% dextrose, to make a 2.5mg/ml 
solution for intravenous injection at a dose of 3mg/kg. ALA hydrochloride in 
98% pure crystalline form was dissolved in phosphate buffered saline, giving a 
100mg/ml solution for oral administration at a dose of 400mg/kg. The Foscan® 
crystals were dissolved in a mixture of polyethylene glycol, water and ethanol to 
produce a 5mg/ml concentration which was administered at a dose of 0.3mg/kg 
body weight IV.
The total dose of 400mg/kg of ALA was delivered in three equal fractions, with a 
one hour interval between each administration, consistent with our current 
clinical protocol (Fan et al 1996). The fractionated ALA dose was chosen on 
the basis of established pharmacokinetic principles (Regula et al 1995).
6.5.3 PDT on Normal Bone
Forty-eight rabbits were divided into six groups as shown in Table 6.3. The four 
treatment groups consisted of two Photofrin® groups, an ALA and a Foscan® 
group and two 'light only' control groups.
Photofrin 
® 1 hour
Photofrin 
® 48 
hours
ALA 2.5 and 
4 hours
mTHPC 
72 hours
Light
alone
Light
alone
Dose/route 3 mg/kg IV 3 mg/kg IV 400 mg/kg 
oral
0.3 mg/kg 
IV
N/a N/a
Wavelength 630 nm 630 nm 630 nm 650 nm 630 nm 650 nm
Drug/laser 
interval, h
1 48 2.5 and 4 72 N/a N/a
Light dose 100 J 100 J 2x 100 J 100 J 100 J 100 J
Number of 
rabbits
9 9 9 9 6 6
Time to
sacrifice,
days
3x3
3x10
3x21
3x3
3x10
3x21
3x3 
3x 10 
3x21
3x3 
3x 10 
3x21
2x3
2x10
2x21
2x3
2x10
2x21
Table 6.3: Treatment protocol for drug and light administration to rabbit tooth 
socket
The rabbit model used in these experiments was as described by Meyer et al 
(1991) (also see Chapter 5) but with some refinements. A cylindrical diffusing 
fibre was used instead of a bare cut fibre to enable more uniform illumination of 
the entire tooth socket.
To simulate the infiltration of tumour into bone, all rabbits in the first part of the 
study had the lower mandibular incisor removed. If one considers the void to 
represent tumour, then PDT of that area will result in the same normal tissues 
being exposed to PDT. The ipsilateral maxillary incisor was also extracted to 
act as a control for the effect of the photosensitiser and trauma of the extraction 
process. Each rabbit therefore yielded two samples of tissue for analysis. 
Ideally controls should have been carried out on the contralateral mandibular 
incisor, but this could have led to feeding problems. The different experimental 
groups are summarised in Table 6.4.
Photofrin® Photofrin
®
ALA MTHPC Light
alone
Light
alone
Extn
alone
Site of 
extraction
Man Max Man Max Man Max Man Max Man Man Max
Irradiation Yes No Yes No Yes No Yes No Yes,
630nm
Yes,
650nm
No
Drug/light 
interval, h
1 48 2.5 & 
4
72
Number 
of rabbits
9 9 9 9 9 9 9 9 6 6 6
Table 6.4: PDT and control groups, treatment schedule
Oral delivery of ALA required the rabbits to be sedated prior to administration.
In all other cases, removal of the tooth and subsequent laser irradiation were 
carried out with the animal anaesthetised using 2mg/kg diazepam administered 
subcutaneously and maintained IV, and 0.3ml/kg Hypnorm administered 
intramuscularly.
The light source was a pulsed 12kHz copper vapour pumped dye laser 
(Cu25/DL10, Oxford Lasers Ltd, Abingdon) and the output was focused into a 
0.4mm core diameter optical fibre with a 1cm cylindrically diffusing tip (PDT 
Systems, Santa Barbara, Ca). The fibre was passed into the base of the tooth 
socket, allowing near uniform irradiation of the whole of the defect (Figure 6.4). 
The power output was selected in order to supply 100mW/cm2 at the fibre tip, 
with an exposure time of 1000 seconds to achieve a total dose of 100J/cm2.
Light administration was carried out at 1 and 48 hours post-sensitisation with 
Photofrin®, and 72 hours post-sensitisation with mTHPC. A fractionated 
irradiation regimen was used with ALA, with a 75 minute break or dark period 
halfway through illumination (100J/cm2 at t = 2.5 hours and 100J/ cm2 at t = 4 
hours).
The maxillae and mandibles of the rabbits which had received PDT to the tooth 
sockets were decalcified using trichloroacetic acid and longitudinal sections 
were taken through the tooth socket. Tissue sections were processed in
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paraffin. Haematoxylin and eosin (H&E) stained sections were examined for 
damage or necrosis to the normal bone in addition to the various stages of bone 
healing. The presence of the following were assessed: haematoma, granulation 
tissue, inflammatory response, osteoid and woven bone formation. Woven 
bone formation was scored semi-quantitatively on a scale of 0 to 3.
6.5.4 Results
6.5.4.1 Bone Healing
There was no significant difference seen between the amount of woven bone in 
any of the control groups (Table 6.5). In each of the drug only groups there was 
woven bone formation at the edge of the socket by 3 days, which filled the 
socket by 10 days and this was similar to the extraction alone group. In the light 
only control group using light at 630nm, woven bone formation was identical to 
the three drug control groups, however, that at 650nm was slightly slower.
With all three photosensitisers, woven bone formation was more rapid in the 
drug only control groups, but by day 21 there was a similar degree of woven 
bone formation in control and treated groups. When healing of all four PDT 
groups were compared, those that had been sensitised with Foscan® had more 
rapid complete bone healing than those which received Photofrin® or ALA 
(Table 6.5). The most important finding was the absence of any necrotic bone 
or non-viable osteoblasts.
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Group Day 3 Day 10 Day 21
Photofrin PDT (1 h) + +++ +++
0 ++ ++
0 ++ +++
Photofrin PDT (48h) 0 ++ +++
0 ++ +++
0 +++ ++
Photofrin drug control + +++ +++
+ +++ +++
+ ++ +++
ALA PDT ++ ++ +++
++ ++ +++
+ +++ +++
ALA drug control + + +++
+ +++ +++
0 +++ +++
mTHPC PDT 0 +++ +++
0 +++ +++
0 +++ +++
mTHPC drug control + +++ +++
+ ++ +++
0 +++ +++
Light 630nm + ++ +++
+ ++ +++
Light 652nm 0 ++ +++
0 ++ +++
Extraction only + ++ +++
+ ++ +++
Table 6.5: Woven bone score of individual maxillary and mandibular specimens 
Key: 0: absence or minimal presence of woven bone along the socket margin 
(score = 0)
+: presence of woven bone along the socket margin (score = 1)
++: socket half filled with new bone (score = 2)
+++: socket at least V* filled with bone (score = 3)
Osteoid formation was present by 3 days in most specimens and granulation 
tissue was also most abundant. No muscle scarring was evident and no 
damage was seen to the salivary tissue in any group.
6.5.5 Discussion
These studies showed that treatment of the tooth socket with PDT, under 
treatment conditions that would bring about tumour necrosis, did not cause
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bone necrosis and only brought about a minor delay in the healing process to 
the bone after tooth extraction. PDT appears to retard bone healing in the early 
stages, but does not affect the long-term outcome. At the concentrations used, 
none of the photosensitisers on their own had any adverse effects on the overall 
rate of bone healing and light alone at 630nm had no apparent effect.
6.6 PDT on Buccal Mucosa
6.6.1 Materials and Methods
The second series of experiments was carried out on both the left and right 
buccal mucosa of ten rabbits drawn from the sensitised groups. After 
sensitisation as described in the previous section the following treatment 
schedule was carried out:
Photofrin® 
1 hour
Photofrin® 
48 hours
ALA
2.5 & 4hrs
mTHPC 
72 hours
Number of 
rabbits
2 2 2 2 2
Wavelength 630 nm 630 nm 630 nm 650 nm 650 nm
Energy
density
125 J/cm2 125 J/cm2 2 x
125 J/cm2
125 J/cm2 31 J/cm2
Table 6.6: PDT on buccal mucosa, treatment schedule
The same drug-light intervals as above were used (1 hour and 48 hours for 
Photofrin®, 2.5 and 4 hours for ALA and 72 hours for mTHPC table 6.5). The 
laser beam was focused onto a 0.4mm core diameter microlens fibre (QLT 
Phototherapeutics, New York, USA) allowing delivery of a uniform, 5mm 
diameter circular spot of light to the buccal mucosa with a power density of 
127mW/cm2. The higher energy density was used to match as closely as 
possible those delivered to the bone defect, as calculated from the size of the 
removed tooth (0.8cm2). The lower fluence was initially used with Foscan® to 
avoid extensive damage observed in clinical cases irradiated with 20J/cm2, but 
these experiments were later repeated with the higher energy density to 
facilitate comparison. Three days following PDT, the animals were sacrificed
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and the ulcers and a margin of normal surrounding buccal mucosa were 
excised.
Following PDT to the buccal mucosa, the ulcers and margin were excised and 
immediately fixed in neutral buffered formalin and processed to paraffin blocks. 
Five micrometer sections were cut and stained with H&E for comparative light 
microscopy studies. Due to variable amounts of sloughing amongst the 
different specimens, the depths of necrosis were gauged by the different tissue 
levels affected. The depth of necrosis was defined as the deepest point at 
which there was necrosis of a tissue layer.
6.6.2 Healing of Buccal Mucosa
Necrosis was present in all specimens. The depth of necrosis in all Photofrin® 
and Foscan® specimens was comparable, while the depth of damage with ALA 
was much more superficial. The low energy density used initially with the 
Foscan® rabbits (31 J/cm2) showed dramatic effects on soft tissue at a very low 
light dose. When the experiments were repeated at the higher dose of 
125J/cm2, slightly greater depth of damage was observed. There was little 
difference in the Photofrin® sections using the different irradiation times.
Similar histological features were observed in the Photofrin® and Foscan® 
samples: necrosis extending well into the muscle layer and vascular damage 
with fibrinoid degeneration and thrombus formation. From these findings it 
seems likely that the cost of greater necrosis as seen with Photofrin® and 
Foscan® is greater tissue disruption which has the potential to cause scarring.
6.6.3 Discussion
PDT in the theraputic range that would be of value to treat cancer is also very 
likely to cause mucosal damage. This is less likely to occur with ALA, where 
the effect is much more superficial. In terms of our understanding of mucosal 
healing following PDT, this study really didn’t take our knowledge significantly 
further than the Meyer studies in 1991.
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6.7 Conclusion
It is clear from these studies that PDT is safe in close proximity with blood 
vessels in the normal setting. It would be quite reasonable to speculate that in 
a clinical setting, where tumour was eroding the vessel wall, PDT would not be 
safe and might precipitate acute haemorrhage. However, as long as tumour is 
close but not eroding the arterial wall, treatment can be carried out safely. The 
main criticism of the experiments outlined above is that we did not look at 
bursting pressures of rabbit carotids using Foscan®. However Kubler repeated 
these experiments using mTHPC on rabbit carotid and femoral vessels and also 
looked at the vagus and femoral nerves. In a dose escalation study he found 
that at high drug doses (0.3mg/kg) and a short drug light interval (24hours) with 
a light dose of 20J/cm2 there was oedema, some thrombosis and disruption of 
the endothelial layer. He also reported up to 75% demyelination, but 
importantly, neither caused any clinical distress and no vessel rupture was seen 
(Kubler et al 2003).
Bone treated with PDT does show some slightly impaired healing. It is not 
entirely clear what mechanism is involved, but microvascular damage with 
reduced blood supply to the healing site is possible. Fortunately, no long-term 
problems were seen with bone healing and this is obviously of great importance 
for any treatment in the oral cavity. In many ways, bone involvement with 
tumour might be a good target for PDT treatment. Radiotherapy is often 
difficult near bone because of the risk of osteoradionecrosis and surgical 
resection is either mutilating or requires tissue transfer reconstruction. This is 
obviously a great deal of treatment for the patient to undergo, especially bearing 
in mind the co-morbidity in this group of patients.
In conclusion, while it is important to be aware of potential problems with normal 
tissue healing after PDT, none of the animal work suggests insurmountable 
problems and a reasonabe amount of safety data suggests PDT is safe to take 
forward into clinical practice.
Chapter 7: PDT Effects on Human Tissue using Three Photosensitisers: 
Photofrin®, ALA and mTHPC
7.1 Introduction
The aim of this series of studies was to determine the effects of PDT on normal 
and tumour tissue with the 3 commonly used sensitisers. The methodology 
varied slightly in each study, but the broad aim was to determine the depth of 
PDT effect and the histological changes in normal and malignant tissue. This 
was considered an essential step of understanding the PDT effect in humans 
and in a clinically relevant setting, so that possible treatment applications could 
be developed. All the studies here were performed on my patients in ethically 
approved studies for which I was principal investigator. Treatments were 
carried out by me or under my supervision by Mr Grant (Photofrin® and ALA) of 
Ms Fan (ALA and Foscan®). The Photofrin® work was performed in 1992- 
1994, the ALA work 1993 -1996 and the Foscan® work 1995 -  1998.
Photodynamic therapy has many applications but it is considered to be 
particularly suitable for local tumour destruction in the oral cavity as 
conventional treatment results either in tissue loss, dysfunction and mutilation 
(surgery) or may produce irreversible side effects (radiotherapy), see Chapter 3 
for more detail.
Photodynamic therapy may be performed as an out-patient procedure and 
excellent healing has been reported following such treatment in animal models 
and pilot clinical trials (Grant et al 1993a, Gilson et al 1988, Barr et al 1987a, 
Meyer et al 1991). It has often been claimed that PDT can be used to achieve a 
selective tumour necrosis but although some agents such as the porphyrins can 
be used as tumour-localising agents in photodiagnosis due to the preferential 
concentration in tumour tissue (Monnier et al 1990), the effect is not sufficiently 
pronounced to allow tumour damage without injury to normal tissue with 
treatment parameters that are required for therapeutic effect. Where selectivity 
of effect is claimed this is often only through the accurate distribution of light, 
confined to the tumour area. Some apparent selectivity may also be seen if the 
illumination is less in the peripheral zone of the spot than centrally.
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For each photosensitiser it is important to know the depth of necrosis with a 
given light dose in order to be certain of satisfactory tumour ablation. This 
highlights the importance of careful assessment of the depth of the tumour.
In these studies, the author aimed to assess the histological nature of PDT 
injury to normal and neoplastic tissue, evidence of selectivity, and the depth of 
injury for a given light and drug dose using Photofrin®, ALA and mTHPC.
7.2 PDT Effect on Human Tissue with Photofrin®
7.2.1 Materials and Methods
Following review by the ethics committee at UCLH NHS Trust, 11 patients with 
histologically proven Ti squamous-cell carcinomas of the oral cavity who were 
scheduled for surgical excision were recruited. This was a treat and excise 
study and the sites treated are summarised in Table 7.1. It was planned to 
formally excise the lesions at a time when necrosis was apparent, but before 
the necrotic slough had chance to separate that is to say between 2 and 7 days. 
Only 1 patient had a delay of 19 days because he declined earlier surgery. All 
patients received Photofrin® (Quadra Logic Technologies, Vancouver, Canada) 
at 2mg/kg iv, 48 hours prior to light exposure of tumours and a surrounding cuff 
of normal tissue. Exposure was with 50J/cm2 laser light at a wavelength of 
630nm with a power density below 150mW/cm2 delivered by either an argon ion 
or copper vapour pumped dye laser. A microlens attachment to the optical 
delivery fibre ensured even light distribution. A multi-jointed articulated arm 
capable of easy manipulation in three planes was used to hold the fibre to 
facilitate light delivery. The distance from the surface of the lesion at which the 
fibre is positioned is apt to change with any movement of the patient's head, 
tongue or lower jaw. This position was therefore constantly checked with a 
depth probe to ensure accurate light dosimetry.
The first three patients were admitted overnight but with increased 
understanding of the technique, subsequent patients were treated as out­
patients. No anaesthetic was required during the treatment, but analgesia was 
frequently required during healing. All lesions were photographed before and at
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a series of times after treatment to document macroscopic tissue response, 
patients being seen every two to three days following PDT until the lesions were 
excised. Following sensitisation, all patients were counselled on the need to 
manage re-exposure to light.
Between two and 19 days following PDT, the treated lesions were excised, fixed 
in 10% buffered formalin and processed with paraffin. Sections were stained 
with haematoxylin and eosin (H&E) and by the elastin-Van Gieson (EVG) 
method and a reticulin stain. Selected sections were further stained for 
cytokeratin using a routine immunoperoxidase method and antibodies to human 
callus keratin (Dako, High Wycombe, UK) and cytokeratin (MNF116; Dako).
The depth of the PDT effect was measured on low-power colour 
photomicrographs using a computer-aided image analysis system (Quantimet). 
Absolute measurements were determined on each photograph by direct 
reference to the original H&E-stained section. Two distinct depths were 
measured at several points to determine a mean value:
Depth of absolute necrosis: this was the thickness of the surface necrotic 
slough, defined as the distance from the surface to the base of the surface 
necrosis, within which no viable cells, either normal or tumour, could be 
distinguished.
Depth of inflammation: this was defined as the depth of tissue showing 
evidence of an inflammatory response measured from the surface of the 
necrosis to the point where there was least evidence of inflammation. 
Inflammation was defined as the presence of extravascular acute or chronic 
inflammatory cells and the presence of polymorphonuclear leukocytes within 
dilated blood vessels.
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7.2.2 Results
7.2.2.1 Clinical
Clinical examination of the treated areas showed no macroscopic difference 
following PDT in the appearance of tumour or its surrounding normal mucosa, 
both being replaced by an ulcer slough within 24 hours. The dimensions of this 
area of slough closely corresponded to the area exposed to laser light. This is 
illustrated in Figure 7.1 (a case not included in the excision following PDT 
protocol as no follow up excision or biopsy was performed) which shows PDT 
response and healing of lip malignancy and surrounding normal tissue.
c d
Fig 7.1 : Two small carcinomas of the lip (a) before treatment and (b) four days 
after PDT (Photofrin® 2mg/kg followed by 50J/cm2 of red light at 630nm, 48 
hours later). There is necrosis covering the entire area exposed to light, which 
included both normal and malignant tissue, (c) Eighteen days after PDT, 
healing is well advanced, (d) Thirty-three days after PDT, healing is complete. 
There is a small scar in the PDT-treated area, where a biopsy had been taken 
prior to treatment; but apart from this, healing has been by regeneration of 
normal tissue with an excellent cosmetic result. In contrast, in the region on the
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opposite side where a small carcinoma was previously removed by wedge 
excision, there is distortion of the lip contour.
7.2.2.2 Histopathology
Both tumour and adjacent epithelium were replaced by an amorphous 
eosinophilic fibrinopurulent slough, confirming the macroscopic findings. 
Throughout the mucosa there was connective tissue necrosis with marked 
eosinophilic fibrinous exudates and varying degrees of inflammatory cell 
infiltration (neutrophils, lymphocytes and eosinophils, Figure 7.2).
Fig 7.2 : Four days after Photofrin® PDT
Floor of mouth lesion, showing an area of deep connective tissue necrosis. 
There are extravascular fibrinous exudates associated with infiltrates of 
inflammatory cells. The blood vessels show loss of an endothelial lining and 
replacement of the wall with a hyalinised eosinophilic coagulum. Most vessels 
remain patent. H&E (bar = 100pm).
Loss of endothelium in the small blood vessels was common with signs of 
haemorrhage, thrombosis and fibrinous exudate, although most vessels 
appeared patent in spite of obvious injury. Larger vessels showed replacement 
of the wall with a hyalinised eosinophilic material with loss of cellularity. No
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evidence of selective tumour necrosis was found. In routinely stained sections, 
necrotic tumour could not be distinguished from the adjacent necrotic 
connective tissue. However, with the aid of immunohistochemical cytokeratin 
staining techniques, necrotic tumour could be distinguished from the connective 
tissue necrosis observed, and reticulin staining helped to distinguish the outline 
of the original epithelium and its basement membrane (Figure 7.3).
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Fig 7.3 : Two days after Photofrin® PDT on a floor of mouth lesion 
Serial sections of necrotic tumour stained with (left) H&E and (right) a reticulin 
stain. The superficial tumour is completely necrotic but is well delineated as 
pale areas (*) surrounded by reticulin-positive connective tissues (bar = 100pm)
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Fig 7.4 : Four days after Photofrin® PDT on a floor of mouth lesion
An area of inflamed connective tissue. Mature collagen (red) and elastic fibres
(black) are preserved (bar = 100pm)
In all cases, EVG staining showed preservation of mature collagen and the 
elastin structural protein framework, disrupted only occasionally by oedema and 
inflammation (Figure 7.4).
In four cases, viable tumour was seen within the resected specimen. In one this 
was seen at the resection margin not exposed to light, but in two, viable tumour 
was encountered beneath the area of necrosis. In one case, resected after two 
days, residual viable tumour islands were noted within an area of necrotic 
connective tissue and fibrinous slough. It was felt that this would eventually 
have undergone sloughing with time had it not been excised.
Beneath the epithelium, connective tissues showed gradually decreasing 
necrosis, oedema and inflammatory cell infiltration. In all cases, necrosis and 
heavy inflammation extended through the full thickness of the mucosa.
112
7.2.2.3 Quantitative Results
Of the 11 patients treated, seven had satisfactory complete PDT ablation of 
their tumours in the resected specimen with tumour-free surgical margins. Of 
the remaining four, three had viable tumour islands present at depths of 4.0, 2.5 
and 1.3mm. These were resected at 2, 5 and 5 days post-treatment 
respectively, after PDT necrosis but before sloughing was complete. The fourth 
patient had residual tumour at one resection margin, for which he subsequently 
received curative radiotherapy.
The absolute necrosis depth was found to range from 1.1 to 4.1mm below the 
surface, with a mean value of 2.1 (sd = 0.9)mm. In most cases, this depth was 
found to be the same as the depth at which evidence of microvascular injury 
could be seen. The depth of inflammation was considerably deeper, ranging 
from 2.8 to 9.9mm, with a mean of 4.8 (sd = 1.8)mm (see Table 7.1).
Patient Site Excision
(days
post-PDT)
Depth 
absolute 
necrosis, 
mm (±sd)
Depth
inflammation, 
mm (±sd)
Presence 
of slough
Depth of 
viable tumour 
below
surface, mm
1 FoM 2 4.1 (±0.3) 9.9(±0.1) No 4
2 FoM 5 1.5(±0.1) 4.3(±0.1) Yes 1.3
3 FoM 3 2.3(±0.1) 5.1 (±0.2) No -
4 T 5 2.2(±0.7) 5.8(±0.7) No 2.5
5 FoM 7 1.1(±0.1) 3.3(±0.0) No Margin
6 FoM 2 2.9(±0.1) 5.6(±0.5) No -
7 FoM 5 2.6(±0.1) 5.0(±0.0) No -
8 BM 19 1.3(±0.1) 2.9(±0.1) Yes -
9 FoM 6 1.7(±0.2) 3.4(±0.4) Yes -
10 A 5 1.9(±0.1) 2.8(±0.1) Yes -
11 T 6 1.1(±0.1) 4.8(±0.4) Yes -
Mean 
2.1 (±0.9)
Mean 
4.8(±1.7)
Table 7.1: Details of tumour location, time of excision and quantitative 
histological findings
Key: FOM -  Floor of mouth, A -  Alveolus, T -  Tongue, BM -  Buccal mucosa
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7.2.3 Discussion
This study did not support the widely held view that PDT using 
dihaematoporphyrin ether/ester (Photofrin®) causes selective tumour 
destruction without normal tissue injury. In the literature the range of light doses 
used in the treatment of oral mucosal lesions varies from 50J/cm2 to 1,620J/cm2 
(Zhao et al 1991, Wile et al 1983, Carruth 1990, Calzavera et al 1989, Feyh 
1992, MacCaughan 1987, Wenig et al 1990). At higher levels the power 
densities used may also cause thermal injury to tissue, which may well be 
clinically beneficial but which makes it difficult to assess the contribution of the 
photodynamic effect.
Light dose regimes have not yet been standardised and light doses used in 
various studies are arbitrary. However, a light dose of 50J/cm2 represents the 
lower limit that has been shown to result in tumouricidal effects in PDT of upper 
aerodigestive carcinomas, and consequently this dose was chosen for this 
study.
This dose also should allow the detection of any evidence for selectivity of 
response and should spare normal tissues from injury. Our comparison of pre- 
and post-PDT photographs of treated lesions showed no evidence of a 
macroscopic difference in response of tumour or its surrounding normal 
mucosa; both were replaced by an ulcer slough, making the tumour site 
indistinguishable from the adjacent normal tissue. The dimensions of this 
slough closely corresponded to the area exposed to laser light. It would appear, 
therefore, that the tumour does not respond any differently from the surface 
epithelium. Monnier et al (1990) noted superficial ulceration of normal buccal 
mucosa using light doses of 60J/cm2 72 hours following HPD administration. 
However, these were macroscopic observations alone. There was no 
histological evidence of selective tumour necrosis. Indeed, it was only with the 
aid of special staining techniques that necrotic tumour could be distinguished 
from the adjacent necrotic connective tissue.
As explained in 4.1.4, photochemical injury results in a different type of injury 
from that observed with heat injury created by thermal lasers or diathermy. This
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non-thermal injury does not damage or denature the sub-epithelial collagen and 
elastin, and reticulin staining confirmed that there was preservation of non- 
cellular supporting elements, suggesting that the tissue architecture may be 
maintained while cellular and vascular elements are damaged. This may 
provide a matrix for regeneration of normal tissues and may explain the 
excellent healing observed both in clinical and animal studies. Similar 
observations have been made in the colon, bladder and trachea in rats and in 
mucosal surfaces and skin in patients (Barr et al 1987a, Pope et al 1991b,
Smith et al 1993). This might be interpreted as selective tumour necrosis, 
whereas in fact there is necrosis of both tumour and normal tissue, with ultimate 
healing by regeneration of normal tissue.
All resected specimens showed evidence of microvascular injury with loss of 
endothelium and a 'fibrinoid' type of necrosis in larger vessel walls. These 
changes were accompanied by the presence of fibrin in the necrotic zones, 
suggesting an increase in vascular permeability. Only a few of the vessels in 
the lamina propria and sub-mucosa were actually thrombosed, and many 
appeared patent. This confirms the view published elsewhere that 
microvascular injury is not solely responsible for tissue necrosis and that direct 
cytotoxic injury may also occur.
The presence of islands of viable tumour at relatively superficial levels is a 
cause for concern. But, in three cases, the tumour was surrounded by 
extensive connective tissue damage and vascular injury with thrombosis, and it 
is probable that sloughing or eventual ischaemic necrosis would eventually 
occur.
Viable tumour was also found at a deeper level than the necrosis, and this 
would not be affected, due to the attenuation of penetrating light (Bown 1990, 
Gluckman 1991b). In these cases, tumour survival is inevitable, and rapid 
epithelial regeneration following PDT could mask the need for further 
intervention. Pre-treatment tumour imaging is clearly extremely important and if 
PDT is to be used for such deep lesions, then light delivery via intersitial fibres 
may be necessary.
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PDT-induced inflammatory changes extended to depths from 2.8mm to 9.9mm 
at this light dose. This variation probably reflects variations in the optical 
properties of the tissues or tumours being treated, and difficulties in delivering 
light uniformly to the irregular surfaces in the mouth.
There was always necrosis to the full thickness of the oral mucosa. Therefore, 
even at this light dose one can be confident of destroying lesions that are 
confined within this level, such as severe dysplasias, carcinoma in situ, and 
early invasive lesions which have not penetrated to the muscle or periosteum.
All patients tolerated PDT without analgesia or significant discomfort at the time 
of treatment. After the first three patients were treated as in-patients, the 
remainder were treated on a day-care basis. Good compliance with instructions 
regarding avoidance of direct sunlight, resulted in no patient experiencing any 
significant cutaneous phototoxic event, though minor skin erythema and 
irritation of the hands and face was experienced by three patients. Most of the 
patients experienced some degree of tanning, which persisted for several 
months.
Pain was experienced at some stage following PDT by all of the patients and in 
some instances necessitated oral opiate analgesia. The use of a local 
analgesic and anti-inflammatory spray prior to meals was also found to be 
useful. In most cases pain commenced 24 to 48 hours after completion of the 
treatment and lasted for several days.
7.2.4 Conclusion
True selective tumour necrosis could not be observed using Photofrin® in this 
study. The depth of necrosis ranged from 1.1 to 4mm below the surface, which 
may be inadequate to clear all tumour cells in superficial cancers of the oral 
cavity. Residual photosensitivity was long but in this study led to no serious 
adverse effects.
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7.3 PDT Effect on Human Tissue with ALA
ALA is now licensed in the USA for use in its topical form in the treatment of 
early basal cell carcinomas and actinic keratosis. In this preparation there is no 
cutaneous photosensitivity except at the local site where the drug is applied and 
even when administered systemically there is only a short period (1 to 2 days) 
of cutaneous photosensitivity (Mustajoki et al 1992). Healing following 
treatment is excellent making it therefore ideal to treat extensive dysplastic 
lesions in the oral cavity. In this series of studies, systemic administration of 
ALA was given as we were not able to find an effective topical preparation for 
intraoral use.
7.3.1 Biodistribution Study
Pre-clinical studies were undertaken initially to elucidate the biodistribution of 
protoporphyrin IX the photoactive derivative of ALA. In these it was clearly 
shown that protoporphyrin IX accumulated preferentially in the epithelium with 
little uptake in the underlying muscle. This raised the possibility of selective 
epithelial damage inflicted by PDT with no damage to the deeper tissue.
Local ethical committee approval was granted for this study, a Medicines 
Control Agency “Doctors and Dentists Exemption from Clinical Trials Certificate” 
was granted, and informed consent was obtained in each case. 4 patients with 
advanced squamous cell carcinomas of the mouth were given 30-60mg/kg ALA 
by mouth then kept in a semi-darkened room for 24h. Serial biopsies were 
performed before and up to 24h after ALA. 10pm frozen sections were looked 
at by quantitative fluorescence microscopy (corrected for autofluorescence) as 
described by Grant et al 1993a. Maximum fluorescence was found 4-6h after 
ALA, and had returned to background levels in 24h (figure 7.5). Tumour 
fluorescence intensity in epithelium was about twice that of the surrounding 
connective tissues, showing the selective ability of tumour tissue to synthesise 
and accumulate porphyrins. This differs from the accumulation of 
phthalocyanines which is concentrated in the submucosal connective tissue 
(figure 7.6). Where normal or dysplastic epithelium could be sampled, this was 
seen to behave similarly to tumour areas. High performance liquid
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chromatography done in one case confirmed the fluorescing porphyrin to be 
>96% PPIX, representing 2-2.5pg/g of tissue at peak fluorescence.
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Fig 7.5 : Tumour protoporphyrin IX fluorescence with time in 4 patients
ALA
Fig 7.6 : Fluorescence images for ALA with histological comparison
Note that ALA fluorescence is maximal in the epithelium as shown by the cold
false colour image.
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7.3.2 Histological Effects
Three patients (the 4 th was responding to radiotherapy) were given 60mg/kg of 
ALA on another occasion and their tumours were exposed to 50-100J/cm 2 laser 
light at 630nm  from a copper vapour laser, at times corresponding to maximum  
fluorescence (4-6h). Although they had some local discomfort, patients 
tolerated the treatm ent well. After treatment, the surface of the tumour became 
oedematous and ulcerated over the next 24h. Biopsies were performed at 48h  
to see if photodynamic necrosis had occurred. Specimens were examined by 
an oral pathologist with experience of photodynamically-induced injury. 
Characteristic coagulative necrosis with evidence of microvascular injury was 
seen in the 3 patients. The pattern of necrosis was entirely as predicted from 
the fluorescence studies -  that is to say necrosis limited to the epithelium where  
the PPIX  was concentrated. There also seemed to be little vascular dam age  
(figure 7.7) Treatm ent was palliative and complete tumour ablation was not an 
aim in these advanced cancers. Treatm ent with ALA did not cause  
abnormalities in electrolyte balance nor haematological indices. 3 of the 4  
patients showed a rise of serum aspartate aminotransferase concentrations, 
which returned to normal within 3 days. 2 had a small temporary rise in total 
bilirubin.
full thickness epithelial necrosis
little vascular dam age
Fig 7.7 Histological effects of ALA PDT
This study shows that oral squamous cell carcinomas can synthesise and 
accumulate photosensitising levels of PPIX after oral ALA. Only tumour
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samples were removed from the mouth to measure fluorescence, and normal 
tissue sensitisation was not examined, although some necrosis of normal 
mucosa next to the tumour and exposed to light was seen. The main 
advantage of using ALA-induced PPIX for photosensitisation is the rapid 
clearance of the sensitiser within 24h, which would make it possible to repeat 
treatments at short intervals until ablation is complete. Giving ALA by mouth is 
more acceptable to the patient than by intravenous injection. The use of 
systemic ALA to induce PPIX photosensitisation is a novel method of tumour 
photodynamic therapy, which may yet prove suitable as a primary treatment for 
early cancers and dysplasias of the oral cavity.
7.4 Further Studies to Determine Depth of Effect Following ALA PDT
A further group of patients was treated using systemic administration of ALA
7.4.1 Materials and Methods
The study was conducted on 15 patients using oral preparations of ALA. All 
patients had histological confirmed malignant or pre-malignant lesions in the 
mouth but none had regional nodal disease. Patients with active liver disease 
were excluded from the study because of the risk of precipitating acute 
porphyria though subsequent clinical experiences suggest that this is not a 
significant risk.
Previous studies have found that the PDT effect with ALA can be superficial 
even with long treatment times and high light doses (Grant et al 1993a, Loh et 
al 1993a, Regula et al 1995). It has been suggested that PDT effects might be 
enhanced through fractionation of the light dose (Foster et al 1991, Messmann 
et al 1995, Pe et al 1994, Van den Veen et al 1994). Van der Veen et al (1994) 
found that a 75 minute break between light fractions enhanced the effect and 
Messmann et al (1995) found that a break of 150 seconds during a 250 second 
exposure enhanced the PDT effect substantially compared to the same light 
dose delivered without a break.
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Details of treatments are given in table 7.2. The study had approval from the 
UCL Ethics Committee and treatment was carried out with informed consent. 
Initially patients were treated as inpatients but subsequent treatments were 
carried out on an out-patient basis. The photosensitiser used in this project was 
supplied by DUSA Pharmaceuticals Inc (Wilmington, MA). All preparations 
were made up in orange juice and given in three divided doses of 20mg/Kg at 0, 
1 and 2 hours following the regimen established by Regula et al (1995). All 
patients were kept away from bright sunlight for 24 hours following drug 
administration and a drug light interval of 2.5 hours was used (4.5 hours after 
the first dose of ALA).
Laser and Light Delivery: A variety of light sources were used. The gold 
vapour laser giving light at 628nm (Dynamic Light Ltd, Milton Keynes, UK) was 
used. This was delivered using a mode scrambled 400um core flexible optical 
fibre with a bare plain cleaved tip giving a circular spot up to 2.5cm in diameter. 
Power dosing was kept below 150mWatts per cm2 to avoid thermal effects 
although this meant that treatment times were long (up to 143 minutes) so 
maintenance of patient and fibre position was sometimes difficult. The 
irradiation regime was varied a little with the first group consisting of eleven 
patients who received a total light fluence of 100J/cm2 in two fractions with a 
minimum of 5 minutes between the two fractions (after Messmann et al 1995) 
and a second group of four patients who received 200J/cm2 in two fractions 
delivered at 2.5 and 4 hours after the first dose of ALA (after van der Veen et al
1994).
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7.4.2 Results
Patient Age/Sex Site Previous 
T reatment
Maximum
Necrosis/mm
Maximum
Inflammation mm/layer
Group
1 73/M BM Nil 0.9 1.2/submucosa
2 69/M FM C 02 0.8 1.5/submucosa
3 52/M FM Nil 1.1 6+/muscle
4 79/M T Nil 0.6 2.5+/submucosa
5 51/M FM Nil 0.1 1.0/submucosa
6 75/M BM C 02 laser 0.6 1.5/mucosa
7 70/M BM/A Nil 0.3 1.2/submucosa
8 87/F T Field change 0.5 1.2/muscle
9 81/F A mandibular
resection
0.5 1.0/mucosa
10 62/M FM Nil 1.3 Not measured
11 65/M BM/A
P/RM
Field change 0.7 1.3/submucosa
Mean 0.7mm 1.8mm
Group 2
1 67/M BM Nil 0.5 1.1/submucosa
2 46/M A C 02 laser 0.2 0.9/submucosa
3 49/M T C 02 laser 0.3 0.8/muscle
4 59/F T C 02 laser 0.6 2.5/muscle
Mean 0.4mm 1.3mm
Table 7.2: Details of tumour location and quantitative histological findings 
Key: Pt-patient; A-alveolus; BM-bucal mucosa; FM-floor of mouth; P-palate; 
RM-retromolar trigone; T-tongue;
+-indicates inflammatory changes extending through full thickenss of biopsy; 
Group 1 received 100J/cm2 in two fractions with 5 minutes between the two 
fractions
Group 2 received 200J/cm2 in two fractions delivered at 2.5 and 4 hours after 
the first dose of ALA
Biopsies were taken between 3 and 8 days post treatment
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Fig 7.8: 4 days after illumination
The treated area becam e inflamed within a few  hours. This was followed by the 
formation of a whitish slough of the superficial layers after 1-2 days. Healing 
then took place over the next three to five weeks (larger lesions taking longer to 
heal than smaller ones) with no evidence of scarring except at biopsy sites.
Depth of PD T Dam age: In the first group of eleven patients -  the group that 
received a total dose of 100J/cm 2 with a five minute break in light delivery at the 
mid point produced a depth of necrosis varying from 0.1 to 1.3mm (mean  
0.7m m ). The depth of inflammatory response ranged from 1 to 6mm (mean 
1.8m m ). Again full thickness epithelial necrosis was seen in all cases with a 
variable depth of inflammatory response.
In four patients in group 2, ie; those that received a total light dose of 200J/cm 2 
with a 90 minute break between light fractions, the depth of necrosis was 0.2 to 
0.6m m  (m ean 0.4m m ). Inflammatory changes extended from 0.8 to 2.5m m  
(m ean 1.3m m ). Epithelial necrosis was seen in all cases.
The depth of P D T effect with ALA seems to be limited to the epithelium. This is 
entirely as predicted from the fluorescence studies which show that there is 
preferential accumulation of protoporphyrin IX (PPIX), in the epithelium only 
with relative sparing of deeper tissues. This certainly implies that it might be
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difficult to get a very deep PDT effect using ALA for cancer but it might be 
effective in the treatment of pre-malignancy.
7.4.3 Discussion
PDT using ALA has a shorter period of cutaneous photosensitivity than with 
Photofrin®, making it more acceptable to clinicians and patients.
The depth of necrosis with ALA was found in this study to be between 0.1 and 
1.3mm and the inflammation ranged between 0.8 and 6mm. Both of these are 
shallower than the findings with Photofrin® (Section 7.2).
Although it was difficult to measure the depth of necrosis accurately due to 
variations in the time between PDT and biopsy ( 3 - 8  days), it was clear that 
there was complete epithelial necrosis in every case and no necrosis was seen 
in muscle - although some cases showed inflammation in muscle.
There was no selectivity of necrosis between normal and abnormal epithelium - 
the area of necrosis always corresponded to the illuminated area. There was 
however selectivity of necrosis between epithelium and underlying muscle - 
consistent with the fluorescence microscopy findings which showed that there 
were much lower levels of PPIX in underlying connective tissue and muscle.
The maximum dose that patients can tolerate orally is 60mg/kg (Regula et al 
1995) which, by extrapolation from animal studies (Messmann et al 1995) may 
be only just above the threshold dose required to produce a PDT effect 
(50mg/kg). An iv formulation of ALA might halve the dose required to achieve 
target tissue levels (Loh et al 1993) and the maximum tolerable dose may be 
higher leading to increased tissue levels of PPIX and a greater depth of 
necrosis. This does not seem to be the case however in the small number of 
post IV ALA PDT biopsies undertakento date.
The maximum depth of necrosis in this study was 1.3mm which clearly limits the 
use of ALA PDT to superficial carcinomas and dysplasia. It would be preferable 
if ALA could produce a greater depth of necrosis as its short cutaneous
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photosensitivity is an attractive feature. It might be possible to further increase 
the IV drug dose to optimise treatment effects. This is clearly a possible way 
forward.
7.5 PDT Effect with mTHPC (Foscan®)
7.5.1 Introduction
Photodynamic therapy using Photofrin® has been shown to be of benefit but it 
is limited by a weak absorption band in the red region of the spectrum and a 
long period of residual photosensitivity. ALA has a shorter period of residual 
photosensitivity (two days) but this is offset by a smaller depth of necrosis. 
Meta-tetrahydroxyphenyl chlorin (mTHPC, Foscan®: (Biolitec) Scotia 
Pharmaceuticals, (Ireland) Dublin) appears to have a number of advantages 
over both of these photosensitisers.
The aim of this study was to determine the histological changes of mTHPC 
photodynamic therapy, in a group of patients with oral squamous cell 
carcinomas or severe epithelial dysplasia.
7.5.2 Material and Methods
Observations were based on a group of 10 patients treated and described in 
Chapters 8, 9 and 10. That is, patients with varying degrees of dysplasia, early 
invasive cancer and field change disease.
Treatment protocol involved the intravenous infusion of 0.15mg/Kg of mTHPC 
which was administered through a filter 96 hours prior to laser irradiation. 
Illumination was carried out using a copper vapour pumped dye laser emitting 
light at 652nm (Dynamic Light, Hornsby, Australia) with a beam delivered via a 
0.5mm diameter flexible microlens system (PDT Systems, Santa Barbara, 
California) to obtain the light dosimetry. Later a diode laser (Diomed, 
Cambridge, UK) was used to effect treatment. The irradiance was kept below 
250mWatts per cm2 to avoid thermal effects and biopsies were taken wherever 
possible at four separate times, if the patient was able to tolerate it. That is to
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say at initial diagnosis, immediately prior to irradiation, during the ulcerated 
stage and when healing is complete. The application of local anaesthetic was 
limited to the site of biopsy to avoid any possible alteration in the PDT effect. 
Specimens were fixed in 10% neutral buffered formalin and processed routinely 
then 5pm sections were cut and stained with haematoxylin and eosin for 
histopathological examination. Routine haematological and biochemical 
investigations were carried out before and after mTHPC administration.
7.5.3 Photodynamic Therapy
Treatments were carried out with the patient conscious in all except one case 
(patient 14) where a general anaesthetic was administered to improve access to 
a lesion on the soft palate. The treatment times were short, ranging from 113 to 
480 seconds, and treatment was generally well tolerated. The lesion plus a 1 to 
2cm margin of normal tissue was treated. This area was marked with small 
dots of crystal violet blue dye to allow repositioning or resizing of the irradiated 
spot, should patient movement occur.
Patients were kept in a dimmed room after receiving mTHPC, and given verbal 
and written instructions on avoidance of bright light during the two to three 
weeks for which they were likely to be photosensitive.
7.5.4 Results
7.5.4.1 Depth of PDT Effect
Although we were able to make an assessment of the depth of PDT effect with 
ALA and Photofrin®, this proved very much harder with Foscan®. Post 
treatment biopsies were taken, but the tissue was often so severely affected 
that meaningful interpretation was not possible, however, the overall depth of 
PDT effect was much deeper than with Photofrin® and of the order of 1cm 
which is in keeping with other estimates. This will in part be a function of greater 
light penetration at 652nm (Foscan®) compared with 635nm (Photofrin®) and 
also the greater quantum yield of free radicals generated by Foscan®.
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7.5.4.2 Clinical Course
Twenty-eight lesions were treated in 26 PD T treatm ent sessions. Within a few  
hours of PDT, the treated area exhibited erythema, oedem a and in some cases 
blister formation. This was followed by a phase characterised by vascular 
stasis and congestion, leading to necrosis, the formation of a fibrino-purulent 
slough and ultimately ulceration. The ulceration typically took five to eight 
weeks to heal, with some scarring in five patients. These effects generally 
improved with time (Fig 7.9: 1a to d), although two patients developed  
complications. One of these had a very large T 4 tumour (32cm 2) on the palate 
irradiated with 20J/cm 2. Reflected and scattered light resulted in ulceration and 
necrosis of normal oral tissue well away from the target lesion. Normal tissues 
in subsequent cases were shielded to avoid this.
The second problem was significant tethering of the tongue after treatm ent of a 
carcinoma in situ in the floor of the mouth. As can be seen by the following 
case this situation improved over time.
Fig 7.9: (a) T i squamous cell carcinoma and surrounding leukoplakia of the 
ventral tongue/floor of mouth before photodynamic therapy (b) 13 days after
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Foscan® photodynamic therapy showing ulceration with the presence of a thick 
fibrino-purulent slough of the entire irradiated site which included normal and 
abnormal regions (c) Seven weeks after PDT with complete healing of the 
treatment site. Scarring is present (hyperplasia was seen on the post-treatment 
biopsy) (d) Eight months after PDT showing disappearance of the scarring at 
the treatment site
Analgesia was required by all patients in the early ulcerative phase, starting one 
to two days post-PDT, with oral opiates being prescribed for one to two weeks 
for most patients. All patients had a full blood count, serum electrolytes and 
liver function tests, before and up to three months after administration of 
mTHPC. There were no changes in either the haematological or biochemical 
indices following PDT.
7.5.4.3 Pathological Changes
Biopsies taken in the early stages (three to seven days), show lesions 
characterised by massive acute inflammation, vascular damage and oedema. 
There was ulceration of the overlying epithelium and necrosis, which frequently 
extended to the submucosa and occasionally into muscle. There was 
prominent separation of muscle fibres by inflammatory cells and oedema fluid 
with scattered infiltrates of eosinophils (Figure 7.10).
The mucosa was replaced by a dense oedematous fibrino-purulent slough, with 
a massive exocytosis of neutrophils and occasional eosinophils (Figure 7.11). 
Small blood vessels, arterioles and venules showed loss of endothelial cells and 
prominent pavementation of polymorphonuclear leukocytes (Figure 7.12). The 
acute inflammatory infiltrate and oedema extended deep into the underlying 
submucosa and muscle when present.
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Fig 7.10: Three days after Foscan® PDT
Disruption of normal tissue architecture -  note disordered collagen, elastin and 
muscle with infiltration of inflammatory cells (bar = 50pm).
Fig 7.11: Characteristic findings three days after PDT  
The epithelium is completely replaced by necrotic ulcer slough and the 
connective tissue is oedem atous and shows inflammation and haemorrhage. 
H&E. (bar = 50pm )
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Fig 7.12: Characteristic changes in blood vessels three days after PD T  
There is extensive vascular dam age with loss of endothelial cells and resulting 
oedem a, extravasation and inflammation. Thrombus formation is prominent. 
H&E. (bar = 50pm )
In biopsies taken at 10 to 12 days there was still evidence of widespread  
ulceration and mucosal necrosis with acute inflammatory cells, but infiltrates of 
lymphocytes and macrophages were few at this stage. At the margins of the 
ulcerated area, growth of new epithelium was frequently seen below the fibrino- 
purulent slough. Deep below the mucosa, and often within muscle, there was 
deposition of immature granulation tissue with proliferating endothelial cells, 
fibroblasts and chronic inflammatory cells. This process of organisation 
suggested that the end result would be scarring, which was consistent with the 
clinical findings and was seen in specimens taken after healing was complete 
(Figure 7 .13).
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Fig 7.13: (a) Biopsy showing severe epithelial dysplasia with evidence of 
microinvasion before PDT. H&E; bar = 50pm. (b) Biopsy of the sam e site three 
months after P D T showing healing with well-ordered epithelium overlying 
fibrous scar tissue. H&E; (bar = 50pm )
7.5.5 Discussion
PD T using m TH P C  has a very powerful effect which appears to be directly 
cytotoxic with som e elem ents of vascular stasis. The disruption to the collagen 
and elastin would suggest that post-treatment scarring is likely and has in fact 
been shown to be the case although over time these changes subside to more 
acceptable levels. (Figure 7.9: a to d).
It is vital that the depth of PD T necrosis be greater than the depth of each  
individual tumour. Surface irradiation of deep tumours may leave residual 
tumour beneath regenerated mucosa, as the red light used to activate the 
photochemical reaction only penetrates a few millimeters. The depth of light 
penetration, and hence sensitiser activation is important whether the 
mechanism of cell kill is direct cytotoxicity or destruction of the tumour 
vasculature. From the histopathology, vascular dam age plays an important role 
in the patients described in this study (Figure 7 .12).
Although P D T with m TH PC  was successful in the treatm ent of the oral 
dysplasias, ALA also adequately eradicates this superficial disease as shown in 
the previous section (7.3)). ALA has the advantage of inducing only one to two 
days of cutaneous photosensitivity, but it may cause elevated levels of liver
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enzymes and the depth of effect is probably inadequate for treating invasive 
cancers (Grant et al 1993a, Regula et al 1995).
7.5.6 Conclusion
Foscan® PDT causes effective necrosis with some scarring using these 
parameters (0.15mg/kg Foscan®, 4 day drug light interval and 20J/cm2 light 
dose at 652nm). Photosensitivity is a problem for three weeks, which is clearly 
inferior to ALA but much better than Photofrin®.
7.6 Comparison of the Three Sensitisers
There were a number of problems common to all three drugs when used for 
PDT treatment in the oral cavity. Accurate light dosimetry within the mouth is 
extremely difficult due to the undulating contours of the mouth and the likelihood 
of movement, especially of the lower jaw and tongue.
More posteriorly it is difficult to ensure that light is delivered at right angles to 
the surface. 1A divergent microlens allows even light emission from the fibre 
and allows the fibre to be placed closer to the surface but in this region of the 
mouth, occasionally elliptical light spots must result. As the power density of 
the light varies inversely with the square of the distance between the fibre and 
the target tissue, even small variations in the distance from the fibre tip from 
that originally calculated will result in large differences in the total energy 
density delivered. In our study, this was optimised by constantly checking and 
correcting this distance to compensate for movements, but it remains a 
technical difficulty that needs to be improved in treatment in the mouth.
ALA has advantages of a short period of cutaneous photosensitivity and the 
very superficial effect makes it safe. Excessive light exposure in the first 2 
hours post sensitisation results in full thickness epithelial necrosis of skin. This 
heals without any significant scarring and realistically does little more than a 
very gentle chemical peel. It may yet have an application in this area. The 
depth of effect is inadequate for the treatment of significant tumour bulk, but 
dysplasia remains a reasonable target. Photofrin® has a much better depth of
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effect -  down to about 4mm. Healing is excellent, but treatment times are long 
and the three month photosensitivity period is inconvenient. Initial studies were 
hampered by technical problems -  light of 635nm could only be delivered from 
a copper vapour or pumped dye laser, these machines were not easily portable 
and also unreliable. The advent of diode lasers has changed this perception 
and Photofrin® PDT has a potential clinical value. The most powerful sensitiser 
examined in this series of studies is Foscan®. The treatment times are short 
and produce a deep effect. There is a cost, however, and that is the potential 
for scar formation. Alteration in treatment parameters (see Chapter 8) might 
overcome some of these problems, but effective treatment of large tumours will 
result in damage to normal surrounding tissue until a truly selective effect can 
be demonstrated.
From these early studies, we went on to explore the clinical effects of PDT in 
different stages of oral precancer and cancer.
Chapter 8: Management of Dysplasia with Photodynamic Therapy
8.1 Introduction
Oral cancers can arise in clinically normal mucosa but are often preceded by 
premalignant lesions. The prevalence of such conditions in the general 
population may be up to 4.6%, (Axell 1987) with the rate of malignant 
transformation in oral epithelial dysplasia and leukoplakia with severe dysplasia 
quoted as 14% and 43%, respectively (Axell 1987, Lumerman et al 1995, 
Maerker and Burkhardt 1978). There are three principal areas of uncertainty 
associated with premalignancy. First, there are no widely accepted criteria for 
defining the presence and degree of dysplasia. Second, it is not clear which 
lesions require treatment, nor how aggressively such lesions should be treated 
(Speight et al 1993). Thirdly, many such patients exhibit a field change effect, 
so it may be necessary to treat large areas. In these circumstances, it may not 
be feasible to treat all affected areas at one time, so re-treatment may be 
necessary. Consequently, a modality with no cumulative toxicity is desirable.
Obviously, the first line of management is the elimination of risk factors such as 
smoking, drinking and Pan chewing. Active therapy includes surgical excision, 
topical cytotoxic therapy, systemic retinoid therapy, cryosurgery, or laser 
therapy, but none are entirely satisfactory or effective (Lamey 1993, Scully
1995),
Pre-malignant conditions of the oral cavity such as a leukoplakia and 
erythroplakia are clinical manifestations of increasing degrees of dysplasia. 
Dysplasia in the oral cavity is associated with an increased lifetime risk of 
malignant transformation. Histological grading of the lesion does not always 
provide a good prognostic factor for such transformation. By contrast Sudbo et 
al (2001), have shown that the DNA content can be used to predict the risk for 
malignant transformation in a wide range of oral precancerous lesions. While 
many clinicians would merely monitor mild dysplasia, few if any would be happy 
to monitor severely dysplastic changes. As dysplasia is caused by a number of 
genetic events, which are frequently widespread in the aerodigestive tract
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where the tissue is clinically normal, even surgical resection of clinically 
dysplastic lesions has a high recurrence rate.
Management of oral dysplasia remains contentious. Clearly the conservative 
management of severe dysplasia amounts to supervised neglect, but at the 
same time, it is difficult to justify ablative treatment for a premalignant condition. 
There is a clear need for an intervention to treat or at least downstage dysplasia 
that is repeatable with no long-term side effects.
The studies reported here were carried out between 1992-1994 for Photofrin®, 
1993-1995 for ALA and 1998-2004 for Foscan®. All cases were treated by me 
or under my supervision except for the Foscan® group that were all treated by 
me.
8.1.2 Photodynamic Therapy for Dysplasia
From the last chapter, it seems likely that PDT is potentially useful in dysplasia 
management. Photofrin® PDT produces a significant depth of effect without 
scarring. ALA has the potential advantage of a short period of photosensitivity, 
but has a fairly superficial effect. Foscan® PDT certainly has the deepest 
effect, however, some scarring might occur, especially when large areas are 
treated. In this chapter, I will describe studies of all three drugs in the 
management of dysplasia.
8.2 Treatment of Dysplasia with Photofrin®
The first drug to be investigated in the treatment of dysplasia was Photofrin®, a 
dihematoporphyrin ether (QLT, Vancouver, Canada). Although Photofrin® has 
been shown to be beneficial in certain clinical situations, (Gluckman 1991a) it 
has an ill-defined composition with poor tumour selectivity and causes 
prolonged cutaneous photosensitivity (6-12 weeks).
Based on experience gained with PDT, the management of dysplasia would 
seem an ideal treatment modality especially when applied to large areas. The 
nature of the photodynamic injury is such that healing should occur without any
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of the side effects of radiotherapy or surgery leaving function and appearance 
preserved intact.
8.2.1 Materials and Methods
Following ethical approval, 6 patients were recruited to this study. All had 
histologically proven dysplasia -  one had moderate dysplasia, the others had 
severe epithelial dysplasia of the oral cavity. All had refused or were unsuitable 
for conventional treatment. Prior to treatment, all had a standard 
haematological assessment which included a full blood count, urea and 
electrolytes.
8.2.2 Inclusion criteria
• Histologically proven dysplasia of the oral cavity
• All lesions were visible and accessible for treatment
• No upper limit on area
• Informed consent
8.2.3 Exclusion criteria
• Patients with history of porphyria
• Patients unable to give informed consent
• Patients with a life expectancy less than 3 months
8.2.4 Photosensitiser
Photofrin® was reconstituted from its freeze-dried formulation with 5% dextrose 
to give a concentration of 2.5mg/ml. Full instructions on light precautions were 
given prior to drug administration of Photofrin® 2 mg/kg body weight by slow 
intravenous infusion over 20 minutes. A drug light interval of 48 hours was 
used and all patients were treated under local anaesthesia as an outpatient.
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8.2.5 Treatment and Results
Laser illumination was carried out using 630nm light from a copper vapour 
pumped dye laser (Cu25/DL 10 Oxford Lasers Ltd, Abingdon, UK). Light was 
delivered down a 400pm fibre which was mode scrambled to produce uniform 
illumination over the spot being treated. The laser power output was adjusted 
to give a fluence rate below 250mW/cm2 to avoid thermal effects. The output 
was calibrated prior to each treatment and 50 -100J/cm2 delivered to the tissue 
target. The outer edge of the treatment area was marked with crystal violet, 
and overlapping spots were used to treat the target area. This comprised the 
full extent of the lesion plus a 0.5cm safety margin of clinically normal mucosa. 
Where treatments were very long, an articulated arm (an ENT snake) was used 
to hold the fibre still. All treatment sites were recorded in the notes and follow 
up biopsies carried out when healing was complete regardless of clinical 
appearance.
Pt
No
Area
cm2
Age/
sex
SoD SoP-M Pre Rx Light
dose
Jem2
EO
6-12
wks
LFU
(mths)
LaFU
(mths)
1 2 65/F MD LI Nil 50 MiD NC (139)
2 3 82/M SED LI S & R T 100 PR MD (4) NC (130)
3 6 57/M SED LIT E 100 CR CR CR (16)
4 3 51/M SED LI Nil 100 CR CR
MD (4)
CR (12)
Died Ca (72) 
Oesophagus
5 6
4
4
73/F SED R BM/ 
R&L 
Mand 
Alv
MS 100 PR C 02
ERD
Recurrence 
(17) further 
PDT died 
(127)
6 9 45/F SED R AlvR 
BM
S 100 CR
HK
CRats
(26)
MCT (19) 
twf PDT
Table 8.1: Results of Photofrin® PDT in the Management of Dysplasia 
Key: Pt No-patient number; SoD-severity of disease; SoP-M-site of pre­
malignancy; EO-early outcome; LFU-longterm follow-up; LaFU-latest follow-up; 
NC-no change; MiD-mild dysplasia; MD-moderate dysplasia; SED-severe 
epithelial dysplasia; MCT-metachronous tumour; twf-treated with further; S- 
surgery; MS-multiple surgery; E-excision; RT-radiotherapy; Ll-lower lip; T- 
tongue; Alv-alveolus; BM-buccal mucosa; Mand-mandibular; HK- 
hyperkeratosis ERD-excision for residual disease CR-complete response 
(clinical and biopsy) ats-at treated site; PR-partial response
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Treatment was carried out without anaesthesia in 3 of the patients. Local 
anaesthesia was used in the remainder. Regional anaesthesia was used in 
preference to infiltration because of concerns about adrenaline in the 
anaesthetic solution. Theoretically, this can reduce the blood supply to the 
treatment site and if this results in a fall in oxygen tension could interfere with 
the PDT effect.
Following treatment, blistering was noted at 24 hours with swelling around the 
treated area. However, over the following 3 weeks, healing took place without 
any scarring. Some patients complained of temporary alteration in salivary flow 
-  usually hyperptyalism -  although this always settled by the time healing was 
complete. The results are shown in Table 8.1.
Apart from phototoxicity, there were no complications of drug administration and 
treatment was well tolerated by all patients.
8.2.6 Discussion - Photofrin®
The number of patients reported in this group is small. While only 3 patients 
had complete responses, 4 of the 6 have long term follow up. While it is not 
possible to make any statistically valid comments, it is interesting to note that 
patients with dysplasia of the lip did well. Although dysplasia was not 
completely eliminated, none of the three patients went on to develop invasive 
disease. One died of an oesophageal tumour 6 years later and the other two 
remain under long-term follow up after more than 10 years.
Of the other patients, one (5) who had a history of field change disease went on 
to develop multiple tumours and eventually died in 2003. She had 
approximately 20 different primary tumours plus widespread dysplasia during 
this time (in addition to diabetes and mitral valve disease). Only one patient 
was lost to follow up (6) who returned to the West Country. She remained 
convinced that it was not the PDT that helped her but Dead Sea Mud which she 
applied to her mouth.
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Although we did not have any significant problems with phototoxicity, this group 
of patients were all carefully counselled and avoided sunlight for up to 3 
months. This was something of a trial to some of the patients especially if the 
treatment was carried out during the summer. One interesting observation was 
that all patients who underwent Photofrin® PDT developed a very obvious 
suntan -  this did not appear to be the case with the other drugs used in this 
chapter (ALA and Foscan®).
Photofrin® seems effective in the management of oral dysplasia. The clinical 
results of healing are excellent even when large areas are treated. Treatment 
was not without drawbacks however. Treatment times were long (1000s per 
spot) and the very large laser we used in these early studies was not always 
reliable and required a degree of medical physics input to generate a single 
photon. Of course this is not the case now that we have access to diode lasers 
that are portable and simply plug into a mains supply. The period of 
photosensitivity of up to 3 months was a problem for some patients and we did 
have some late phototoxicity problems although none of this group had serious 
problems.
8.3 5-Aminolevulinic Acid for Premalignant Lesions of the Oral Cavity
8.3.1 Background
ALA is unusual in that it is converted to a photoactive substance in vivo via the 
heme biosynthetic pathway. The systemic administration of ALA overcomes the 
feedback inhibition of ALA synthetase leading to the overproduction and 
accumulation of porphyrins pre-cursors to heme, in particular protoporphyrin IX 
(PPIX) (Pottier et al 1986). PPIX is the main photoactive substance produced 
following sensitization with ALA, (Pottier et al 1986, Kennedy et al 1992, 
Mustajoki et al 1992, Grant et al 1993b) and PDT using topical ALA has already 
been shown to be valuable in the treatment of basal cell carcinomas of the skin 
(Kennedy et al 1992). A major advantage of ALA is that, even after systemic 
administration, cutaneous photosensitivity only lasts 1 to 2 days (Mustajoki et al 
1992). In addition, PDT-treated tissues heal remarkably well, making it feasible 
to treat extensive superficial lesions that often pose problems for conventional
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management in the mouth (Grant et al 1993b). Further, in the authors’ 
preclinical and clinical studies, PPIX has been shown to accumulate more in the 
epithelium than in the underlying muscle (Grant et al 1993b, Loh et al 1993b), 
with the consequent possibility of selective damage to this layer following PDT. 
The present study investigated the efficacy of PDT using ALA in the 
management of premalignant lesions in the mouth. The PDT effect produced 
by ALA would seem to be ideal for the treatment of dysplasia.
In previous studies performed in this centre, the effect of PDT using ALA was 
found to be very superficial, even with long treatment times (Grant et all 993b, 
Loh et al 1993a, Regula et al 1995). The main concern was that the depth of 
effect would be insufficient if epithelial dysplasia is generated by an interaction 
between epithelium and deeper mucosal elements.
8.3.2 Materials and Methods
Twelve patients with histologically proven premalignant lesions of the mouth 
were sensitized with 60mg/kg ALA by mouth and treated with laser light at 628 
nanometers (100 or 200J/cm2). These patients were treated with a gold vapour 
laser, elsewhere copper vapour pumped dye lasers and diode lasers have been 
used generating light of 630 -  635nm. The results were assessed 
macroscopically and microscopically. Biopsies were taken immediately prior to 
PDT for fluorescence studies, a few days after PDT to assess the depth of 
necrosis, when healing was complete, and up to 88 weeks later.
The study was approved by the hospital ethical committee, and all treatment 
was carried out with fully informed consent from the patients.
8.3.3 Inclusion and Exclusion Criteria
• See 8.2.2 and 8.2.3
ALA was supplied for this project as the hydrochloride in powder form by DUSA 
Pharmaceuticals (Tarrytown, New York). For clinical use, this was dissolved in 
orange juice and given by mouth in three separate doses of 20mg/kg at 0, 1,
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and 2 hours (total dose, 60mg/kg) using the regimen established by Regula et 
al (1995). The light source used was a gold vapour laser giving red light at 
628nm (Dynamic Light, Milton Keynes, UK). This was delivered to the patient 
using a single mode scrambled, 0.4mm flexible optical fire with a bare flat- 
cleaved tip that gave a circular spot of light up to 2.5cm in diameter on the 
target tissue. The area to be treated was defined as the target lesion together 
with a margin of 5mm of surrounding normal tissue. Appropriate fibre positions 
and treatment times were calculated to give the desired light doses before 
treatment started, using one of the two dose regimens described below (Study 
Groups 1 and 2). Whenever possible, the entire lesion was treated from a 
single fibre position. However, due to the difficult shape of the mouth, this was 
often not practical, and up to seven different fibre positions had to be used in 
each patient. The power density was kept below 250mW/cm2 to avoid thermal 
effects. As many of the total exposure times were quite long (up to 143 
minutes), the fibre was positioned in a multi-jointed arm to keep its tip in the 
correct place over the area to be treated. Patients were given systemic 
analgesia and topical anaesthetic with occasional sedation if necessary. 
Injected local anaesthetic was limited to the site of biopsy.
Study Group 1 (7 patients) received a total fluence of 100J/cm2 in two equal 
fractions, with a minimum of one 5-minute interval between fractions. With the 
long treatment times required, it was sometimes uncomfortable for patients to 
keep their mouth open continuously, so in these cases there were further 
breaks during treatment.
Study Group 2 (5 patients) received a total light fluence of 200J/cm2 in two 
equal fractions. The first fraction was delivered 2.5 hours after the first dose of 
ALA, and the second was delivered at 4 hours.
The depth of necrosis in these two groups was not statistically significantly 
different, so for the purposes of clinical outcome were treated as one group.
Patients were kept in a dark room for 24 hours after receiving ALA. Routine 
haematologic and biochemical investigations were performed before and 1 to 2 
days after ALA ingestion (longer if any abnormalities were found).
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8.3.4 Results
Complete epithelial necrosis was present in all cases. All 12 patients showed 
improvement (repeat biopsy was normal or less dysplastic) and the treated 
areas healed without scarring. No patient had cutaneous photosensitivity for 
longer than 2 days. Patients reported experiences ranging from mild discomfort 
to severe pain during the time of irradiation, in some cases requiring more 
analgesia than had been anticipated. Significant discomfort was experienced 
by 6 of 12 patients. Nausea and vomiting was experienced by four. Nausea 
was often an early feature presenting during the period of drug administration, 
whereas vomiting started several hours after ALA ingestion and resolved by 24 
hours. Only one patient had cutaneous photosensitivity lasting longer than 24 
hours, but this resolved by 48 hours. After PDT, the treated area became 
inflamed within a few hours. This was followed by sloughing of the superficial 
layers after 1 to 2 days, leaving a shallow ulcer. Oral analgesics were usually 
required from the first or second day after PDT for approximately 1 week. 
Excellent healing was found in all areas irrespective of the size of the original 
lesion, although larger lesions often took longer to heal (3 to 5 weeks). There 
was no evidence of scarring in those lesions that had not undergone previous 
surgery, other than at the site where biopsy specimens were taken (Fig1).
Once healed, patients did not perceive any changes in function or sensation 
within the oral cavity.
8.3.5 Clinical Outcome
All 12 patients were reassessed when healing was complete, and 9 underwent 
further biopsies at this stage (2 to 12 weeks after PDT). Long term follow-up 
data were available on all 12 patients, 10 of whom underwent a late follow-up 
biopsy. Those who refused repeat biopsies usually did so because the treated 
areas looked macroscopically normal. Details of the specimens taken and the 
histologic finding are given in Tables 8.2 and 8.3.
All seven patients with moderate dysplasia improved after treatment, i.e., the 
mucosa became normal or only mildly dysplastic. However, in one case that 
only showed hyperplasia just after healing, moderate dysplasia was seen again
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48 weeks later (Table 8.2). In four of five patients with severe dysplasia, there 
was no evidence of residual disease after treatment with 36 to 78 weeks of 
follow-up, although one refused biopsy at the long term follow-up. In the other 
patient, moderate dysplasia was seen at early and late follow-up (Table 8.3). It 
is notable that in three of the patients with regression but not clearance of 
dysplasia (Patients 1, 3 and 9), there was no macroscopic evidence of disease, 
the mucosal surfaces appearing clinically normal once the PDT-treated area 
had healed.
One patient initially included in the SED group underwent a pre-PDT biopsy that 
showed just severe dysplasia. It was only after ALA PDT, when 88% of the 
mucosal lesion had cleared, that a biopsy was performed on the residual lesion 
and it was found to be microinvasive SCC with changes extending down the 
salivary ducts (Fig. 12). This suggested that PDT using ALA was able to deal 
with the severe dysplasia in this case but not the deeper invasive disease. As 
this patient was not suitable for surgery, further PDT was carried out using 
Photofrin® with no evidence of tumour at 11 months follow-up.
No changes were noted in the haematologic indices, although elevation of liver 
enzymes was observed in nine cases compared with baseline values obtained 
before ALA ingestion. The enzyme most commonly affected was aspartate 
transaminase (AST). The AST level rose above the normal range in only five 
cases, (maximum: 3.5 times the upper limit of normal), with bilirubin elevated in 
only two. Monitoring of liver function was only continued more than 2 days after 
ALA ingestion in cases with elevated AST levels. In all cases this was 
asymptomatic and returned to normal levels within 10 days, with the exception 
of one patient in whom liver enzymes were elevated for 30 days -  this patient 
had a history of excess alcohol intake. One patient developed a pruritic rash 1 
week after treatment, which on biopsy was diagnosed as a cutaneous lichenoid 
reaction. This gradually resolved uneventfully over the following 3 weeks.
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Pt Age/sex Site Previous Histology
no. Treatment healed/wk
Size of lesion 
before/ 
Healed
Histology
longest
1 73/M BM Nil Mild (5) 2.6cm"Vl.7cm
2
Mild (40)
2 69M FM C 0 2
laser
Normal (5) 6.2cm2/0cm2 Normal (32)
3 52 M FM Nil Mild (4) 7.1cm2/0cm2 N (28)
4 79M T Nil Mild (6) 3.1cm2/0cm2 Mild *56)
5 67/M BM Nil Normal (5)f 1.8cm2/0cm2 Moderate
(48)
6 69/F T Nil Mild (5) 3.1 cm2/0.8cm
2
Mild (64)
7 46/M A C 0 2 N (5) 1.0cm2/0cm2 Normal (64)
laser
BM: buccal mucosa; FM: floor of mouth; N: no clinical disease macroscopically, but 
biopsy refused; Normakhistologically proven no dysplasia;T: tongue; NM: not 
measurable; A: alveolus.
Inflammatory changes extend through full thickness of biopsy specimen, 
hyperplasia seen, but no dysplasia.
Full-thickness epithelial necrosis and sloughing present in all cases.
Patients 1-4 received 100J/cm2; patients 5-7, received 200J/cm2.
Table 8.2: Clinical Outcome of Patients with Moderate Dysplasia
Pt Age/sex 
no.
Site Previous
Treatment
Histology
healed/wk
Size of lesion
before/
Healed
Histology
longest
follow-up/wk
8 51/M FM Nil Normal (5) 6.3 cm^/Ocm^ Normal (6)
9 75/M BM C 0 2 laser Moderate 7.1cm2/0cm2 Moderate
(2) (54)
10 70M BM/ Nil Normal (8)* 8.8cm2/0cm2 N (36)
A (5)
11 49M T C 0 2 laser N (12) 8.0cm2/0cm2 Normal (78)
(5)
12 59/F T C 0 2 laser N (12) 4.8cm2/0cm2 Normal (76)
FM: floor of mouth; BM: buccal mucosa; A: alveolus; N: no clinical disease
macroscopically, but biopsy refused; Normal.histologically proven no dysplasiaT; T:
tongue.
Hyperplasia seen, but no dysplasia.
Full-thickness epithelial necrosis and sloughing present in all cases.
Patients 8-10 received 100J/cm2; patients 11 and 12 received 200J/cm2
Table 8.3: Clinical Outcome of Patients with Severe Dysplasia
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8.3.6 Discussion - ALA
ALA PDT has considerable attractions for treating premalignant and early 
malignant lesions of the mouth. It is relatively easy to apply, there is no 
cumulative toxicity, and healing is superior to other forms of local tissue 
destruction as the epithelium and lamina propria heal mainly with regeneration 
and only necrosed muscle is likely to scar.
Reviewing results in the present ALA series, patients with dysplasia did well. All 
12 patients showed improvement after PDT. Ten patients (83%) showed 
clinically (macroscopic) normal mucosa when healing was complete, although 
of the nine that underwent biopsy at this time, one showed moderate and four 
showed mild dysplasia. It was of some concern that persistent dysplasia was 
seen in lesions that macroscopically had reverted to normal, although the 
changes in these areas were never more than moderate dysplasia. Even 
patients in whom the biopsy specimen was normal after PDT cannot be 
regarded a cured, but the risk of malignancy should have been reduced and 
they can be given PDT with ALA again if necessary for regression. One of our 
patients with moderate dysplasia had a normal biopsy specimen after PDT but 
subsequently regressed to moderate dysplasia again on check biopsy 1 year 
later. This is not surprising as one is dealing with a field cancerisation process 
and premalignant lesions of the mouth have a high recurrence rate after all 
forms of treatment. Nevertheless, the risks are lower with milder degrees of 
dysplasia, and oral leukoplakia associated with mild dysplasia only has a 3% 
risk of malignant transformation (6). PDT seems to down regulate the severity 
of dysplasia in these patients; as it can be repeated if necessary, it is 
reasonable to hope that their disease can be kept under control for many years 
with minimal morbidity.
The maximum depth of necrosis (Chapter 7) was 1.3mm, comparable to the 
results found by Regula et al (1995), in gastrointestinal tumours. And it would 
be clearly preferable if the PDT with ALA could produce a greater depth of 
necrosis. Techniques for achieving this are outlined in Chapter 7.
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The convenience of the short cutaneous photosensitivity using ALA means that 
PDT can be repeated at short intervals if necessary.
8.4 Foscan® Photodynamic Therapy in the Treatment of Severe Epithelial 
Dysplasia
The main disadvantage of ALA treatment is the limited depth of effect (1mm) 
which makes it inadequate in the presence of co-existing early invasive disease. 
Added to that are prolonged treatment times up to 1000 seconds a spot. 
Photofrin® PDT was used as well with a slightly better depth of effect (5mm) but 
prolonged skin photosensitivity up to 6 weeks. Meta tetrahydroxyphenyl chlorin 
(mTHPC, Foscan®®, Biolitec) has been shown to be an effective 
photosensitiser in treating invasive disease, but with conventional doses of 
0.15mg/kg produces excessive tissue necrosis with scarring (Hopper). Kubler 
et al (2003) have shown that it is possible to treat skin cancer with a reduced 
drug dose and light doses and still produce a good depth of necrosis. In this 
study we aim to show that it is possible to treat severe epithelial dysplasia 
(SED) in the mouth using low dose Foscan® PDT.
8.4.1 Introduction
Foscan® PDT can effectively ablate disease of the oral mucosa down to a 
depth of up to 1cm. In the last chapter we demonstrated that the cost one 
bears with this is some degree of scarring with tethering of sensitive tissues 
such as the tongue. However, it is possible to get a reasonable depth and 
effect using Foscan® PDT by reducing either the drug or the light dose. We, 
therefore, carried out an incremental study using different light doses of 5 up to 
15J/cm2 and a drug dose of 0.1mg/Kg. This is by no means a comprehensive 
study but does go some way to demonstrate the ability one has to modify the 
side effect profile by changing the treatment parameters.
8.4.2 Materials and Methods
22 patients with histologically proven SED were recruited for this study. They 
underwent surface illumination PDT using Foscan® injected 96 hours prior to
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treatment with a diode laser. The study was approved by the ethics committee 
of University College London Hospitals and patients were fully informed and 
consented about the procedure. The male to female ratio was 1:1 with a mean 
age of 65 years (age range 34 - 98yrs). Mean follow up was 30 months (2-68m) 
while mean disease free interval was 12.8 months (2-63m). Mean disease free 
interval was defined as the time between treatment and the diagnosis of a new 
lesion.
8.4.3 Inclusion and Exclusion Criteria 
• See 8.2.2 and 8.2.3
8.4.4 Photodynamic therapy
Foscan® was supplied in 5ml vials with a concentration of 4mg/ml. The 
intravenous dose of 0.1 mg/kg was administered to the patient 96 hours prior to 
the treatment. Due to systemic skin photosensitivity after the iv injection of the 
photosensitiser, every patient was instructed on the need to avoid direct sun 
exposure for 3 weeks and was given written light precautions. Patients were 
allowed exposure up to 100 lux of light for the first day (60W light bulb) and 
increased by increments of 100 lux per day for the following three weeks. A 
Biolitec® diode laser was used emitting red light at 652nm wavelength.
45% (10/22) of the patients had their treatment carried out under local 
anaesthetic. 55% (12/22) had a general anaesthetic in order to improve access. 
Treatment times ranged between 50-600 seconds with a mean of 202 seconds. 
The treatment area was defined as the lesion with 1cm margin of normal tissue. 
This area was marked with a marker pen to allow repositioning or resizing of the 
irradiated spot made necessary by patient movement. The average number of 
spots per patient was 1.8 (range 1-6). The average size of the spot was 2.5cm 
with a range between 1.5-4cm. 27 sites were treated, 77% of patients had one 
site treated while 23% had 2 or more sites treated. 48% of lesions were on the 
tongue. Other sites included palate, floor of mouth, alveolar and buccal 
mucosa. Three different light doses were used. The first three patients were
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treated with a light dose of 5J/cm2. The next 14 patients were treated with 
10J/cm2. The last 5 patients were treated with 15J/cm2.
8.4.5 Results
The first three patients were treated with a light dose of 5J/cm2 (table 8.4). All 3 
patients went on to develop further areas of SED which required further 
treatment. 2 out of 3 patients went on to develop squamous cell carcinoma 
requiring major surgical resection +/- radiotherapy. Based on these results we 
decided to abandon the 5J/cm2 light dose and increased it to 10J/cm2. 14 
patients were treated using this light dose. 4 patients showed complete 
response (CR) and are disease free with a mean follow up of 18 months. 10 
patients showed partial response (PR). 3/10 went on to develop SCC while the 
other 7 developed further areas of mild/moderate/ severe epithelial dysplasia. 1 
developed another primary in the larynx and the oesophagus. 1 died of 
unrelated disease. 9/10 patients required further treatment for their disease. In 
total 11/14 patients are now disease free. 12/14 patients are alive. Mean 
disease free interval is 13 months. Median disease free interval is 7.5 months. 
The latest protocol involves using 15J/cm2. Five patients were treated with 
100% complete response. Mean follow up of 9.6 months.
The main complications noted were pain and swelling. All patients required 
analgesics in the early ulcerative phase, with oral opiates prescribed for 1-2 
weeks post PDT. No cutaneous photosensitivity was noted. It was noted that 
the site of iv injection of Foscan® was the most photosensitised in comparison 
to the rest of the body and extra care and light precautions were needed for at 
least six weeks. The procedure was well tolerated by the patients under local 
anaesthetic. No scarring was noted in the histological samples or clinically at 
sites of treatment. The treatment times ranged between 50 and 600 seconds 
with a mean of 262 seconds which is much quicker than PDT with other 
photosensitisers.
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Patient Age/
Sex
Site Prev
Rx
Light Dose 
J/cm2
DFI
(m)
Further
Rx
Outcome
1 65/M P L 5 15 S, RT NCD
2 60/F T ALA 5 17 S, PDT, 
ALA
Mild ED
3 70/F T Nil 5 14 L Mod ED
4 57/M T SCL 10 4 L, PDT Mild ED
5 42/F T Nil 10 23 NCD
6 78/M T, P, FoM S 10 1 PDT SCC (RIP)
7 73/M T Nil 10 63 SED
8 51/M T, FoM Nil 10 10 L Mild ED
9 54/M T RT, C 10 31 NCD (2na L)
10 73/M T ALA 10 5 L NCD
11 98/M AM S 10 3 S, L Mild ED 
(SED out)
12 75/F T Nil 10 20 NCD
13 64/F T Nil 10 2 L NCD
14 80/F P S,
LPDT
10 10 NCD
15 74/F P, AM Nil 10 3 S, L NCD
16 67/M BM S, PDT, 
ALA, L
10 4 PDT, 
ALA, L
NCD
17 34/F T L 10 12 ALA NCD (SED 
out)
18 43/F T Nil 15 13 NCD
19 83/M BM, P S 15 11 L NCD
20 68/M P Nil 15 7 NCD
21 62/F P S 15 10 NCD
22 62/F P Nil 15 7 NCD
Table 8.4: Treatment results - 22 patients
Key: T-Tongue, P-Palate, FoM-Floor of Mouth, AM-Alveolar Mucosa, BM- 
Buccal Mucosa, DFI-Disease Free Interval, Rx-Treatment, S-Surgery; C- 
Chemotherapy; L-C02 Laser; RT-Radiotherapy; PDT-Foscan® PDT; ALA- 
Photodynamic therapy with 5-aminolaevulinic acid; NCD-No clinical disease; 
Mild ED-Mild Epithelial Dysplasia; Mod ED-Moderate Epithelial Dysplasia; 
SED-Severe Epithelial Dysplasia; 2nd L-Second primary in larynx.
8.4.6 Discussion - Foscan®
The results of this study were slightly less predictable than one would have at 
first thought. Despite the fact that clinical responses were quite impressive at 
10J/cm2 and 0.1mg/Kg this did not translate into an acceptably high ‘cure’ rate. 
We know from other studies that 20J/cm2 and 0.15mg/Kg (the dose usually 
used for treatment of early invasive squamous cancer -  see Chaper 9) provides 
a suitable depth effect for treatment of this condition. However, it would seem 
that to safely ablate severely dysplastic disease (which may indeed carry foci of 
microinvasive disease) 15J/cm2 and 0.1mg/Kg would seem to be a safe dose. 
This is indeed borne out by parallel studies by Kubler et al (2003) in Cologne.
“Field cancerisation”, a concept introduced by Slaughter et al in 1953, described 
the potential for patients to develop multiple primary cancers from independent 
premalignant foci. This is well represented in our cohort of patients. It was 
interesting to note that 55% of our patients had previous treatments for either 
SCC or SED including one or more modalities of treatment. A further 8/18 
developed further areas of SCC or dysplasia following their PDT treatment.
This may represent sample bias, and perhaps treatment should have been 
confined to virgin cases of dysplasia. By including patients who had developed 
dysplasia after previous treatment, we had already selected a group who were 
likely to have widespread genetic damage, even though this might not be 
clinically apparent. It would seem likely that this group had an increased risk of 
dysplasia and metachronous tumours.
Foscan® PDT provides an alternative approach to treating SED. It is not only 
well tolerated but also simple and quick to execute. There is no cumulative 
toxicity and as such if response is incomplete areas can be retreated with PDT. 
Areas heal much better than other forms of local tissue destruction as the 
epithelium and lamina propria regenerate. At the reduced dose of Foscan® at 
0.1 mg/kg, minimal scarring if any was noted on the post PDT biopsies. 5J/cm2 
and 10J/cm2 light doses are not adequate to treat SED and thus the 
recommendation is to treat SED with 15J/cm2. Visible dysplasia should be 
treated with a wider margin to improve outcome. 22% of patients went on to 
develop SCC, which corresponds to the rate of malignant transformation quoted
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in the literature (malignant transformation of epithelial dysplasia quoted as 14% 
oral epithelial dysplasia and leukoplakia with severe dysplasia 43%, Axell 1987, 
Lumerman et al 1995, Maerker and Burkhardt 1978).
8.5 Conclusions
Photofrin® is useful in the management of selected cases of widespread 
dysplasia. However, the need for a better drug with a shorter treatment time 
and a shorter period of photosensitivity is obvious.
ALA produces consistent epithelial necrosis with excellent healing in dysplasia 
of the mouth and is a simple and effective way of managing patients. There are 
obvious limitations.
Foscan® PDT provides a very good option to treat SED in cases of wide field 
change with few complications. There are small but definite benefits from 
changing the drug light prescription for the management of pre-malignant 
disease which seems to reduce morbidity in terms of scarring and 
photosensitivity. In this study we have not addressed the other variable which 
is the drug light interval and recent work in Russia would suggest that reduction 
of this time period would allow an even greater reduction in the amount of drug 
used in the photosensitisation and also the amount of light to precipitate a 
photochemical effect. Having found a level at which dysplastic tissue can be 
treated effectively with a reduced drug and light dose has two major benefits. 
Firstly the period of photosensitivity is reduced. By reducing the drug from 
0.15mg to 0.1mg/Kg the need for avoidance of artificial light is greatly reduced. 
There is obviously a need to return to normal sunlight exposure in a controlled 
fashion but the photosensitive period is reduced by approximately four days by 
using this cocktail. By reducing the light dose somewhat the amount of pain 
and collateral damage from reflected light also seems reduced. This is a rather 
empirical finding and has not been quantified in this study.
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8.6 Summary
PDT with a variety of sensitisers is effective treatment of oral dysplasia, 
although the three drugs described have their advantages and disadvantages 
(table 8.5). ALA has the shortest period of photosensitivity but has a limited 
depth of effect. Photofrin® has a better depth of effect, but treatment times, 
along with ALA are long and there is also the added problem of prolonged 
photosensitivity. Foscan® can be used with a modified dose regime and seems 
to produce a consistent effect with a 2 week photosensitivity period. The great 
advantage is that treatment times are very short. It is also possible that 
alteration s in the drug light interval will allow an even shorter period of 
photosensitivity. Clearly, careful case selection is required but at the present 
time, Foscan® would seem to be the drug of choice for SED, especially when 
microinvasion is suspected, but not found in the biopsy specimen. ALA can 
also be useful, but careful evaluation of each case is necessary as the effect is 
so superficial.
Drug Dose DLI Wavelength Depth of 
effect
Photosensitivity
period
Treatment 
time /spot
Photofrin® 2mg/kg 48hrs 630nm 5mms 6 weeks + 1,000s
ALA 30 (IV) 60 
(PO)mg/kg
2 - 5
hrs
628-635nm 1-1.5mms 24 - 48hrs 1,000s
Foscan® 0.1 mg/kg 96hrs 652nm 5 -7  mms 2 weeks 150s
Table 8.5:Treatment parameters and depth of effect in dysplasia management
Chapter 9: Photodynamic Therapy in the Management of Early (T1) 
Squamous Cell Carcinoma of the Oral Cavity
9.1 Introduction
The mainstays of treatment for early disease are surgery and radiotherapy, 
either alone or in combination. The results of treatment vary considerably with 
the site and stage of the primary lesion. Initial local control is achieved in 67% 
to 95% of Ti tumours dropping to 50% to 81% with T2 disease (Munro 1995, 
Hong et al 1990).
The probability of local control at two years for patients with Ti or T2 SCC of the 
tongue is 76% to 79% (Munro 1995, Hong et al 1990).
The specialised functions of the oral cavity and face mean that the surgical 
treatment even of small volume tumours can cause functional and aesthetic 
impairment leading to withdrawal and social isolation. Treatment for T2 tumours 
may involve major surgical ablation and reconstruction in certain anatomical 
sub-sites. Radiotherapy is used extensively because it has less impact on 
structure and function, but it is not without problems. It is generally given as a 
single treatment course requiring daily hospital attendance for four to six weeks. 
It has complications caused by damage to tissue vasculature, which impairs 
wound healing, and this further complicates surgical salvage after failed 
radiotherapy. In the oral cavity, there is distressing xerostomia, which is 
permanent and almost impossible to treat (Fein et al 1994). Late complications 
of osteoradionecrosis, soft tissue necrosis, spinal cord myelitis, vascular 
damage and endoarteritis are also recognised (Fein et al 1994). In the younger 
population or in those with field change disease there is the potential for 
radiation-induced tumours (van der Laan et al 1995).
Most depressingly, there seems to have been little improvement in overall 
survival, which has not changed in the last 30 years (Blair 1994). Treatment 
strategies therefore should be targeted at the maintenance of aesthetics, 
function and quality of life, in addition to survival.
Even with small tumours there is an annual risk of 10% to 30% of developing 
metachronous tumours. Management of the second primary or recurrent 
tumour in previously treated areas is a difficult problem (Carr et al 1989, 
Gluckman et al 1983). There is clearly a need for alternative treatments that 
are repeatable in the field of previous radiotherapy without the tissue ablation 
associated with surgery. PDT may provide such a treatment. In this chapter, 
experiences with three different photosensitisers are described in the 
chronological order in which they were used. Broadly speaking, the Photofrin® 
was used from 1991 to 1994, ALA was studied from 1993 to 1994 and Foscan® 
from 1994 to 2000 with the latest follow-up at January 2005. All the studies 
described here underwent internal peer review with myself as principle 
investigator. All patients were under my sole care and the treatments were 
carried out by research fellows Mr W Grant and Ms K Fan under my supervision 
or by myself.
9.2 Photofrin® PDT
This was the first drug to be used in widespread clinical practice (see section 
3.3). Results with porphyrins or their derivatives with a light activating 
wavelength of 630nm are encouraging (see section 7.2), but the exact 
treatment parameters in the published works are variable an d often impossible 
to compare (Li et al 1990, Gluckman 1991b, Grant et al 1993b, Biel 1998).
Initial studies using the drug were reported in advanced disease, however, it 
seems much more logical to use this treatment in early disease where the total 
volume of disease can be treated. We had demonstrated that in the clinical 
setting, PDT damage could be inflicted on normal oral tissues with excellent 
healing, probably as a result of the preservation of collagen and elastin.
9.2.1 Aim
The aim of this study was to establish the efficacy of PDT treatment using the 
commercially available di-haematoporphyrin ether/ester mixture (Photofrin® 
QLT Vancouver, Canada) in the treatment of early (T1) squamous cell 
carcinoma of the oral cavity.
9.2.2 Materials and Methods
Four patients with histologically proven early invasive squamous cell 
carcinomas of the oral cavity, were included in the study group. (See Table 
9.1). All tumours were diagnosed as Stage 1 (TiN0N0) oral cancers and no 
deep extension to underlying muscle or bone was suggested by the clinical, 
histological or radiological findings. No patient had received radiotherapy. 
Informed consent was obtained in each case.
Photofrin® at a dose of 2mg/kg was given by intravenous infusion 48 hours 
prior to surface illumination of the tumour. A copper vapour pumped dye laser 
was used to deliver monochromatic red light at 630nm. An optical fibre with a 
microlens affixed ensured homogeneity of the illuminating light spot, and a 
multi-jointed articulated arm was used to facilitate positioning of the fibre in 
three planes.
All four patients were treated in a single session with a single spot of light. A 
light dose of 50 to 10OJ/crn2 was delivered to each patient. Power densities 
were kept below 150 mW/cm2 to avoid any possibility of thermal injury, and no 
patient reported any sensation of heat, although some described various 
sensations such as tingling and tickling during light exposure. Patients were 
counselled to avoid direct sunlight following sensitisation. Patients were 
prescribed analgesics and benzydamine local analgesic or anti-inflammatory 
spray.
Lesions were photographed and treatment areas were recorded 
diagrammatically on referral. Following treatment patients were reviewed and 
photographed twice in the week after PDT and then approximately weekly until 
healed, and thereafter every two to four weeks.
Three patients had biopsies of regenerated clinically normal mucosa, at sites 
where invasive carcinoma had been previously diagnosed. Each was taken 
more than three months after PDT.
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9.2.3 Results
All treatments w ere performed without local anaesthetic or sedation and were  
satisfactorily tolerated by each patient, on an outpatient basis. During the three 
to four days after PD T the treated areas underwent obvious surface necrosis 
with the developm ent of a superficial slough, and local oedem a. W hile no pain 
was associated with the treatm ent itself, all patients reported some degree of 
pain over the following days, usually lasting about one week, but this was  
effectively relieved by oral analgesia. Eating tended to exacerbate pain and a 
sloppy diet was advised and found to help. Treated areas took between three 
and five weeks to heal fully, depending on the size of area treated.
At assessm ent following healing, six to eight weeks after PDT, all four patients 
showed a complete response to treatment. The healed mucosa was of normal 
colour with no evidence of leukoplakia or erythroplakia (Figure 9 .1a and 9.1b).
Fig 9.1: Early S C C  left cheek before and after Photofrin® PDT
This patient had a retromolar trigone area treated, but was excluded from the
study because of the extensive sublingual keratosis.
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Patient
No
Age/Sex Disease
Stage
Site Previous
Treatment
Light
Dose
J/cm2
Outcome 
6-12 wks
Longest
FU
(mths)
1 60/F T1 Tongue Surgery 100 Mild dys CR 36
2 33/F T1 Tongue Nil 100 CR CR 48
3 40/M T1 Lip Surgery 50 CR CR 60
4 62/M T1 FOM ALA PDT 100 CR CR 16
Table 9.1: Clinical responses with Photofrin® PDT 
Key: FOM-Floor of mouth; CR-Complete response
9.2.4 Discussion
From this very small sample, the results of treatment were really quite 
encouraging. However, the difficulties of unreliable lasers, long treatment times 
and long periods of photosensitivity led to the abandonment of this drug in my 
clinical practice.
9.3 ALA PDT
There was much excitement when we first started using ALA for photodynamic 
therapy in the oral cavity. Unfortunately the depth of effect as described in 
chapter 7 would tend to suggest that it would not have been an ideal approach 
for the treatment of invasive cancer. The initial thought was that if light of 
630nm penetrated up to 5mm that while surrounding tissues may be left 
undamaged, any tumour of epithelial origin would be susceptible to the PDT 
effect. Unfortunately this was not borne out in the clinical study and while the 
treatment was very well tolerated by all patients without any side effects of 
scarring the clinical results soon resulted in the approach being stopped.
9.3.1 Materials and Methods
Six patients with histologically proven SCC lesions of the mouth were sensitized 
with 60mg/kg ALA by mouth and treated with laser light at 628nm (100 or 
200J/cm2). The results were assessed macroscopically and microscopically.
Patient
No
Age/Sex Disease
Stage
Site Previous
Treatment
Light
Dose
J/cm2
Outcome 
6-12 wks
Longest
FU
(mths)
1 60/F T1 Tongue Surgery 100 Mild dys CR 36
2 33/F T1 Tongue Nil 100 CR CR 48
3 40/M T1 Lip Surgery 50 CR CR 60
4 62/M T1 FOM ALA PDT 100 CR CR 16
Table 9.1: Clinical responses with Photofrin® PDT 
Key: FOM-Floor of mouth; CR-Complete response
9.2.4 Discussion
From this very small sample, the results of treatment were really quite 
encouraging. However, the difficulties of unreliable lasers, long treatment times 
and long periods of photosensitivity led to the abandonment of this drug in my 
clinical practice.
9.3 ALA PDT
There was much excitement when we first started using ALA for photodynamic 
therapy in the oral cavity. Unfortunately the depth of effect as described in 
chapter 7 would tend to suggest that it would not have been an ideal approach 
for the treatment of invasive cancer. The initial thought was that if light of 
630nm penetrated up to 5mm that while surrounding tissues may be left 
undamaged, any tumour of epithelial origin would be susceptible to the PDT 
effect. Unfortunately this was not borne out in the clinical study and while the 
treatment was very well tolerated by all patients without any side effects of 
scarring the clinical results soon resulted in the approach being stopped.
9.3.1 Materials and Methods
Six patients with histologically proven SCC lesions of the mouth were sensitized 
with 60mg/kg ALA by mouth and treated with laser light at 628nm (100 or 
200J/cm2). The results were assessed macroscopically and microscopically.
Biopsies were taken prior to PDT, a few days after PDT to assess the depth of 
necrosis, when healing was complete, and up to 88 weeks later.
The study was approved by the hospital ethical committee, and all treatment 
was carried out with fully informed consent from the patients. The supply of 
ALA, preparation and treatment methods are the same as outlined in Chapter 8. 
After treatment, patients were kept in a dark room for 24 hours after receiving 
ALA. Routine haematologic and biochemical investigations were performed 
before and 1 to 2 days after ALA ingestion (longer if any abnormalities were 
found).
9.3.2 Results
Following treatment, all patients showed superficial ulceration at the site of 
illumination. There was no evidence of a selective tumour effect, but there was 
also no evidence of damage to deeper structures such as muscle. Although the 
treatment itself was often painful (even with administration of copious local 
anaesthetic), the post treatment recovery was quite uneventful with only minor 
analgesics being required. In the first two patients (1,2 Table 9.2) healing was 
complete at 2 weeks and the results were very encouraging -  one had a 
complete response that has been sustained for almost 10 years. The second 
patient, although she had persistent mild epithelial dysplasia on post treatment 
biopsy remained well until she died of a stroke over 5 years later. The results 
with the other patients were less satisfactory and all had to go on to further 
treatment. This was typically demonstrated by case no 5 which is illustrated in 
figure 9.2.
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Fig 9.2: a) Before PDT, with severely dysplastic lesion; b) Four weeks after 
PD T with ALA, residual patch found to be microinvasive disease.
O f the partial responders with persistent invasive disease, it was necessary to 
go on to further treatment. O f course this remains one of the most useful 
aspects of PD T treatment -  that it does not adversely affect other treatments 
such as surgery and radiotherapy. However, this result might have been 
predicted from the studies conducted in Chapter 7 where the depth of effect 
was shown to be a maximum of 1 -  1.5mms.
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Age/Sex Site Previous
Treatment
Pre
Treatment
Post
Treatment
Histology FU
(mths)
1 52/F FOM CO2 laser 1.8cm2 No clinical 
disease
Normal 100
2 85/F P Surgery 4.6cm2 0.8cm2 Mild
dysplasia
67 (RIP 
CVA)
A further four patients were treated but all had invasive squamous cell 
carcinoma and had progressive disease requiring further treatment hence not 
evaluable except for safety data. Patients 3 4 and 6 went on to surgery and 5 
gained a complete response with Photofrin®
Age/Sex Site Previous
Treatment
Pre-
Treatment
Post-
Treatment
Histology/longest 
FU (mths)
3 87/F T Surgery 4cm2 0cm2 NA
4 81/F A Mandibular
resection
16.7cm2 0.6cm2 NA
5 62/M FOM Nil 8cm2 1cm2 NA*
6 65/F BM,
RM, AP
Surgery 8.5cm2 Unchanged NA
Table 9.2: Clinical Response with ALA PDT
Key: T-Tongue; A-Alveolar; FOM-Floor of Mouth; BM-Buccal Mucosa; RM-
Retro Molar; P- Palate; AP-Anterior Palate
^'Subsequent photodynamic therapy with a different sensitiser.
Patients 3 - 6 received 100J/cm2; patients 1 and 2 received 200J/cm2.
9.3.3 Discussion
Despite the obvious attractions of ALA in the treatment of invasive disease -  a 
short drug light interval, a short period of photosensitivity and excellent post 
treatment healing, the superficial effect made it impossible to continue this 
therapy for invasive disease.
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9.4 Foscan® PDT
Foscan®, is a pure, synthetic chlorin. It has the advantages of short light 
activation times with a depth of effect possibly to as much as a centimetre when 
activated with red light at 652nm (Berenbaum et al 1986b) and photosensitivity 
is limited to two to three weeks (Ris et al 1991). Several pilot studies have been 
published suggesting Foscan® PDT is a useful treatment in early oral cancer 
(Dilkes et al 1995, Savary et al 1997, Fan et al 1997). In this section the results 
of a multicentre study are presented for which the author was writing committee 
chairman. Also, the results of the patients enrolled into the study from the 
authors practice are included as the follow up is now several years.
9.4.1 Study Aims
To determine the response rate of early SCC (Tis, Ti and T2 up to a maximum 
diameter of 2.5 cm, maximum depth of 0.5 cm) to single dose Foscan® PDT 
and to assess the tolerability and safety of the treatment.
9.4.2 Study Design
This was a multi-centre, open-label, single group Phase Mb study into the effect 
of Foscan® PDT on patients with a histologically confirmed primary SCC of the 
oral cavity. This description covers the 114 patients recruited from all centres. 
Results from the 12 patients recruited from UCLH have been extracted from the 
main body of the data and summarised in section 9.48.
Foscan® (0.15mg/kg body weight) was administered by intravenous injection 96 
hours before tumour illumination with 20J/cm2 of laser light of 652nm 
wavelength (Diomed, Applied Optronics Corporation (AOC), Laserscope) 
delivered by superficial illumination via a standardised optical fibre and 
microlens diffuser (Medlight, Pioneer).
Following treatment, patients were observed on Days 1, 2 and 7 and Weeks 2,
4, 6, 8 and 12. The response at the tumour site was assessed according to 
standard WHO criteria (WHO 1979). Biopsies were taken where possible 12
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weeks after PDT. Assessments of safety variables were also made during the 
study.
9.4.3 Materials and Methods
Local ethics committee approval was obtained for the study and each patient 
was required to give informed written consent. Excluding the 7 protocol 
violators, 69 male and 45 female patients were enrolled to the study with a 
mean age of 64 years (Table 9.3). The 7 protocol violators were withdrawn for a 
variety of reasons (Table 9.4).
Demographic characteristics for all patients in the 12
week study
N = 114
Mean age (range) 64 (30-99)
Male 69 (60%)
Female 45 (40%)
Table 9.3: Demographic characteristics
7 patients recruited to the study were withdrawn at an early stage due to 
protocol violations (Table 9.4).
Reason for withdrawal, protocol violations 
N = 7/121
2 Laser failure
1 Miscalculation of light dose
1 Adjunctive treatment used (CO2 laser) before 
PDT treatment
2 Tumour found to be deeper than 5mm
1 Illumination delayed due to intercurrent patient 
illness
Table 9.4: Withdrawals due to protocol violation
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Male or non-pregnant, non-lactating female patients aged 18 years and over 
who had primary SCC of the lip, oral cavity, oropharynx or hypopharynx; a 
Karnofsky status of > 70; and who presented with a single discrete locally 
treatable Tis(3), Ti(94), T2(17), N0, M0 tumour (< 2.5cm diameter, < 0.5cm 
estimated depth), which was clearly visible and accessible for illumination were 
entered into the study. The maximum diameter of 2.5cm was selected to 
enable treatment with a single spot illumination of the whole tumour with an 
adequate margin of normal tissue. Tumour depth was estimated by clinical 
palpation and standard imaging techniques (CT, MR ultrasound). The 
maximum depth was limited to 0.5cm to ensure the treated tumour volume was 
consistent with the known depth of penetration of Foscan® PDT (Table 9.4).
Exclusion criteria: Patients who had undergone (or were scheduled for) 
radiotherapy or neck dissection in continuity, or were receiving chemotherapy; 
and patients with active hepatic or renal disease, or any disease caused or 
exacerbated by light were excluded from the study.
Disease assessment for patients entering the study N = 114
Site of tumour
Lip 23 (19%)
Tongue 22 (19%)
Gum 2 (2%)
Floor of mouth 44 (38%)
Palate 7 (6%)
Buccal mucosa 12(11%)
Other 4 (3%)
Tumour TNM class
Tis 3 (3%)
Ti 94 (83%)
t2 17(14%)
No 113(99%)
Nx 1 (1%)
M0 114(100%)
Tumour depth (mm)*
Mean 3.0
Range 0 1 cn b
Tumour area (cm2)
Mean 2.1
Range 0.1 -8.1
Tumour largest diameter (cm):
Mean 1.7
Range 0.5-2.5
Table 9.5: Disease assessment
9.4.4 Photodynamic Therapy Regimen
Foscan® was administered at a dose of 0.15mg/kg body weight by slow 
intravenous injection into a peripheral vein. For 24 hours after administration of 
Foscan® the patient remained in a darkened room (curtains drawn, light bulbs 
not brighter than 60W). The patients made a gradual return to unrestricted light 
exposure over two weeks. Permissible light levels were 100 Lux on the day of 
injection, increasing by 100 Lux per day. Guidelines for light exposure and a
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light meter were given to patients prior to the initiation of treatment, and 
investigators were advised to tell the patients and their families or friends who 
attended them during the treatment about the importance of avoiding sunlight. 
Patients were to avoid high levels of ambient light for a month and avoid 
ophthalmic procedures involving fundoscopy for three months after 
administration of Foscan®.
The total light dose for treatment was 20J/cm2 at a light intensity of 100mW/cm2 
Treatment times were 200 seconds. The illuminated area extended beyond all 
visible tumour margins by a distance of at least 0.5cm. This is in keeping with 
the surgical approach to the management of these tumours where a margin of 
normal tissue is included in the resection.
9.4.5 Overall Results (combined from all centres)
The complete response rate in the patients treated according to protocol was 
85% (97/114) at twelve weeks. Response rates were higher for smaller 
tumours (Table 9.6). Of the 17 patients not documented as having a complete 
response at 12 weeks, 1 was not assessed, 1 refused further treatment and 
died of extensive disease one year later. 2 patients were initially lost to follow 
up but were subsequently traced and found to be disease free. The remaining 
13 were partial responders who went on to receive other therapy. Of these, 9 
obtained a CR. 5 had disease progression and have since died (Table 9.7).
Tis Ti t 2 Overall Confidence intervals
3/3
(100%)
83/92
(90%)
11/19
(58%)
97/114
(85%)
77-91
Table 9.6: Complete response rates by tumour T-stage
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Partial responders, withdrawals and patients lost to follow up 
N = 17/114; CR = 10/17; PR = 7/17
1 Not able to assess; died nine weeks after treatment of intercurrent illness
1 Patient lost to follow up (refused treatment)but found one year later with 
extensive disease which was too advanced to treat. Patient died of 
progressive illness
2 Patients initially lost to follow up -  subsequently traced and found alive and 
disease free
1 PR, treated again with PDT: CR
6 PR, treated with surgery: four CRs, two died of progressive disease
2 PR, treated with radiotherapy: one CR, one died of progressive disease
3 PR, treated with surgery and radiotherapy: two CRs, one with advanced 
disease
1 PR, treated with radiotherapy and chemotherapy: died of advanced disease, 
not clear if new tumour or recurrence
Table 9.7: Partial responders, withdrawals and patients lost to follow up.
Key: CR-complete response; PR-partial response 
The 12 week post-treatment biopsy was undertaken for purposes of 
confirmation of efficacy. However, where the treated areas were assessed 
clinically as being normal, no biopsy produced evidence of residual tumour.
9.4.6 Toxicity and Side Effects
In contrast to treatment with either surgery or radiotherapy, Foscan® PDT was 
relatively well tolerated and free of major toxicity. There were a number of 
transient alterations in haematology and biochemistry, but no overall trend was 
identified as being of clinical significance.
Adverse events in the immediate post-treatment phase included pain and 
swelling in most patients requiring short-term treatment with opiates in addition 
to non-steroidal anti-inflammatories. Pain symptoms commonly persisted for 
between two and four weeks. Although some patients experienced little post­
treatment pain, others required moderate analgesic support for up to twelve 
weeks. At the treated site, there was localised pain and tissue necrosis: there 
appears to be a clear correlation between reported pain and leukocytosis 
(Figure 9.3). This probably reflects the necrosis and separation of the necrotic
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tissue, which is the cause of the leucocytosis. In addition, there was oedema 
and an inflammatory response that usually resolved within three weeks.
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Fig 9.3 : Pain and leukocytosis following treatment with Foscan® PDT
Photosensitisation did not appear to be a significant problem. 16 patients (13%) 
exhibited photosensitivity reactions: in 14, this was only mild erythema with no 
long-term sequelae. Only 2 of these were considered to be significant in 
patients who failed to comply with the light regimen. One of these required skin 
grafting to a burn on his arm. The low incidence of light-related complications 
was due to adherence with the light exposure regimen described above and the 
value of careful pre-treatment counselling cannot be over-emphasised.
Scarring at the treatment site was noted in 11 patients, but only severe in 1.
9.4.7 Survival
1 patient died during the initial 12 week follow up period of the study: the death 
was not considered to be related to treatment with Foscan® PDT. 10 further 
deaths occurred within the first year: 2 from unknown causes, 2 from metastatic 
disease, 2 from progressive disease and 4 from unrelated causes. In the 
second year, there were 11 further deaths: 3 from metastatic disease, 4 from 
progressive disease, 1 unknown and 4 from unrelated causes. The four 
patients who died of metastatic disease in the first 2 years of the study all 
showed complete response at the primary site.
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The complete response rate at one year was 86%  and at two years was 79%  
(Figure 9.4).
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Fig 9.4 : Duration of complete response, n = 95 
Mean duration of complete response = 621 days (se=24)
1 year = 86% , 2 years = 79%
The survival rate at one year and two years was 90%  and 77%  respectively 
(Figure 9.5).
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Fig 9.5 : Survival
n = 113; M ean 1 year survival rate = 90% , 2 year survival rate = 77%
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All successfully treated patients had ablation of their disease without significant 
tissue loss or reduction of function in terms of speech and swallowing. The 
mouth remained moist with normal healing. Some of the sub-sites treated were 
especially impressive particularly those areas where surgery causes functional 
deficit, or over bone where radiotherapy carries a significant risk of 
osteoradionecrosis.
Fig 9.6 : Results of Foscan® PDT for squamous cell carcinoma of the floor of 
the mouth - note tongue mobility and moist environment, (a) Before PDT 
treatment; (b) 2 days postillumination; (c) 7 days postillumination; (d) 21 days 
postillumination; (e) 42 days postillumination. Note proximal migration of 
submandibular duct orifice without glandular compromise. (Courtesy A Kubler, 
Cologne)
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The response rates seen with Foscan® PDT compare favourably with response 
rates seen with surgery and radiotherapy (Fein et al 1994, Laramore 1989, Wolf 
et al 1993, Shah et al 1999). A direct comparison is impossible as most other 
studies collected data retrospectively and not on an intention to treat basis. Not 
only that, the other large studies comprised a heterogeneous mix of tumours. 
Histological confirmation of complete response was obtained in 71% (biopsy 
was refused by the remaining 29%. In those patients who had a complete 
clinical response and who also had a post-treatment biopsy, not a single clinical 
false negative was found. Those patients who did not achieve a complete 
response still had the option of re-treatment or conventional therapy. Of the 15 
patients who went on to further treatments it is important to note that 8 went on 
to achieve a complete response. Previous treatment with Foscan® PDT did not 
compromise additional treatment with PDT, radiotherapy or surgery if indicated.
Long term follow up data from the full study are limited at this stage, however 
the one- and two-year complete response rates of 86% and 79% are 
encouraging. The genetic basis of oral cancer evolution suggests that these 
patients would have a high risk of metachronous tumours (De Vries 1990, 
Partridge et al 1997) and the lack of cumulative toxicity with this treatment gives 
it an advantage over existing modalities (Fan et al 1999). The centres involved 
in this study and the number of patients recruited at each are given in table 9.8
9.4.8 The Foscan® 01 Study Group
My thanks to the other participating study centres and investigators in the 
Foscan® 01 Study Group:
France: T Patrice, C Beauvillain, Clinique ORL, Nantes. Norway: J Evensen, 
Norwegian Radium Hospital, Oslo. South Africa: K Butow, Department of 
Maxillofacial Surgery, University of Pretoria; B Smit, Department of Radiation 
Oncology, Tygerberg Hospital, Tygerberg. United Kingdom: J Brown, 
Fazakerly Hospital, Liverpool; J de Carpentier, Royal Preston Hospital, Preston; 
J Carruth, Southampton General Hospital, Southampton; M Dilkes, G Kenyon, 
St Bartholomew's Hospital, London, F Roberts, Cookridge Hospital, West 
Yorkshire; N Sudderick, Royal Surrey Hospital, Guildford, Surrey
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Study identification Institution Patients entered
101 -105 Royal London Hospital UK 5
201 -2 1 3 University College London 
Hospitals UK
12
301 - 302 Southampton General 
Hospital UK
2
401 -4 0 7 National Cancer Institute 
Amsterdam The Netherlands
16
501 -  504 Royal Surrey Hospital UK 4
600 -  623 University Hospital Koln 
Germany
24
701 + 706 Norwegan Radium Institute 
Oslo Norway
2
801 -  824 The Ulster Hospital Belfast 
UK
22
901 Clinique ORL Nantes France 1
1001 - 1004 Tygerberg Hospital South 
Africa
4
1101 +1102 Cookridge Hospital UK 2
1201 -1 2 05 Fazakerley Hospital Liverpool 
UK
5
1401 -1411 Cumberland Infirmary Carlisle 
UK
10
1501 -1 5 1 0 Royal Preston Hospital UK 9
1601 -1 6 0 3
University of Pretoria South 
Africa
3
Total enroled 121
Table 9.8 Recruitment: total of 121 patients, 15 centres, 5 countries. 7 patients 
were withdrawn at an early stage due to protocol violations as indicated in table 
9.4.
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9.4.8.1 UCLH Patients
The 12 patients UCLH patients are included in the full analysis given above, but 
for completeness, the results for these individuals are summarised here. All 
except 1 were T1 tumours with a mean maximum diameter of 1.3 cm and depth 
of 2.8mm compared with a mean diameter of 1.7mm and mean depth of 3mm in 
the main study. Their mean age was 59 years with a slight female 
preponderance (Table 9.9). This is similar to the total study group. Out of the 
12, only 1 had a metachronous tumour requiring treatment within the 2 year 
follow up. One died of a perforated duodenal ulcer and this might well have 
been secondary to post treatment analgesic use.
Patient Stage Depth (mm) Site Age (years) Sex
1 T1 (1.3cm) 3 P 68 F
2 T1 (1.8cm) 4 MA 46 M
3 T1 (1.5cm) 5 FOM 42 M
4 T1 (1.0cm) 2 T 49 F
5 T1 ( 1.7cm) 3 T 78 F
6 T2 (2.3cm) 4 FOM 54 F
7 T1 (0.8cm) 1 T 56 F
8 T1 (1.0cm) 2 MaxA 62 F
9 T1 (1.7cm) 4 FOM 48 M
10 T1 (0.5cm) 2 T 78 M
11 T1 (1.4cm) 2 BM 63 M
12 T1 (1.8cm) 1 P 68 F
Mean 1.3cm 2.8mm 59 (42-78) years 7F 5M
Table 9.9: Patients recruited to the 01 Study from UCLH 
P: Palate M: Mandible A: Alveolus FOM: Floor of Mouth T: Tongue 
Max: Maxilla BM: Buccal mucosa
The longer term follow up was a little less impressive as demonstrated by the 5- 
year follow up on these 12 patients. Nearly half of this group are dead (5/12) 
although only one died of disease progression. 2 died of an unrelated cause, 2 
died from metachronous tumours and of the remaining group that are alive, 2
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have been successfully treated for metachronous tumours (Table 9.10). This is 
hardly surprising given the high levels of comorbidity associated with oral 
cancer patients, but reinforces the need for effective treatments with reduced 
long term morbidity.
Patient Foscan®
date
Histological
CR
Progress Outcome Comments
1 03.05.96 28.08.96 Withdrawn
22.10.96
Died
723 days
Metachronous tumour S 
RC
2 08.08.96 07.11.96 A/W 7.3y
3 18.10.96 26.02.97 No primary 
site
disease
AAA/ 7.5 yrs Metachronous 
Palate S Pharynx R
4 07.12.96 30.04.97 Withdrawn 
22.10.98 S
Died
29.05.01 (4.5y) 
Cardiomyopathy
Metachronous tumour S
5 03.02.97 02.04.97 No primary 
site
disease
Died 18.12.03 
(6.8y)
Multiple metachronous 
tumours PDT
6 28.08.97 16.09.97 No primary 
site
disease
Died neck 
disease
16.09.99 (749d)
7 12.10.97 06.01.98 No
disease
A/W 6.6y
8 02.04.98 02.06.98 No
disease
A/W 6y
9 22.05.98 30.06.98 No
disease at
primary
site
A/W 6y Metachronous tumour
10 13.08.98 AE Death Clinical
CR
Died 139d Perf DU/renal failure
11 09.11.98 Withdrew A/W 5.5y Tracked to Ireland -  
recent check no disease
12 25.02.99 15.06.99 No
disease
A/W 5.5y
Table 9.10: Results from study patients with Ti disease treated at UCLH with 
Foscan® PDT
Key:- S - Surgery R -  Radiotherapy C - Chemotherapy
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These data support the safety of Foscan® PDT in the treatment of early oral 
SCC. The perceived problems of prolonged photosensitivity have not been 
observed in this study as residual photosensitivity of the drug is low compared 
with first generation sensitisers. Patients were able to monitor incremental light 
exposure in the post-sensitisation period. Given the age and socio-economic 
status of the oral cancer population, it is notable that the level of photosensitivity 
complications remained low. This was related to the strictly increasing light 
regime that patients followed, and the self-monitoring that was carried out using 
portable light meters.
9.5 Discussion
The management of the No neck in early oral cancer remains controversial 
(Yuen et al 1997, Leemans et al 1998, Pitman et al 1997, Gallo et al 1996). In 
most treatment protocols the neck is managed with either an elective neck 
dissection or close observation. In this study the close observation protocol 
was utilised. During the recorded period of follow-up, three patients at UCLH 
developed neck metastases, which were managed with conventional treatment.
Pain at the treatment site was managed with a combination of opiate, opioid 
and NSAID analgesia. Pre-emptive analgesia was found to be the most 
effective way of managing post-treatment pain. Analgesia was found to be 
necessary in most patients for up to four weeks.
Infection was rarely found to be a problem. In the moist environment of the oral 
cavity, necrotic slough was sometimes associated with a fetor, which responded 
to the use of topical or systemic metronidazole. In general, treated sites re- 
epithelialised within six weeks. In certain sensitive sites such as the soft palate 
or posterior tongue, the use of dexamethasone to reduce post-treatment 
oedema was found to be useful.
Treatment of tumours overlying bony structures may result in the exposure of 
bone. Even when this occurred, spontaneous resolution took place, although 
re-epithelialisation was delayed. Throughout this study no patients required any 
form of airway management or enteral feeding. No patients required nutritional
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support apart from minor dietary modifications in the immediate post-treatment 
phase.
Normal laser safety precautions were required for the patient and the operators. 
In addition to the general light precautions outlined above it is important to 
shield surrounding normal tissue from reflected light during treatment. This is 
most commonly achieved by the use of surgical drapes, gauze and copper wax.
It is possible to carry out many treatments using local anaesthesia, with or 
without intravenous sedation. As some of the PDT effect is thought to be 
directed at the vasculature, adrenaline free anaesthetics were used for 
infiltration although we consider it preferable to use lidocaine with adrenaline for 
regional blocks. General anaesthesia is often given to facilitate access to the 
more difficult sites within the oral cavity. Light exposure in many patients is in 
fact painless.
The short light activation time of 200 seconds is due to the potency of Foscan® 
and confers an additional treatment benefit which enables some treatments to 
be carried out on an outpatient basis. The equipment costs for this treatment 
are modest. Although the drug cost is high, we believe that Foscan® PDT will 
offer a cost-effective alternative to radiotherapy or surgery (Hopper et al 2004a).
9.6 Comparison Between the Three Photosensitisers
There is a paucity of prospectively acquired information on treatments for head 
and neck cancer generally. The decision making process for management of 
patients with head and neck cancer is largely based on retrospectively acquired 
evidence which often consists of a heterogeneous mixture of clinical stages and 
anatomical sites of disease.
9.6.1 Photofrin®
A small number of patients were treated using this drug. Only 4 pureTI patients 
were treated. In 1993, there were compelling reasons for abandoning the use 
of this drug. Treatment times were long -  typically 1000s, the light sources
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available at the time were metal vapour pumped dye lasers that were unreliable 
and required high maintenance and the long term photosensitivity (up to 3 
months with Photofrin®) was a nuisance. Outcomes were very good both in 
terms of the cosmetic and functional results with 100% cure rate at mean follow 
up of 4 years. This is despite the fact that treatment depth was limited due to 
the moderate tissue penetration of the activation wavelength (Grant et al 1997).
Since then, although many of the original problems persist, the laser light can 
now be generated by diode lasers that are portable, reliable and relatively 
maintenance free, so Photofrin® might still have a role to play in the 
management of early oral cancer. From the histological studies in Chapter 7, 
there really is good preservation of collagen and elastin which is superior to 
Foscan® and if a moderate depth of effect is required and prolonged 
phototoxicity is not an important issue, Photofrin® again might still have a place 
in the management of early oral cancer.
9.6.2 ALA
Some benefit was observed in five of six patients with squamous cell 
carcinoma, but only two became tumour free (one with persistent mild 
dysplasia). Clearly, it is inappropriate to continue with this approach to invasive 
SCC. It might be possible to increase the depth of effect of ALA PDT by 
changing treatment parameters. There has been an ongoing debate as to the 
optimum wavelength of light for maximum depth of treatment effect and it 
seems that 635nm probably gives an effect twice as deep as 628nm.
Treatment breaks and the addition of iron chelators might be of value, however, 
the effect is so superficial that it seems unlikely that ALA will have a major role 
to play in the management of oral cancer.
9.6.3 Foscan®
This is the largest prospective study of PDT treatment of early oral cancer to 
date (there has been one larger study on advanced cancer treated with 
Foscan® PDT that includes 128 patients - D’Cruz at al 2004). Foscan® PDT 
was shown in this study to be a safe effective way of treating early oral SCC.
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There is the potential for some scar formation but there are still clear 
advantages over conventional treatment in terms of improved function and 
cosmesis and PDT should be available to all integrated head and neck 
oncology teams.
9.7 Summary
ALA PDT has too superficial an effect to be of real value in treating invasive oral 
cancer, however, both Photofrin® and Foscan® are very effective and probably 
as good as radiotherapy and surgery as a primary treatment. The limiting factor 
in making this comparison is not the quality of data for treatment outcomes with 
PDT rather the complete absence of outcome data from conventional treatment. 
The above (Foscan®) study is the only intention to treat study in the literature of 
early oral cancer, which is a damming indictment of research into head and 
neck cancer.
Chapter 10: A Study to Investigate the Efficacy of Photodynamic Therapy 
in the Treatment of ‘Field Cancerisation’ of the Oral Cavity
10.1 Introduction
Section 2.2 described the greatly increased chance of developing a second 
primary cancer when pre-malignant lesions such as leukoplakia and 
erythroplakia co-exist with an existing primary (Sarasin 1933, Wilkins and 
Vogler 1957, Moertal and Foss 1958, Shibuya et al 1986). Leukoplakia, a term 
describing a white patch or plaque that cannot be characterised clinically or 
pathologically as any other disease entity (Kramer et al 1978) has a definite 
propensity for malignant transformation. This is variously estimated as being 
between 0.13 and 17.5 per cent (Pindborg et al 1968, Silverman et al 1976, 
Silverman et al 1984). The presence of an erythematous component, 
erythroplakia, or erythroleukoplakia increases almost four-fold the risk of 
malignant transformation (Silverman et al 1984).
The incidence of multiple oral carcinomas in patients with primary tongue 
carcinomas associated with leukoplakia has been found to be five times greater 
than that of subjects without leukoplakia (Shibuya et al 1986). The prognosis of 
patients who develop synchronous or metachronous second primary cancers is 
poor with overall five-year survival ranging from nine to 22 per cent (Marchetta 
et al 1965, Gluckman and Crissman 1983). Slaughter et al (1953) first 
proposed the concept of field cancerisation to explain the multi-centric origin of 
squamous cell carcinoma arising in a given anatomical region, exposed to the 
same carcinogenic agents. The diagnosis of a secondary primary tumour in the 
same anatomical site, or the co-existence of pre-malignant lesions such as 
leukoplakia or erythroplakia, suggests that the entire mucosa is at risk of 
malignant change. Satisfactory treatment for patients with such a wide field 
change should ideally be non-mutilating and repeatable.
Early clinical experience with PDT showed that it was effective in the treatment 
of superficial lesions, particularly those such as urothelial bladder cancer, early 
bronchogenic carcinomas and dermatological tumours (Hayata et al 1984, 
Benson 1988, Carruth 1990, Edell and Cortese 1990, Pope and Bown 1991a).
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Variable outcomes have been reported in the treatment of head and neck 
cancers. Possible reasons for failure include inappropriate patient selection, or 
failure to expose deep extensions of the tumour to adequate light (Gluckman 
1991a).
The patient with wide field change in the oral cavity presents a difficult 
management problem. Screening of these patients results in detection of areas 
of invasion while still at an early stage. The ability of PDT to ablate superficial 
tumours, while at the same time minimising loss of normal tissue, suggests that 
it should be ideally suited to the treatment of this disease.
10.2 Photofrin®
The first study reports clinical experience with photodynamic therapy using 
Photofrin® Lederle Laboratories (at the time of the study) in the treatment of 
superficial early carcinomas with co-existing premalignant lesions and areas of 
carcinoma in situ occurring in the oral cavity. Photofrin® PDT has been shown 
to be capable of destruction of tumour to an approximate depth of 0.5cms and 
still heal with little or no scarring. It would therefore seem to be a reasonable 
technique to use in the management of field change disease. Clearly it is better 
in the treatment of superficial disease and not really appropriate for thicker 
tumours, although the extent or number of lesion is not a limiting factor. The 
first study was carried out to investigate the potential of Photofrin® PDT for the 
treatment of field change disease.
10.2.1 Materials and Methods
Eleven patients with one or more histologically proven early invasive squamous 
cell carcinomas of the oral cavity, occurring in association with widespread pre- 
malignant disease such as leukoplakia, erythroplakia or ‘erythroleukoplakia’ 
were included in the study group. Six patients had synchronous or 
metachronous second primary carcinomas, and five had a first primary lesion, 
occurring in association with one or more non-contiguous areas of leukoplakia 
of more than 5mm in diameter (see Table 10.1).
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Pt Tumour
site
Associated
pre-malignant
disease
Appearance 
of treated 
areas at 6-8 
weeks
FU
(mths)
Comments
Primary cancer with associated pre-ma ignant disease
1 R bucco-
gingival
sulcus
R and L buccal 
mucosa
CR, Normal* 10 HIV positive
2 R lateral 
tongue
R tongue base, L 
buccal mucosa
CR, Normal 8 Leukoplakia at 6 
months; mild 
dysplasia
3 L buccal 
mucosa
L buccal mucosa 
-  3 sites
CR, non­
healing ulcer
9 Ulcer excised at 3 
months: inflammatory
4 Tongue
(excised)
L and R buccal 
mucosa
CR, Normal 3
5 L bucco-
gingival
sulcus
L buccal mucosa CR,
Persistence of 
OSF
19 Erythroplasia 1 year 
-  moderate 
dysplasia. OSF
Multiple primary with associated pre-malignant disease
6 L buccal 
mucosa -  2 
sites
L buccal mucosa 
-  2 sites
CR, Normal 9
7 R alveolar ridge 
-  2 sites
R buccal mucosa, 
floor of mouth
CR,
Normal*
10 Metachronous 
primary 8 months
8 L alveolar ridge 
and buccal 
mucosa
R buccal mucosa 
and alveolus
CR, Normal 7
9 Tongue tip 
L lateral tongue
Dorsum and R 
lateral tongue
IR, Some 
leukoplakia
18 Biopsied; moderate 
dysplasia
10 Palate/L
buccal/R
alveolus
R tongue and 
buccal mucosa
CR,Normal* 6 Metachronous 
primary 3 months
11 Lip - 2 sites Lip CR, Normal 18
Table 10.1: Photofrin® PDT in field change disease
Key: Pt-patient; FU-follow-up; CR-complete response: no evidence of abnormal 
mucosa, either histologically or clinically, at time of assessment; IR-incomplete 
response: residual pre-malignant lesion in treated areas; OSF-oral submucous 
fibrosis; *-biopsied: histologically normal mucosa.
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All tumours were diagnosed as Stage 1 (T1N0N0) oral cancers and no deep 
extension to underlying muscle or bone was suggested by the clinical, 
histological or radiological findings. Six patients had had previous oral tumours 
surgically excised, five on more than one occasion, and now presented with 
independent second primary carcinomas. One patient had previous CO2 laser 
excision of dysplastic areas of leukoplakia. Four patients had no prior treatment 
but had histologically proven squamous cell carcinomas associated with one or 
more non-contiguous areas of leukoplakia. One patient underwent a 
combination of surgical resection of a T1 lesion of the tongue and PDT to 
extensive areas of leukoplakia in both buccal regions. No patient had received 
radiotherapy. Informed consent was obtained in each case.
Photofrin® at a dose of 2mg/kg was given by intravenous infusion 48 hours 
prior to surface illumination of the tumour and all clinically apparent areas of 
leukoplakia or erythroplakia. A copper vapour pumped dye laser was used to 
deliver monochromatic red light at 630nm. An optical fibre with a microlens 
affixed ensured homogeneity of the illuminating light spot, and a multi-jointed 
articulated arm was used to facilitate positioning of the fibre in three planes.
Two patients were treated for very extensive disease on two separate 
occasions. Ten patients required more than one spot to treat the target areas.
A light dose of 50 to 100J/cm2 was delivered to each area. Power densities 
were kept below 150mW/cm2 to avoid any possibility of thermal injury, and no 
patient reported any sensation of heat, although some described various 
sensations such as tingling and tickling during light exposure. Patients were 
counselled to avoid direct sunlight following sensitisation. Patients were 
prescribed analgesics and benzydamine local analgesic or anti-inflammatory 
spray.
Lesions were photographed and treatment areas were recorded 
diagrammatically on referral. Following treatment patients were reviewed and 
photographed twice in the week after PDT and then approximately weekly until 
healed, and thereafter every two to four weeks.
Where treated areas healed with, or subsequently developed, evidence of 
recurrence of ulceration, erythroplasia or leukoplakia, these lesions were 
conventionally excised or biopsied to determine the nature of the abnormality 
and the presence or otherwise of pre-malignant or malignant recurrence.
Three patients had biopsies of regenerated clinically normal mucosa, at sites 
where invasive carcinoma had been previously diagnosed. Each was taken 
more than three months after PDT.
10.2.2 Results
All treatments were performed without local anaesthetic or sedation and were 
satisfactorily tolerated by each patient, on an out-patient basis. During the three 
to four days after PDT the treated areas underwent obvious surface necrosis 
with the development of a superficial slough, and local oedema. While no pain 
was associated with the treatment itself, all patients reported some degree of 
pain over the following days, usually lasting about one week, but this was 
effectively relieved by oral analgesia. Eating tended to exacerbate pain and a 
sloppy diet was advised and found to help. Treated areas took between three 
and five weeks to heal fully, depending on the size of area treated.
At assessment following healing, six to eight weeks after PDT, 10 of the 11 
patients showed a complete response to treatment. In eight, the healed 
mucosa was of normal colour with no evidence of leukoplakia or erythroplakia 
(Figures 10.1 a and b).
Fig 10.1: Patient 10: before (a) showing invasive squamous cell carcinoma of 
the left hard palate and buccal mucosa; and (b) three months after Photofrin® 
PDT showing appearance of palate following healing
Five patients who had had multiple surgical resections (patients six to ten, Table 
10.1) showed evidence of scarring related to previous surgical intervention, but 
healed with essentially normal mucosa. The three cases in which clinically 
normal regenerated mucosa was biopsied after three months, showed 
histologically normal epithelium in two cases (Figures 10.2 a and b) and an 
atrophic epithelium without atypia or dysplasia in the third.
Mlwmm
Fig 10.2: Photomicrographs of histological sections showing: (a) early invasive 
carcinoma of the right lower bucco-gingival sulcus before Photofrin® PDT and 
(b) showing appearance following healing, with normal mucosa.
One patient (Pt 5) with pre-existing oral submucous fibrosis healed with 
scarring, similar in appearance to adjacent untreated mucosa. One patient (Pt 
3) had a persistent non-healing ulcer associated with dental trauma. This was
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excised after three months and showed simple ulceration with chronic 
inflammation.
One patient (Pt 2) had an incomplete response, but had almost the entire 
surface of his tongue treated in two separate sessions. More than 75% healed 
with regeneration of mucosa of normal colour but with some atrophy. The 
persistence of a patchy grey-white lesion on the dorsum, showing histological 
mild dysplasia, meant that this constituted an incomplete response (Figure 10.3 
a and b). However, the patient has undergone several re-treatments and is 
currently alive and well ten years after this study. Interestingly he has remained 
disease-free over the last three years.
Fig 10.3: Patient 9: before (a) and after (b) PDT for extensive field cancerisation 
of the tongue. Patient had multiple prior surgical resections of tongue and lower 
lip. Appearance at 16 months following PDT
Follow up ranges from 3 to 19 months, with a mean of 11 months. No patient 
developed any evidence of recurrence of invasive squamous cell carcinoma in 
the treated sites. One patient developed a small area of leukoplakia at the 
treatment site at six months. This was excised and histology showed 
hyperkeratosis with moderate epithelial dysplasia.
The patient with oral submucous fibrosis developed further erythroplakia at one 
year which, when excised, also revealed moderate epithelial dysplasia. Two 
patients developed further metachronous primary carcinomas at sites away 
from the treated areas, while maintaining a complete response in the treated 
area. These were treated with excision and radiotherapy.
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The remaining seven patients had no evidence of recurrent carcinoma or further 
pre-malignant disease.
10.2.3 Discussion
The complete response of 10 of the 11 patients treated in this study 
demonstrates the efficacy of Photofrin® PDT in ablation of early invasive and 
pre-malignant lesions in the oral cavity. The finding that in most cases the 
abnormal epithelium healed with regeneration of essentially normal mucosa 
indicates that early superficial carcinomas and associated dysplastic lesions 
can be effectively destroyed in situ with minimal tissue loss using PDT.
For simultaneous primary cancers surgical resection may be feasible if two or 
more primary lesions are in close geographical proximity, but may require 
extensive reconstruction with unacceptable loss of function. The two cases that 
developed recurrent areas of dysplasia at six months and one year respectively 
were disappointing but, given the nature of their field change, not unexpected. 
Both patients subsequently had these lesions excised, but further PDT would 
certainly have been a treatment option. The development of metachronous 
primary cancers in two patients is also not unexpected and again reflects the 
field change nature of the disease rather than any influence of PDT, as the sites 
were not related.
The incidence of second or multiple cancers arising in the upper aerodigestive 
tract has a profound influence on survival, and therefore management (section 
2.2). Management of areas of dysplastic oral mucosa is a considerable 
problem because of multiple sites, often diffuse margins and variable and 
unpredictable risk of malignant transformation. When leukoplakia occurs in 
conjunction with one or more primary tumours, indicating the likelihood of a 
wide field change, these difficulties are greatly compounded.
Therapeutic options for patients with extensive field cancerisation will depend 
on several factors, including the timing of presentation of the tumours, whether 
simultaneous or metachronous, the site and stage of the lesions, and the age 
and general health of individual patients. Concern has frequently been
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expressed about the possibility of radiotherapy converting pre-malignant 
disease into anaplastic and frankly invasive carcinoma, and the long-term effect 
of radiation (section 2.2.2). Robinson et al (1991) report decreased mean 
survival from 102 months to 55 months for second primaries compared with first 
and this fell to 20 months if the first primary had been irradiated. For 
metachronous lesions curative surgery is undertaken on the merits of the 
individual case, but the problems of function and cosmesis are the same.
Photodynamic therapy has been shown to be effective in vitro and in vivo for the 
ablation of small areas of malignant disease. Although current photosensitisers 
do not have a totally selective effect, the ability of surrounding normal tissues to 
heal by regeneration results in ultimate selectivity of tumour destruction (see 
section 4.1.4 and Chapters 5 and 6).
Clinical studies demonstrate excellent healing of skin and mucosal surfaces 
following PDT with Photofrin® (Gilson et al 1988, Barr et al 1990). 
Photodynamic therapy results in minimal tissue loss with preservation of 
function. This study demonstrated that diffuse areas of superficial malignancy 
and pre-malignant disease can heal with clinically or histologically normal 
mucosa following treatment.
Early clinical reports of PDT in the head and neck comprise feasibility studies in 
patients with advanced disease and demonstrate variable tumour response and 
palliation. Visible light penetration is maximal in the red region of the spectrum, 
but is not capable of causing necrosis more than a few millimetres from the 
surface so that surface illumination of bulky tumours is likely to be of little value.
More recently it has been suggested that PDT is more appropriate for the 
treatment of superficial lesions. Wenig et al (1990) used PDT to treat 26 
patients with early stage head and neck cancer who had refused conventional 
treatment or had failed previous treatment of surgery, radiotherapy, 
chemotherapy or combination therapy. These authors used an idealised 
mathematical light dosimetry model to match light delivery to magnetic 
resonance imaging of tumour volume.
Complete responses were reported in 20 (77%) and partial responses in five 
(19%) as assessed at three months. Nine of these patients had oral cavity 
tumours. Unfortunately there appear to be a wide variation in the optical 
properties of individual tumours and few conform to idealised geometries (Grant 
et al 1992).
Gluckman (1991b) treated 13 early (Ti and T2) carcinomas of the oral cavity 
and oropharynx by surface irradiation. He obtained complete response in 11 
(84%) at one month, with the remaining two being partial responses. However, 
of these 11, four recurred between eight and 12 months. He concedes that this 
high late recurrence rate may have been due to a variety of factors and 
expresses concern about the possibility of deep tumour being left untreated.
The same author, in the only other study to address field cancerisation patients, 
reports results in eight patients with condemned mucosa (defined as biopsy 
proven multi-centric pre-malignant and overtly malignant lesions). He obtained 
excellent results in seven patients in the short term. A number developed 
recurrent leukoplakia on long-term follow up but only one was positive on 
biopsy. Seven out of eight patients with condemned mucosa had a complete 
response at follow-up from 6 to 53 months.
He found that results achieved in aiming to palliate eight patients with advanced 
cancer were disappointing and in fact skin photosensitivity may have worsened 
their quality of life and therefore he abandoned PDT for this indication. These 
and other experiences with PDT both in the head and neck and in other 
situations have contributed to the growing body of opinion that PDT should be 
confined to the treatment of early superficial malignancies. However, improved 
photosensitisers and interstitial techniques have made the treatment of large 
tumours a viable option.
10.2.4 Conclusions
If histological examination confirms that the lesion is confined to the mucosa 
then PDT with Photofrin® is an effective management option. However, 
Photofrin® in this setting is less than ideal due to the failure of light at the
activating wavelength to penetrate more than a few millimetres beneath the 
surface (section 4.1.3). Also, the prolonged residual photosensitivity can be 
difficult for patients to accept.
10.3 ALA PDT
At the outset of clinical investigation of ALA there was great optimism about the 
PDT effect. It was thought possible that this technique could be used to treat 
cancer down to a similar depth as Photofrin®. Initial studies suggested that 
PPIX accumulated in malignant tissue, but was virtually absent from normal 
tissues other than epithelium. The light of 635nm had been shown to penetrate 
0.5cm so it was assumed that the effect could be generated to this depth. This, 
however, was not the case -  the PDT effect was only to a depth of about 1 mm, 
so not surprisingly, ALA PDT was soon abandoned for this indication, however, 
a small number of patients were treated.
10.3.1 Materials and Methods
Three patients with histologically proven field change disease of the mouth were 
sensitised with 60mg/kg ALA by mouth and treated with laser light at 628nm 
(100 or 200J /cm2). The results were assessed macroscopically and although 
microscopic assessment was also planned, this was only possible in one 
patient. The study was approved by the hospital ethical committee, and all 
treatment was carried out with fully informed consent from the patients.
ALA was supplied for this project as the hydrochloride in powder form by DUSA 
Pharmaceuticals (Tarrytown, New York). For clinical use, this was dissolved in 
orange juice and given by mouth in three separate doses of 20mg/kg at 0, 1, 
and 2 hours (total dose, 60mg/kg) using the regimen established by Regula et 
al (1995). The light source used was a gold vapour laser giving red light at 
628nm (Dynamic Light, Milton Keynes, UK). This was delivered to the patient 
using a single mode scrambled, 0.4mm flexible optical fire with a bare flat- 
cleaved tip that gave a circular spot of light up to 2.5cm in diameter on the 
target tissue. The area to be treated was defined as the target lesion together 
with a margin of 5mm of surrounding normal tissue. Appropriate fibre positions
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and treatment times were calculated to give the desired light doses before 
treatment started, using one of the two dose regimens described in Chapter 7. 
One patient was treated with 10OJ/crn2 and the other 2 were treated using the 
200J/cm2 interrupted treatment regime. If possible, the entire lesion was 
treated from a single fibre position. The power density was kept below 
250mW/cm2 to avoid thermal effects. As many of the total exposure times were 
quite long (up to 143 minutes), the fibre was positioned in a multi-jointed arm to 
keep its tip in the correct place over the area to be treated. Patients were given 
systemic analgesia and topical anaesthetic with occasional sedation if 
necessary. Injected local anaesthetic was limited to the site of biopsy.
A diagnostic biopsy specimen was taken before patients were considered for 
inclusion in this study, further biopsies were performed when healing was 
complete and at long term follow-up to assess treatment results.
Patients were kept in a dark room for 24 hours after receiving ALA. Routine 
haematologic and biochemical investigations were performed before and 1 to 2 
days after ALA ingestion (longer if any abnormalities were found).
10.3.2 Results
Complete epithelial necrosis was present in all cases. No patient had 
cutaneous photosensitivity for longer than 2 days. Patients reported 
experiences ranging from mild discomfort to severe pain during the time of 
irradiation, in some cases requiring more analgesia than had been anticipated. 
After PDT, the treated area became inflamed within a few hours. This was 
followed by sloughing of the superficial layers after 1 to 2 days, leaving a 
shallow ulcer. Oral analgesics were usually required from the first or second 
day after PDT for approximately 1 week. There was no evidence of scarring in 
those lesions that had not undergone previous surgery. Some benefit was 
observed in only one patient, who became tumour free (with persistent mild 
dysplasia). The other two patients were unable to be evaluated because they 
had to go on to further treatment for metastatic neck disease and progressive 
tumour.
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Patient
No
Age/Sex Site Previous
treatment
Histology
healed/wk
Size of lesion 
before/healed
Histology
longest
follow-
up/wk
1 85/F P Field
change*
Mild (4) 4.6cm^/0.8cnV! Mild (76)
2 87/F T Field
change*
N 4.0cm"70cm^ NAt
3 65/F BM/A/P/RM Field
change* 0.7
SCC (12) S.Scm^/S.Scm^ NAT
BM: buccal mucosa; P: Palate; T: tongue; N: no clinical disease macroscopically, but biopsy refused; NA: 
not applicable; A: alveolus. SCC: squamous cell carcinoma; RM: Retromolar trigone.
All three patients with field change disease had multiple excisions of dysplastic areas and carcinomas 
over 5-12 years before photodynamic therapy, 
developed metastatic neck disease.
^Subsequent photodynamic therapy with a different sensitiser.
Full-thickness epithelial necrosis and sloughing present in all cases.
Patients 2 and 3 received 100J/cm2; patient 1 received 200J/cm2.
Table 10.2: ALA PDT in field change disease 
At inclusion, all patients were N0M0
10.3.3 Conclusion
There seems little point wasting much time discussing ALA in field change 
disease. Clearly given our current state of knowledge, the depth of effect is too 
shallow making it an inappropriate treatment for this stage of disease except in 
dyplasia.
10.4 Foscan® PDT
Based on the histological effects of Foscan®, this would seem to be the best 
drug to treat field change disease. The only potential problem is scarring when 
extensive lesions are treated. The depth of PDT effect is up to 10mms, which 
should be sufficient to destroy dysplastic tissue. Of great concern, however, is 
the repopulation of treated areas. If this is from genetically damaged tissue, it is 
likely that recurrence will be inevitable. Mapping of such abnormalities is 
essential if treatment is to be successful. At present, while fluorescence and 
elastic scattering techniques are being developed, the best we are able to do is
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treat obvious disease with a margin of clinically normal mucosa. The extent of 
this is purely arbitrary but 5 -  10mm is usually selected.
10.4.1 Materials and Methods
Eight patients were included in this study with a mean age of 57 years (30 -  65 
years), all of whom had at least one histologically confirmed squamous cell 
carcinoma, all of whom conformed to the criteria of Warren and Gates (1932): 
histologically confirmed malignant primary neoplasms with each tumour being 
distinct. The total number of lesions was 16 (1-5 lesions per patient) and 6 
patients had received extensive prior therapy. The study was approved by the 
Ethics Committee of the University College London Hospitals and treatment 
carried out with informed consent.
Photodynamic therapy: The mTHPC was supplied as crystals, which were 
dissolved in a solvent of polythene glycol, water and ethanol to yield a 
concentration of 4mg mTHPC per ml. The drug dose was 0.15mgs/kg body 
weight and this was administered intravenously through a filter with care being 
taken to avoid extravasation. Illumination was carried out 72 -96 hours post 
injection. The light source used was a copper vapour pumped dye laser 
emitting red light at 652nm (Dynamic Light Hornsby, Australia) and delivery was 
via a 0.4mm microlens system (PDT Systems, Santa Barbara, CA).
Treatment was carried out under local anaesthesia in all but one patient (patient 
2) and treatment times were short ranging from 113 -  480s. The treatment area 
was marked with dots of crystal violet and included a margin of normal tissue of 
1 cm. This allowed checking of the position to allow for patient movement. 
Power density was kept below 250mW/cm2 to reduce thermal effects and where 
possible single treatment spots were used. This was not always possible due to 
the undulating contours of the mouth so it is possible there was some overlap of 
treatment sites. This was considered acceptable as it was felt important that at 
least the prescribed light dose be delivered. Escalating light doses were given 
from 5 - 2 0  J/cm2 as detailed in 10.4.2.
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Patients were kept in reduced light following drug administration with controlled 
re-exposure over 2-3 weeks.
10.4.2 Results
Pts Age/
Sex
Site Stage
TNM
Previous
treatmen
t
Light
dose
Histology
(wks)
healed
Size
cm2pre/p
ost
Hist/FU
(wks)
longest F/U
1 30/M T T1 S 5J/cm2 PD 1.5/0.1 S &RT (12)
2 54/M LT T2 Nil SJ/cm^ HK (26) 6.1/0 NCD (88)
LBM T2 Nil 5J/cm2 Normal(26) 12.6/0 NCD (88)
SP T2 Nil 5Jcm2 PD 1.2/0.6
10 J/cm2 PD 0.6/0.3
20J/cm2 NCD 2.4/0 NCD (21)
RBM T2 Nil 10J/cm2 PD 12.6/7.1 PR
10 J/cm2 PD 7.1/7.1 NR
RMA T1 Nil 5J/cm2 PD 3.1/1.2 NR
10J/cm2 PD 1.2/1.2 NR
3 61/F BM T2 S 10 J/cm" PD 4.9/0.8
20Jcm/2 NCD 0.8/0 NCD(35)
LA T2 S 10 J/cm2 NCD 2.0/0 NCD(44)
P T1 S 10J/cm2 PD 1.2/0.03
20J/cm2 NCD 0.03/0 NCD(35)
4 59/M BM D S 5J/cm2 NCD 24.3/0 NCD(89)
A T1 S 10J/cm2 Hyperplasia 0.3/0 Mild ED(64)
5 65/F P T1 S,C,PDT SJ/crn"1 PD 6.2/3.1 NCD(52)
20 J/cm2 NCD 3.1/0
A T1 S,C,PDT 5J/cm2 PD 2/1.3 For further
10 J/cm2 PD 1.3/0.6 PDT
15 J/cm2 PD 0.8/0.3
6 60/M LFO Tis S 10J/cm" Fibrosed 9.6/0 NCD(24)
M mucosa(8)
7 64/M T T1 nil 1OJ/crn^ Mild ED 1.1/0 NC (84)
8 59/M RM T2 S,CY,RT 10J/cmz PD 1.2/0.8 Lost to F/U
Table 10.3: Foscan® PDT in field change disease
Key: T-tongue, BM-buccal mucosa, A-alveolus, (S)P-(soft) palate, FOM-floor of 
mouth, RM-retromolar, S-surgery, R-radiotherapy, C-chemotherapy, CY- 
cryotherapy, D-dysplasia; HK-hyperkeratosis; PD-persistant disease; NCD-no 
clinical disease, NC-no change; PR-partial response, NR-no response, ED- 
epithelial dysplasia, L-left, R-right.
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Light
Dose
Dysplasia Tis T1 T2
5J/cm^ 1 CR 4 PD 2CR
1PR
lOJ/crn^ 1 CR 2CR 1 CR
2PR 1PR
1NR 1NR
15 J/crn^ 1PR
20J/cm2 2CR 2CR
Table 10.4: Response rates with escalating light dose.
Key: CR-complete response, PR-partial response, NR-no response
Eight patients with field change disease were treated on this protocol. Within a 
few hours of treatment, the treated area showed erythema, oedema and 
blistering. This was followed by the formation of a mucopurulent slough which 
healed gradually over 1-2 months. Some of the patients who achieved a partial 
response at low light doses were re-sensitised and treated ata higher ligt dose 
Table 10.3
As can be seen from the results in tables 10.3 and 10.4, the low light doses of 5 
and 10J/cm2 were insufficient to clear the disease and it was only at higher 
doses of 20J/cm2 that one could be confident of disease elimination. Of course 
this has the potential to cause some scar formation although this was only seen 
in 1 case in this series.
10.4.3 Complications
All 8 patients experienced pain on administration of Foscan®. This was 
occasionally severe, but settled fairly quickly. It is our current practice to 
administer a small amount of 0.5% lignocaine before injecting mTHPC. 
Treatment was well tolerated although 2 patients required local anaesthesia. 
Post-operative pain was unpredictable, but could be severe. The onset 
coincided with the ulcerative phase and subsided with healing. Opiate 
analgesia was used by most patients for a period of about 2 weeks. Scarring
was seen in one patient (6) who had a degree of tongue tethering. This was in 
part due to previous surgery that included a skin graft in the floor of mouth.
There were no biochemical or haematological changes following treatment and 
two patients had mild photosensitivity reactions following sunlight exposure
10.4.4 Discussion
The treatment results are clearly better with higher light doses. 10J/cm2 was 
sufficient to clear in situ disease, but only 2 out of the 5 T1 tumours was 
cleared. Both the T1 and T2 tumours treated with 20J/cm2 were cleared, 
suggesting the need for higher light doses. In this study, the number of patients 
is small, however, in this difficult group, who often have no therapeutic 
alternatives, Foscan® PDT does seem to offer an alternative to extensive 
surgical intervention.
10.4.5 Conclusions
Foscan® PDT can be of value in the management of field change disease. 
Treatment times are short, allowing large areas to be treated in a reasonable 
time, phototoxicity can be a problem, but can be overcome by careful controlled 
re-exposure to light. Not all patients had a good outcome, but given that the 
majority of patients were referred following conventional treatment failure, that is 
hardly surprising.
10.5 Summary
These studies demonstrate the efficacy of PDT in the ablation of early invasive 
and pre-malignant lesions of the oral cavity. It may therefore be a viable 
therapeutic alternative to extensive mutilating surgery. While long-term follow- 
up is necessary to determine recurrence of pre-malignant and overtly malignant 
foci, unlike conventional techniques such as surgery or radiotherapy, PDT may 
be repeated without loss of normal tissue. Irreversible side effects such as 
those seen in salivary, bony and vascular tissues with radiotherapy are also 
avoided.
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Clearly there are problems with all approaches to the management of field 
change disease. The neck remains a difficult area and this is probably best 
managed with conventional surgery and radiotherapy.
PDT, with ALA would seem to have too superficial an effect to be of clinical 
value. Photodynamic therapy with Photofrin® or Foscan® offers a viable 
therapeutic alternative in the treatment of multi-focal field cancerisation of the 
upper aerodigestive tract. Its use alone, or where a small area of tumour 
persistants, with surgical excision, offers functional and cosmetic advantages 
over conventional treatment modalities for this difficult condition.
Chapter 11: Interstitial PDT for the Treatment of Advanced Head and Neck 
Cancer
11.1 Introduction
The treatment of advanced head-and-neck cancer continues to pose a major 
challenge. Although some early cancers are cured effectively, the overall 
outcome remains unsatisfactory and the overall survival rates have remained 
unchanged for several decades (Black et al 1997, Parker et al 1997, Pisani et al 
1999). About 30-40% of patients with head-and-neck cancer have persistent or 
recurrent locoregional disease after completion of definitive treatment. 
Therapeutic options for these patients are often limited by previous radiotherapy 
or surgical procedures. In the majority, surgical salvage is either not feasible or 
carries a high risk of complications due to fibrosis generated from previous 
treatment or tumour invasion into vital structures (Ridge 1993, Watson et al 
1998). Similarly, re-irradiation is often impossible and only a very small number 
of patients with recurrent disease treated by full-dose re-irradiation are long­
term survivors. Also, the incidence and severity of late toxicity is markedly 
increased in comparison to that observed after the first irradiation (De 
Crevoisier et al 1998, Stewart 1999).
In the clinical setting, many studies have confirmed the treatment efficacy of 
PDT on several types of human cancers, emphasizing the potential for 
improved functional and cosmetic outcome in a wide group of patients, while 
achieving comparable tumour control (Dougherty et al 1998, Hopper 2000).
One of the main limitations of PDT is the penetration of light in tissues and 
although it is possible to obtain good palliation of advanced disease with 
surface illumination, theoretically at least, clinical benefit is only likely to be seen 
in tumours that can be completely illuminated. This imposes an approximate 
maximum depth of effect of 1cm with current drugs in clinical use. The use of 
photosensitisers with a greater red shift such as bacteriochlorins (activation 
wavelength 730nm) should result in a greater depth of effect but wavelengths 
above 750 -  800 nm produce insufficient photon energy to trigger a PDT effect. 
However, interstitial treatment could overcome most of the constraints of
196
superficial treatment. Multiple fibres can be inserted directly into tumours under 
image control and large volumes of tumour can be destroyed in sites that are 
inaccessible to surgery or where surgery would cause damage to vital adjacent 
structures (Bown et al 2002, Nathan et al 2002). In this study, the safety and 
efficacy of interstitial PDT (IPDT) as a salvage treatment for recurrent head- 
and-neck cancers is investigated.
11.2 Materials and Methods
11.2.1 Patients
Between July 1997 and December 2002, a total of 45 patients with recurrent 
head-and-neck cancers were treated with salvage IPDT. Six patients were 
excluded from analysis because of insufficient data. Of the remaining 39 
patients (61 treatments), 25 were men and 14 were women and their median 
age was 58 years old (range 8-84) (Table 11.1). Thirty-six patients (92%) had 
received prior radiotherapy, either alone or adjuvant to surgery or combining 
with chemotherapy as the primary treatment (35/36) or as a salvage treatment 
(1/36). Among those who received radiotherapy as part of their primary 
treatment, 25/35 had external irradiation only, 3/35 had both external irradiation 
and brachytherapy, whilst the other 7/35 had concurrent chemotherapy. Fifteen 
patients (38%) received surgery, either alone or as part of the combined primary 
treatment modalities. Sixteen patients (41%) received prior salvage treatment, 
including surgery (12/16), brachytherapy (3/16) and palliative chemotherapy 
(3/16), after recurrence was encountered. Table 11.1 summarizes the details of 
patient characteristics.
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Median age 58 years (range 8-84)
Sex
Male 25(64%)
Female 14(36%)
Primary treatment
Surgery 15(38%)
Radiation 35(90%)
External only 25
External & brachytherapy 3
Concurrent chemotherapy 7
Salvage treatment after recurrence noticed 16 (41 %)
Surgery 12
Brachytherapy 3
Palliative chemotherapy 3
Table 11.1: Patient characteristics
All patients were referred because the recurrent tumours were either considered 
unresectable or the patients were not suitable for further surgery due to their 
general condition and were not candidates for further irradiation. Thus all the 
patients selected in this study were regarded as having a poor prognosis.
The sites and pathology of the recurrent tumours were diverse. Almost every 
anatomic sub-site of the head and neck region was involved (Table 11.2). 
Squamous cell carcinoma was the most common pathology (27/39, 69%) whilst 
other tumours like adenoid cystic carcinoma, olfactory neuroblastoma, follicular 
cell carcinoma, hemangiopericytoma, branchiogenic carcinoma, primitive 
neuroectodermal tumour and sarcomas were also encountered. The stage of 
recurrent tumours was very advanced, rT4, rN2 or rN3, in 85% of the patients 
(33/39). Recurrent T3 and T2 diseases were also noted in 4 and 2 patients, 
respectively. Table 11.2 summarizes the details of tumour characteristics.
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No of patient sites
Anterior tongue 6
Buccal mucosa 2
Floor of mouth 4
Alveolar ridge 3
Hard palate 3
Tonsillar region 5
Tongue base 1
Oropharyngeal wall 2
Maxillary sinus 2
Nasal cavity 3
Nasopharynx 1
Parotid 2
Thyroid 1
Neck 4
Stage
rT2 2
rT3 4
rT4 31
rN2 1
rN3 1
Pathology
Squamous cell carcinoma 27
Adenoid cystic carcinoma 3
Basal cell carcinoma 1
Olfactory neuroblastoma 1
Follicular cell carcinoma 1
Hemangiopericytoma 1
Branchiogenic carcinoma 1
Primitive neuroectodermal tumour 1
Osteosarcoma 1
Malignant fibrous histiocytoma 1
Alveolar soft part sarcoma 1
Table 11.2: Tumour characteristics
Pre-treatment evaluation included a complete physical examination, chest X- 
ray, complete blood cell count, and biochemical profile. A tissue diagnosis was 
obtained from all patients to confirm the recurrence of disease. All patients 
received either computed tomography (CT) or magnetic resonance imaging 
(MRI) to assess the extent of tumour and to determine the stage of recurrent 
disease. The experimental nature of the treatment was thoroughly explained 
and all patients gave informed consent.
11.2.2 Interstitial Photodynamic Therapy
Patients were sensitised with 0.15 mg/kg intravenous meso-tetrahydroxyphenyl 
chlorin (Foscan®, Biolitec Pharmaceuticals Ltd), kept in reduced room lighting 
to prevent skin photosensitivity and treated 4 days later. The light source was a 
diode laser (Diomed or CeramOptec, wavelength 652nm) with its primary beam 
feeding into a beam splitter to produce 4 treatment fibres (core diameter 0.4mm, 
bare tip). The power of each treatment fibre was 100mW and a power-meter 
was used to ensure the power output at the tip of each fibre. 18 gauge needles 
were then positioned percutaneously into the tumours. Initially this was carried 
out freehand, but subsequently ultrasound-, CT-, or MRI-guidance was used. 
The treatment fibres were passed through the needles using a flagging system 
to ensure that the fibre tip was exposed to the tissues and not still inside the 
needle. Four fibres were positioned at a time and a pullback technique was 
used using 1cm steps to treat thicker tumours. The energy applied to each 
treatment “station” was 20J (energy at point sources is in joules, with no surface 
area, unlike surface illumination). Ten treatments performed in this study were 
under local anaesthesia whilst the other 54 treatments were under general 
anaesthesia. After the administration of the sensitiser, patients were protected 
from bright sunlight for a total of 3 weeks. They were exposed to light of 100 lux 
on the first day, increasing by 100 lux per day. At 14 days, they were allowed 
outside using sensible precautions against sunlight.
11.2.3 Assessment and Follow-up
Criteria for response were as follows: a complete response (CR) was defined as 
complete regression of all evidence of disease; a partial response (PR) required
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a 50% decrease of the summed products of the two largest perpendicular 
diameters of all measurable lesions, without an increase in size of more than 
25% in any lesion or the appearance of new lesions; stable disease (SD) was 
defined as no significant change or any change in tumour size that was less 
than a partial response but not large enough to be considered progressive 
disease; progressive disease (PD) was defined as an increase of at least 25% 
in the size of measurable lesions or the appearance of any new lesion. 
Treatment effects were assessed 4 weeks after IPDT and the responses were 
monitored using post-treatment scans. Where possible, these were of the same 
type as the pre-treatment scans to facilitate direct comparison. Patients with 
partial or complete responses were followed-up every month for 6 months then 
every 3 months thereafter. In addition to the quantitative measurement of 
tumour response, a qualitative measure was also used. Because the tumour 
extent in most patients of this study was very extensive, most treatments were 
carried out for palliative intent, thus, an index symptom was identified and 
benefit was assessed in relation to this response. For most of the patients, 
treatment objectives were often very limited although 7 patients were treated 
with curative intent (Table 11.3).
Number of patients Achieved
Cure 7 3(43%)
Palliation
Swelling 26 18(69%)
Pain 6 3(50%)
Bleeding 3 3(100%)
Dyspnoea 2 1(50%)
Aphonia 1 1(100%)
Brachial Plexus Compression 1 1 (100%)
Table 11.3: Treatment Objectives 
11.3 Results
The median overall (intent-to-treat) survival time of the patients was 14 months 
(Figure 11.1). A total of 61 treatments were performed in this study. Twenty-
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four patients (62%) received only a single treatment; ten patients (26%) 
received two treatments, four patients (10%) received three and one patient 
received five treatments. For those who received treatment more than once, 
the median interval between each treatment was 6 months (range 1-16 
months). The response of IPDT could be assessed in 56 treatments. Among 
them, CR was achieved in 8 treatments (14%); PR was achieved in 42 
treatments (75%), SD was noted in 4 (7%) whilst PD was encountered in 2 
treatments (4%).
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Fig 11.1 : Overall survival (Kaplan-Meier curves)
The median disease-free survival time was 22 months (Figure 11.2) whilst the 
overall response rate (CR + PR) was 89%. The local control rate at 6 and 12 
months were 54% and 41%, respectively. The age and sex of patients; 
modality of prior treatment; tumour site, pathology and stage did not correlate 
with the survival of the patients.
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Fig 11.2: Disease-free survival (Kaplan-Meier curves).
However, survival benefit was observed in patients whose response of initial 
treatment was CR or PR (responders in the initial treatment). They had 
significant better survival time than the non-responders (Mantel-Cox log-rank 
test, p < 0.01; Figure 11.3).
1 .00
CR+PR0.75
SD+PD
0.50
|  0.25
30
TinieimoiTthsi
Fig 11.3: Cumulative survival (Kaplan-Meier curves) of responders and non­
responders to their initial treatment.
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Thirty-two patients were treated with palliative intent. The symptoms to be 
palliated were swelling in 26 patients, pain in 6 patients, bleeding in 3 patients, 
dyspnoea in 2 patients, aphonia in one and brachial plexus compression in 
another one patient (some patients had more than one treatment objective).
The treatment objectives could be achieved in 18/26 (69%) patients with 
swelling, 3/6 (50%) patients with pain, 1/2 (50%) patient with dyspnoea (Table 
11.3). All patients with bleeding, aphonia and brachial plexus compression 
were successfully palliated by IPDT. Two patients who were treated with 
palliative intent initially were disease-free (proven by biopsy) after IPDT and 
were still alive and well at the last follow-up. Seven of the patients in this study 
were treated with curative intent because of the relatively “early” stage of 
recurrent disease (rT2 , rT3 and one extensive but superficial rT4). Among them, 
three patients are still disease-free to date (Table 11.3).
Post-treatment tissue swelling and pain were noted in most of the patients but 
would usually subside within 2-4 weeks. Skin photosensitivity was noted in only 
one patient who failed to comply with the light regime, exposing himself to 
outdoor natural light early in the photosensitive period. The only major 
treatment-related side effect in this series was carotid blow out. It was 
encountered in one patient during the very early days of this study. IPDT was 
performed to treat the patient’s recurrent neck disease, which was very close to 
the carotid artery. After the treatment, it was initially uneventful, but 
unfortunately carotid blow out occurred 2 weeks later. Postmortem materials 
suggests that tumour had already eroded the carotid artery wall (Fig 11.4).
Fig 11.4: Cytokeratin antibody staining of tumour on the internal wall of the 
carotid artery. Postmortem finding 14 days after PDT
Since then, ultrasound-, CT-, or MRI-guided insertion of treatment fibres (Figure 
11.5) has been routinely performed to avoid injury to vital organs.
Fig 11.5: a - Recurrent adenoid cystic carcinoma of the right maxilla. Symptoms 
of epistaxis and nasal obstruction, b and c showing titanium needle placement 
under MR control, d - treatment response resulting in relief of epistaxis and 
obstruction. Note visualisation of needles by artefact only
11.4 Discussion
Despite the advances in oncological disciplines during the last decades, most of 
the recurrent head-and-neck cancer patients still succumb to their disease. 
There are many different treatments available including surgery, re-irradiation 
and chemotherapy; each has certain benefit to limited groups of patients. But 
generally, to re-treat these patients with any existing modality carries a 
significant morbidity without much survival advantage (Ganly et al 2000).
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Among these treatment modalities, surgery is frequently employed to salvage 
recurrent head-and-neck cancer patients. It was also observed in this study 
that 12 of the 16 patients who had received prior salvage treatment had salvage 
surgery (Table 11.1). However, surgical salvage of local recurrence is 
dependent on the site and previous treatment of the primary tumour as well as 
the patient’s general condition. It is known that recurrent glottic cancers that 
failed primary radiotherapy and are still confined to the laryngeal framework can 
be treated by surgery with curative intent (Nibu et al 1997, Maipang et al 1989). 
But larger recurrent tumours over other sub-sites of the head-and-neck region 
are rarely curative and carry high risks of surgical complications (Ridge 1993, 
Watson et al 1998). Marcial et al (1980), reported a 27% 5-year actuarial 
survival from oropharyngeal cancer patients who undertook surgical salvage 
(Marcial et al 1980). However, serious complications occurred in 21% of their 
patients. Rate et al (1991), combined surgical resection with intraoperative 
radiotherapy to salvage recurrent head-and-neck cancers and they achieved a 
54.9% 2-year survival rate (Rate et al 1991). But again, perioperative mortality 
was 8.5% and severe complication occurred in 32.5% of the remaining patients. 
In the present study, the majority of our patients were considered non-surgical 
candidates because of tumour extent as well as history of previous surgery and 
radiotherapy that could carry a very high risk of peri- and post-operative 
morbidity or even mortality. However, there was only one treatment-related 
mortality in the very early days of this study and it was successfully prevented in 
future patients by the use of image-guide treatment. There was no peri- or 
post-treatment morbidity or complication and photosensitivity was also not a 
problem as long as the patient could comply with the light regime. Thus, IPDT 
seems to be a relatively safe measure for surgically high-risk recurrent head- 
and-neck cancer patients.
Apart from its role as a main treatment modality for primary head-and-neck 
cancers, radiotherapy has been widely used in the treatment of recurrent 
diseases. Since most of the head-and-neck cancer patients have received 
radiotherapy in their primary treatment, the main concern for re-irradiation is the 
damage to the previously irradiated tissues that may result in more severe late 
complications. Many different radiotherapy regimens have been used; among 
them, external beam re-irradiation is the commonest form but better local
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control could only be achieved when the radiation dosage is greater than 60Gy 
(Ganly et al 2000). A large-scale study using full-dose re-irradiation to treat 
unresectable head-and-neck carcinoma showed the overall survival at 2 years 
was 21% (median survival 10 months) (De Crevoisier et al 1998). However, the 
incidence and severity of immediate and late toxicity (including 5 carotid blow­
outs) was markedly increased compared to that observed after primary 
irradiation (De Crevoisier et al 1998). Alternatively, lower doses of re-irradiation 
can be given with brachytherapy (Harrison 1997). With either “high-dose-rate” 
or “low-dose-rate”, brachytherapy has been shown to be effective in the 
treatment of recurrent head-and-neck cancers (Puthawala et al 2001, Krull et al 
1999, Glatzel et al 2002). Using interstitial high-dose-rate brachytherapy, Krull 
et al (1999) reported a local control rate of 49% at 12 months (overall median 
survival time less than 12 months (Krull et al 1999) whilst Glatzel et al (2002), 
reported a 74% response rate and overall median survival was 6 months in 
patients with recurrent tumours (Glatzel et al 2002). Puthawala et al (2001), 
used interstitial low-dose-rate brachytherapy and achieved a 21.7% 5-years 
overall survival rate (Puthawala et al 2001). However, moderate to severe 
complications occurred in 27% of their patients. Radiotherapy is also notorious 
for causing tissue fibrosis and constrained blood supply that may interfere with 
the efficacy of further treatments. Despite the fact that the majority (92%) of our 
patients had prior irradiation (including 6 with brachytherapy and 7 with 
chemoradiation), the response rate to IPDT in the present study was 89%, the 
overall median survival time was 14 months and local control rate at 12 months 
was 41 %. Five of our patients are alive without evidence of recurrence to date 
and no late complications have been noticed. Because of extensive variation in 
patient selection criteria and treatment methods employed, a judicious 
comparison of these studies is not possible. However, our results clearly 
demonstrated that IPDT could be effective in treating recurrent tumours that 
have failed radiotherapy (including external beam, brachytherapy and 
chemoradiation). The survival data presented herein also forecast an 
encouraging potential to use IPDT as part of combined treatment modalities for 
recurrent head-and-neck cancers.
Perhaps the most commonly used and investigated chemotherapeutic agents in 
recurrent head-and-neck cancers are cisplatin and 5-FU. Used either as a
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single agent or in combination, the median survival is 6 months in both cases, 
although combination chemotherapy increases overall response rates from 
10%-20% to 30%-40% (Clavell et al 1994, Forastiere et al 1998, Vokes 1996, 
Jacobs et al 1992, Forastiere 1994). A randomised trial comparing the 
effectiveness between CABO (cisplatin, methotrexate, bleomycin and vincristin), 
PF (cisplatin and 5-FU), and cisplatin alone in recurrent head-and-neck cancers 
showed similar response rates for CABO (34%) and PF (31%) but better than 
cisplatin alone (15%) (Clavell et al 1994). However, there was no difference in 
overall survival between the three arms. New chemotherapeutic agents have 
also been tried in recurrent head-and-neck cancers. Unfortunately, the major 
response rates were not significantly better than traditional cisplatin-based 
chemotherapy and the overall survival has not been improved (Catimel et al 
1994, Forastiere et al 1998). It is generally agreed that results of chemotherapy 
in the treatment of recurrent head-and-neck cancers show only moderate 
response rates and these are of short duration producing little or no increase in 
survival. Compared with chemotherapy, IPDT not only achieves a better 
response rate (89% response rate) but also significant survival benefit (overall 
median survival 14 months), especially in those who were responders to their 
initial treatment. Thus, IPDT could be a reasonable alternative in the palliation 
of recurrent head-and-neck cancers.
It is agreed that improving the patient’s quality of life (QOL) is a very important 
goal in palliative cancer treatments. Consensus concerning the definition and 
measurement of QOL is difficult because of the complexity of the concept.
There are few judicial and objective measurements (Aaronson 1990), but there 
are a number of different questionnaires used to investigate the QOL in head- 
and-neck cancer patients (Sherman et al 2000, Bjordal et al 1994, Nguyen et al 
2002, Hammerlid et al 2001). Currently there are versions of the University of 
Washington and EORTC questionnaires specifically designed for head and 
neck cancer patients -  for a comparison of these two see Rogers et al 1998. It 
is also difficult to evaluate patients’ QOL in very advanced head-and-neck 
cancer patients if they are gastrostomy fed, as seen in most of our patients. As 
an alternative, treatment objectives could be specified and monitored as an 
indirect indicator of the patients’ QOL (Schleicher et al 2001). In this study, we 
identified treatment objectives for each patient and evaluated if the symptoms
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could be palliated with IPDT (Table 11.3). Generally, about 70% of the 
symptoms could be successfully palliated with IPDT. Compliance to the light 
regime was not a big problem to the patients because their daily indoor 
activities were not restricted and outdoor activities could be recommenced 2-3 
weeks after treatment. Patients’ willingness to be re-treated could also 
indirectly reflect their satisfaction in treatment and improvement in QOL. Thirty- 
eight percent of the patients in this study received more than one IPDT 
treatment. The real percentage of patients who were willing to repeat their 
treatment might be higher than that value because some of the remaining 62% 
patients didn’t survive long enough to receive the second treatment (median 
interval between treatments was 6 months).
To improve the current limitation in the depth of tissue penetration with surface 
illumination PDT, newer photosensitisers were developed with longer activation 
wavelengths (Hsi et al 1999). It is known that the depth of light penetration 
increases with longer wavelengths of light. However, there is an inverse 
correlation between the wavelength and energy of light. Thus, it would appear 
there is an absolute maximum depth to which light of clinically useful 
wavelengths can penetrate. Alternatively, the limitation in tissue penetration 
could be overcome by interstitial treatment. Using a powerful photosensitiser 
Foscan®, which can produce effects to about 1cm, Nathan et al (2002), have 
shown that IPDT is a safe and effective measure for recurrent prostate cancer 
after radiotherapy (Nathan et al 2002). Animal studies also demonstrated that 
IPDT with Foscan® was sufficient to induce massive tumour destruction with 
minimal muscle damage (Andrejevic-Blant et al 1998). These results imply that 
IPDT with Foscan® could be a reasonable treatment option for tumours in 
unfavourable localisations in the oral cavity or pharynx that are surrounded by 
abundant muscles. Another advantage of interstitial treatment over surface 
illumination is that better light dosimetry can be achieved. With the 
improvement in imaging technology and facilities, we will be able to refine the 
light dosimetry to cover the whole extent of tumour with no or only minimal 
injury to the surrounding normal tissues. As a result, the treatment efficacy 
could be improved whilst complications could be minimised. A large-scale 
prospective study is warranted to verify this point.
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11.5 Conclusions
Because of the complex regional anatomy and close proximity to vital 
structures, recurrent head-and-neck cancers are extremely difficult to treat. In 
this study, we have shown that IPDT could be an effective salvage measure for 
recurrent head-and-neck cancers. It is a minimally invasive procedure and can 
be used in carcinomas and sarcomas, in patients of all age groups, as well as in 
medically compromised patients that could not withstand complications of 
radiotherapy or may be too debilitated to undergo surgery. Thus, IPDT may 
serve as an important treatment option for the integrated head-and-neck 
oncology team.
Chapter 12: Future Developments of PDT
12.1 Drug Development
There are a number of limitations with current photosensitisers in clinical use 
and there are various ways of overcoming these.
12.1.1 Selectivity
So far, there has been little to suggest that a selective PDT effect -  that is to 
say necrosis of tumour while preserving normal tissue from which a tumour has 
arisen -  can be achieved with the treatment parameters and drugs in current 
use. All the current selectivity is purely as a result of the positioning of the light 
although ratios of photosensitiser in brain tumours compared with normal brain 
might prove an exception, but even in this site there are potential problems as 
normal brain is extremely sensitve to PDT even when concentrations of 
photosensitiser are low.
Work is currently being undertaken to see if it is possible to link an antibody 
fragment to a sensitiser (figure 12.1) and generate ratios of 
100(tumour):1 (normal). If successful this would dramatically increase PDT 
applications, especially in bladder tumours where good antibody fragments are 
available. This would overcome the problems of muscle damage and small 
volume bladder that restrict PDT application in this condition.
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Fig 12.1: Principle of selectivity when specific antibody fragments are linked to 
photosensitiser resulting in increased selectivity of photosensitiser binding to 
tumour, (Photobiotics London UK)
12.1.2 Drug Light Interval
Most photosensitisers have an optimum drug light interval of hours to days 
before the recommended time of photoactivation. Clearly this is inconvenient 
for the patient and also makes the use of adjunctive intraoperative treatment 
difficult. If a surgeon is performing a neck dissection, then he or she would 
need to identify patients preoperatively when it is thought that it would be 
impossible to safely resect all the tumour. This is a major problem with drugs in 
current use as they all cause photosensitivity problems under operating lights.
It would be much more useful to have a drug that could be injected systemically 
and activated in a matter of minutes at the end of an operation just prior to skin 
closure. One such drug under investigation is Tookad® which is being studied 
in prostate cancer.
There is also a great deal more to learn about optimisation of the drug light 
interval. All of the current treatment parameters were derived from animal 
experiments on drug kinetics and biodistribution. The idea was that the drug
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light interval was set when drug concentrations in normal tissue had fallen, but 
w ere still high in the target tumour. Recent Russian studies (Stranadko et al 
2003) on skin cancer suggest that this might be of academ ic interest, as it has 
been possible to successfully treat basal cell carcinoma with Foscan® at 24  
hours (as opposed to 96hrs) with a greatly reduced drug dose and increased 
light dose (figure 12.2). The reduced drug dose also has an obvious beneficial 
impact on the duration of photosensitivity.
Fig 12.2: 78yr old m ale with 15mm diam eter BCC treated with Foscan® PD T  
Treatm ent parameters: Drug dose 0.04m g/kg DLI 24hrs Light 60J/cm 2 C R  at 7 
months (Stranadko et al 2003).
12.1.3 Drug Level Monitoring
There is obviously great scope for non invasive techniques to m easure tissue 
drug levels in real time. Optical pharmacokinetics is one such potential method 
of doing this. The technique has certain similarities to elastic scattering 
spectroscopy (vide infra) and is at very early stage of development, however, it 
has the potential to revolutionise pharmacokinetic studies not only of 
photosensitisers, but also a number of other drugs. It is an intriging prospect 
that future drug level measurem ents might be possible non invasively in real 
time.
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12.2 Laser Development
Currently, nearly all treatments are carried out using light from laser sources. 
W hile this has proved successful, there are laser safety issues to consider and 
non laser light sources might be more widely applied. This is already the case 
in dermatology, where light emitting diodes (LEDs) and filtered Xenon light 
sources are widely used. One curious observation has been m ade using LED  
sources and that is a very large volume of tumour necrosis can be achieved by 
using low fluence rates and treating over several hours. This becomes practical 
in the treatm ent of tumours of the pancreas or liver with indwelling devices  
which can be placed at laparotomy, ported through the skin, activated for 
several hours and then simply withdrawn. One such system under investigation 
is the LED system from Light Sciences (figure 12.3).
Fig 12.3: LED source for P D T treatm ent (Light Sciences Corporation Seattle  
US).
O ne other innovative approach to light delivery is BioLuminescence Activated 
Destruction of Cancer (BLADE or the “Firefly” concept). If light can be 
generated within malignant tissue, sensitisers can be activated and cause the 
cells to self destruct. This is achieved by dosing the administering D-luciferin 
which is cleaved by transfected luciferase previously introduced into the tumour 
attached to tumour specific antibodies. This is the mechanism by which fireflies 
produce visible light (520 -  540nm ) but in this setting, rather that attracting a 
mate, results in lethal photosensitisation, (figure 12.4).
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Fig 12.4: Bioluminescence of cells generated by luciferin/luciferase reaction 
(T.Theodossiou 2003)
12.3 Tumour Delineation
The crucial factor to give the best chance of curing any local disease such as 
oral cancer is comprehensive treatm ent of the whole tumour. This requires two 
things -  accurate mapping of the extent of tumour and then ensuring the total 
disease volume is treated. This has a great deal in common with interstitial 
radiotherapy techniques, many of which can be applied here.
12.3.1 Surface Mapping
Histology remains the gold standard for tumour diagnosis, but there are a 
num ber of non invasive techniques that can be used to map tumours pre­
treatm ent. This can be of great value when a tumour arises in a widespread
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area of dysplasia. Detailed description of these techniques is outwith the scope 
of this thesis, however, the following seem  to be applicable clinically.
12.3.1.1 Fluorescence Techniques
These rely on alterations in red/green fluorescence which correlate with 
increasing malignancy. These changes can be enhanced by the use of an 
aminolaevulinic acid mouthwash and improve the sensitivity and specificity of 
the technique.
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Fig 12.5 : Enhanced fluorescence image and numerical readout 
The numerical sam ple relates to clumps of approximately 5 cells within the 
white area of fluorescence -  note red/green fluorescence ratio well above the 
normal 1:1 ratio -  indicating malignancy. The blue numbers reflect background 
fluorescence.
12.3.1.2 Elastic Scattering (ESS)
ESS  is a technique in which a short pulse of white light is fired into tissue and 
the returning signal, collected by a second immediately adjacent fibre, is 
displayed on a spectroscope. Intensity changes and alteration of gradients in 
the spectra have been shown to correlate well with surface tumours in vivo and 
in formalin fixed tissue.
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Fig 12.6 : Elastic scattering spectra of different oral tissues
Note high light scattering of malignant tissue at short wavelengths and low
scattering at longer wavelengths.
12.3.1.3 Raman Spectroscopy
This is an elegant technique that looks at changes in the wavelength of incident 
laser light as a result of tissue interaction. It has found application in Barretts 
Oesophagus and breast cancer (among others) but requires sensitive and 
expensive equipm ent as the signal intensity is weak.
Fig 12.7: Exam ple of diagnostic potential of Ram an (vibrational) Spectroscopy 
(A = incident photon AA= wavelength shift after tissue interaction).
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Fig 12.8: Scatter plot of Ram an spectra in Barretts Oesophagus (Courtesy Dr 
Nick Stone, Head of Biophotonics Research Group, Principal Clinical 
Scientist/Senior Lecturer, G loucester Hospitals NHS Trust, Gloucestershire 
Royal Hospital, G reat W estern Road, Gloucester, GL1 3NN).
12.3.1.4 in Vivo Microscopy
This also appears to be useful and if linked to a spectroscopic system or 
staining technique might be helpful. At present, in common with many of the 
techniques above, it still needs expert interpretation of the results. For any 
system to be widely adopted, a simple semi automated readout will be required.
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Normal Cancer
Fig 12.9: In vivo microscopy images of benign and malignant oral mucosa 
(Courtesy JP Allen, PW Allen & Co Ltd, Allen House, Alexandra Way, 
Ashchurch Business Centre, Tewkesbury, GL20 8TD, UK).
12.3.2 Assessment of Tumour Volume
Clinical examination and imaging remain the mainstay of assessment of tumour 
volume. Accuracy with these techniques has been discussed in earlier 
chapters, but they all have limitations.
12.3.2.1 High Frequency Ultrasound
This may be of value in determining tumour depth when treatment is planned 
with surface illumination. It appears that there is good correlation between 
ultrasound and histopathology. This can be easily applied to surface lesions 
such as skin tumours, but there is an obvious need in the head and neck for 
small probes suitable for evaluating oral tumours.
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Pre treatment Post treatment
Fig 12.10: Clinical appearance of cutaneous BCC with time matched high 
frequency ultrasound before and after ALA PDT treatment (Photo courtesy of Dr 
A Sahota)
12.3.2.2 Functional Imaging Using Positron Emission Tomography
(PET scanning) might offer more information about tumour target volumes. It is 
still experimental, but it is relatively simple to compare PETCT data with CT 
scans to position treatment fibres at the site of glucose avid tumours (figure 
12.11). There remains some doubt regarding the accuracy of these technique, 
so until it has been fully validated, it has to be cross checked with MR images. 
Co-localisation techniques -  that is to say fusion of physiological and 
anatomical detail is currently in its infancy, but will almost certainly be more 
useful in the future.
Fig 12.11: 3 Dimensional PETCT scan with glucose avid tissue identified at 
base of tongue
One of the main advantages of PDT over other treatments is the ability of 
normal tissue around a tumour to withstand the treatment and heal satisfactorily 
even when it has been included in a treatment margin. This often allows us to 
be slightly more radical with safety margins and depends on the type of drug 
used, for example, circumferential treatment of the oesophagus is well tolerated 
with ALA, but not with conventional Foscan® treatments (drug dose 0.15mg/kg, 
drug light interval 96hrs, 652nm light at 20J/cm2) which causes muscle damage 
and an unacceptable degree of stenosis.
12.4 Delivery Systems
Most published data on PDT concentrates on surface illumination techniques. 
While drugs like Foscan® produce clinically useful effects down to about 10 -  
15 mm, the application of this therapy needs greater development in interstitial 
treatments. In Chapter 11,1 have shown that this approach can be used 
effectively. However, there is still a great deal to be done to bring this therapy 
into regular practice.
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12.4.1 Bare Fibres Versus Diffuser Fibres
There are clear advantages of using bare fibres -  they are cheap, reusable and 
the distribution of light can be modified to almost any situation. Using a beam  
splitter and Foscan®, large tumour volumes can be treated in a short time. 
However, there is a great need to look at the exact distribution of light in human 
tissue. This can be done with Monte Carlo Modelling. Figures 12.12 -  12.15  
show the results of one such model that was used to validate the treatm ent 
param eters we have been using. Unfortunately, there is a significant 
discrepancy between the 1cm radius of necrosis we see in clinical practice and 
the modelled figure of 0.5cm s so clearly further work needs to be done on this.
500
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m  50
The colour code for the diagrams of figures 12.12, 12.13, 12.14 and 12.15.
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□Fig 12.13: Diffuser fibre:652 nm 
(fibre is in plane of paper)
Fig 12.12: Bare Fibre:652 nm 
(fibre perpendicular to paper)
Fig 12.14: Interstitial bare fibres Fig 12.15: Interstitial bare fibre arranged 
in a triangle 652nm with pull back 652 nm
(fibres perpendicular to paper) (fibres in plane of paper)
12.4.2 Fibre Positioning
The exact technique for fibre placement with interstitial treatment is open to 
debate. Radiotherapists with expertise in brachytherapy favour the use of 
plastic tube devices that can be loaded with diffuser fibres of variable length and 
computer generation of light dosimetry. This is clearly a very similar concept to 
afterloading techniques and has the potential to be quite accurate and effective. 
However, it is immensely time consuming and unlikely to be adopted by large 
numbers of oncology units. At the other end of the spectrum is the technique
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described in Chapter 11, in which a series of point sources is used with a 
pullback technique. I suspect there will be some convergence of ideas, perhaps 
with positioning of catheters under image control, then removing the trocar and 
treating through the clear plastic cannula. While it is possible to undertake this 
treatment now, a great deal of work still has to be done on the detail.
12.5 Treatment Monitoring
Once all the tumour target has been identified, it is then necessary to treat all of 
it. This can be done using the surgical philosophy of treating all the disease 
with a surgical margin. PDT necrosis in normal tissue adjacent to tumour is 
acceptable as long as it heals satisfactorily and this seems to be the case in the 
mouth. However, we still need to ensure that our treatment has been delivered 
as we intend to our target. This can be done by:-
12.5.1 Light Measurement within Tissue
At the time the treatment is carried out, light transmission through the tissue can 
be measured in real time. This will enable us to overcome differences in light 
transmission through different types of tissue and compensate for changes that 
occur during the course of treatment. For example, vascular tissue seems to 
transmit more light than fibrous tissue. Treatment parameters could therefore 
be altered for different targets -  for example a tongue tumour might require 
20J/cm (for interstitial treatment with diffuser fibres) whereas prostate might 
require twice or three times this dose.
12.5.2 Measurement of Oxygen in the Tissues
Oxygen is consumed during PDT. This can be measured by continuous real 
time recording of in vivo HbSat levels during and after PDT by means of Visible 
Light Reflectance Spectroscopy. This spectrographic system calculates the 
changes in oxyhaemoglobin (HbO), and deoxyhaemoglobin (Hb) in pmol/l from 
changes in the spectral attenuation derived from the light reflectance spectra 
acquired by the spectrometer over its 485-635nm detection range. From these 
values one can derive the total haemoglobin (HbT) in pmol/l as the sum of the
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HbO and Hb, and the haemoglobin oxygen saturation (HbSat, expressed as a 
percentage), which is HbO divided by HbT (Figure 12.16). There would seem 
little point continuing to treat when tissue oxygen levels are low and this kind of 
technique would help adjust treatment parameters such as treatment breaks to 
make them maximally efficient.
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Fig 12.16: Experimental arrangement for the visible light spectrometer (VLS) 
with the PDT fibre and the VLS probe positioned on the surface of the liver at a 
fixed centre-to-centre separation (Woodhams J 2004)
12.5.3 Measurement of Active Drug in Tissues
It is possible to measure markers of drug in tissues -  currently we can use a 
CCD camera to measure fluorescence during ALA PDT. (figures 12.17-12.18). 
When the fluorescence pattern returns to presensitiser baseline, it may be that 
there is little point in giving more light. It is important to note that just because 
all the active photosensitiser (PPIX) has been photobleached, it does not
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necessarily mean treatment is adequate, merely that there is no value in 
prolonging treatment.
Fig 12.17: Showing fluorescence images pre ALA
Fig 12.18: Showing fluorescence images after treatment
Similarly changes in elastic scattering may be helpful in monitoring drug levels 
during treatment and currently optical pharmacokinetics seems the most 
promising technique for real time use. This technique is currently under 
development at NMLC.
12.6 Combination Therapy
Most meaningful work on PDT so far is using it as a single therapy. Initially, this 
has been very important in order that we can work out the nature of the PDT 
effect. However, it might be that it will find a place as a therapy in combination 
with other techniques. Below is a series of possibilities -  the list is far from 
complete and merely scratches the surface of possible future developments.
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12.6.1 Hyperthermia
Apart from the obvious fact that heat kills tissue, all reactions tend to be 
accelerated by increasing temperature. The photochemical effect is no 
exception and combinations of heating with PDT result in greater treatment 
effects. There is already a considerable literature on hyperthermia and results 
look encouraging. The work has been going on since the early days of PDT and 
a variety of sensitisers have been studied (Levendag et al 1988, Yanase et al 
2005).
12.6.2 Sensitiser Combinations
As shown in chapter 7, different sensitisers produce different effects and 
combinations of drugs may be used to optimise tumour ablation although not 
necessarily with improved selectivity. The same sensitiser can produce 
different effects over time in keeping with its pharmacokinetic characteristics, so 
that if treatment is carried our shortly after Foscan® sensitisation there might be 
a predominently vascular effect, whereas if treatment were carried out at one 
day unwanted skin and muscle damage might be seen and these effects would 
be minimised if treatment were carried out at day five. Also, some sensitisers 
can be activated at different wavelengths, for example, ALA can be activated by 
red (635nm) or blue light (407-420nm) and Foscan® by red (652nm) or green 
light (511 nm). These secondary absorption peaks might have different 
characteristics such that treatment effects are not too extensive around 
sensitive structures. For example, the treatment of Barrett’s oesophagus with 
Foscan® activated by 652nm red light, would produce deep necrosis, whereas 
activation with green light of 511nm results in a more superficial effect that is 
still clinically useful in the ablation of dysplastic mucosa without the risk of 
stricture or perforation.
12.6.3 Photochemical Internalisation
There are a number of ways in which malignant cells develop resistance to 
cytotoxic drugs. One of these is to enclose the drug in organelles such as 
lysosomes and hence prevent them reaching the usual target (such as the
nucleus). PD T is capable of causing cell death, but in addition, caused  
sublethal cell dam age around the necrotic centre. In this process, there is 
dam age to intracellular organelles with release of the cytotoxic agent which is 
then free to act on the cell. This is demonstrated in figures 12.19 and 12.20. 
The first graph shows the effect of increasing adriamycin concentrations on 
adriamycin sensitive and adriamycin resistant cell lines. The resistant cell lines 
show a consistent cell survival fraction of 70% . If the experiment is repeated  
with P D T  alone this figure falls to 50%  but if the two treatments are combined it 
falls to 20% . Even this figure is higher than the true situation as the assay is a 
colourimetric (M TT) assay in which readings do never fall to zero.
Survival
Fraction
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Adriamycin cone (nM)
Fig 12.19: Effect of increasing adriamycin concentration on 
M C F 7 (sensitive) cell lines — A —
MCF7/ADR (resistant) cell lines — ■—  (After Lou NMLC)
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Fig 12.20: Effect of combinations of PDT and adriamycin on MCF7/Adriamycin 
cell lines (After Lou NMLC)
12.6.4 Combinations of Drug/PDT Treatment
Other therapies can be combined with PDT for example, antiangiogenic 
treatments such as Thalidomide and bioreductive agents such as RSU 1069 
(Bremner et al 1992) can be used to enhance the clinical effectivness of 
treatment. Certain specific agents can be used to alter sensitiser metabolism 
and improve treatment effects. For example, an iron chelator such as 
desferrioxamine can be used in ALA PDT. This further slows the conversion of 
protoporphyrin IX to haem, leaving more PPIX within tissue to be available for 
light activation. The other prerequisite for PDT in addition to light and sensitiser 
is of course oxygen. It would be tempting to think that the use of hyperbaric
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oxygen would enhance the treatment effect. While this may be possible, 
experience from radiotherapy trials has not been encouraging.
12.6.5 Other Combinations
One of the first applications of the porphyrins was as a radiosensitiser. Currently 
this has not been shown to be of great clinical value, but it remains an 
interesting area for research.
12.7 Summary and Conclusion
PDT is a clinical reality now. There are some established indications and 
indeed some licensed indications for its use. This however is merely the 
beginning. A great deal of preclinical and clinical work still needs to be done to 
improve and optimise this therapy if it is to become a useful clinical treatment. 
Currently, this is focused on techniques to match the PDT effect to the full 
extent of the tumour, including a sefety margin in the knowledge that normal 
tissues can tolerate treatment. This requires refinement of dosimetry and real 
time treatment monitoring. Ultimately, these parameters need to be calculated 
and incorporated into the treatment in a semi automated way. If PDT is to find 
wide application, it must be easily learned and carried out, or it will suffer the 
same fate as brachytherapy in Europe -  that is to say it will decline until it is 
only carried out in a small number of institutions, even though it is of proven 
value.
It may be that future applications will also be in totally different spheres of 
medicine such as the treatment of benign disease like lymphangioma, 
neurofibroma and haemangioma, or in microbiology. We would do well to 
remember that the original observation of the PDT effect was the result of 
sunlight falling on a paramoecial culture. Multiple resistant staphylococcus 
aureus is currently reaching epidemic levels in our intensive care units and 
hardly a year goes by without the discovery of another “superbug,” so we may 
yet need to revisit this important indication for PDT.
Plus ca change. plus c’est la meme chose!
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Appendix
Appendix 1
UICC TNM Classification of Malignant Tumours (4th edition, 2nd revision), 
published by P Hermanek and LH Sobin and published by Springer Verlag, 
Berlin, 1992
TNM Criteria for Oral Squamous Carcinoma and Minor Salivary Gland 
Carcinoma 
Primary Tumour Size (T)
TX Primary tumur cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour less than 2cm in greatest dimension
T2 Tumour 2-4cm in greatest dimension
T3 Tumour more than 4cm in greatest dimension
T4 Tumour with extension to involve adjacent structures (eg through cortical 
bone, into deep (extrinsic) muscles of the tongue, into maxillary sinus or skin)
Regional Lymph Node Involvement (N)
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Metastasis in one ipsilateral node less than 3cm in greatest dimension
N2 N2a Metastasis in a single ipsilateral lymph node 3-6cm in greatest
dimension
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 
6cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none more 
than 6cm in greatest dimension 
N3 Metastasis in a lymph node more than 6cm in greatest dimension
Stage Grouping
Stage TNM Classification
Stage 0 Tis NO MO
Stage I T1 NO MO
Stage II T2 NO MO
Stage III T3 NO MO
Stage IV
T1,T2, T3 
Any T4 lesion 
Any N2 or N3 lesion 
Any M1 lesion
N1 MO
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Appendix 2
ICD Codes in the Head and Neck WHO Classification of Diseases
140 Malignant neoplasm of lip
141 Malignant neoplasm of tongue
142 Malignant neoplasm of major salivary glands
143 Malignant neoplasm of gum
144 Malignant neoplasm of floor of mouth
145 Malignant neoplasm of other and unspecified parts of mouth
146 Malignant neoplasm of oropharynx
147 Malignant neoplasm of nasopharynx
148 Malignant neoplasm of hypopharynx
149 Malignant neoplasm of other and ill-defined sites within the lip, oral cavity
and pharynx
Appendix 3
Suppliers of equipment:
Diomed Ltd, Cambridge Research Park; Ely Road; Cambridge CB5 95E; UK 
Applied Optronics Corporation, 111 Corporate Boulevard, Building J, South 
Plainfield, New Jersey, USA 0870
Laserscope, 3052 Orchard Drive, San Jose, California, USA 95134-2011 
Medlight SA, Ch des Larges Pieces, CH-1024 Ecublens, Switzerland 
Pioneer Optics Company, 1000 Old Country Circle, Windsor Locks, Connecticut 
CT 06096, USA
CeramOptec GmbH, Siemensstrasse 44, D-53121, Bonn, Germany 
Suppliers of Drugs:
Foscan®: Scotia Pharmaceuticals, Scotia House, Castle Business Park,
Stirling, Scotland FK9 4TZ, United Kingdom
ALA: DUSA Pharmaceuticals Inc, USA
Photofrin®: QLT Phototherapeutics, Vancouver, Canada
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